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Abstract
Diabetes  is  a  progressive  multi-factorial  metabolic  syndrome  with
serious  short  and long term complications  affecting  many of  organs
with high increasing prevalence in the world.  Using herbs and their
derivatives for treating diabetes  has a long history in many traditional
cultures  across  the  world.  Molecules  and  compounds  were  isolated
from herbs are the basis of many therapeutics which we are using in
medicine  for  treating  a  variety  of  health  conditions.  The  seeds  of
fenugreek,  Trigonella foenum graecum, commonly used as a spice in
Middle Eastern countries and widely used in South Asia and Europe,
are  known  to  have  anti-diabetic  properties.  In  1979,  Hardman
identified  an  unusual  amino  acid  (2S,  3R,  4S)  4-hydroxyisoleucine
(4HO-Ile)  in  a  fenugreek  seed  extract  as  an  active  compound  in
fenugreek seed.  It was so far found only in fenugreek seed, which is
responsible  for  its  anti-diabetic  properties.  Studies  on  4-
hydroxyisoleucine  effects  on  type  2  diabetes  and  insulin  resistant
animal models revealed that it has anti-diabetic properties of enhancing
insulin  secretion  under  hyperglycaemic  conditions,  and  increasing
insulin sensitivity. Unfortunately, the available published researches for
4-hydroxyisoleucine are  limited  and its  mechanism of  actions is  not
clear. Here we describe for the first time the anti-diabetic activity of 4-
hydroxyisoleucine  in  a  model  of  type 1 diabetes as  all  the previous
works focused on 4-hydroxyisoleucine activity in type 2 diabetes and
insulin resistant condition.  Treatment of streptozotocin-treated type 1
diabetes  rats,  where  levels  of  insulin  are  much  reduced,  by  65%,
compared to normal animals, with daily doses of 4-hydroxyisoleucine
at  50 mg/kg/day for four weeks could reduce plasma glucose in the
diabetic group. Moreover the high levels of lipids (cholesterol, HDL,
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LDL and  triglyceride)  and  uric  acid  in  the  diabetic  rats,  could  be
restored to levels found in non-diabetic controls by the treatment with
4-hydroxyisoleucine.  These  results  demonstrate  that  4-
hydroxyisoleucine  has  significant  anti-diabetic  activities  in  type  1
diabetes  as  well  as  previously  studied  type  2  diabetes  and  insulin
resistance model that are independent of insulin.  The findings suggest
the potential of 4HO-Ile as an adjunct to diabetes treatment and for type
1 as well as type 2 diabetes. 
To investigate the insulin-independent effects of 4-hydroxyisoleucine
further, the cell based experiments were designed to assess the effect
of 4-hydroxyisoleucine on cellular  glucose uptake and ATP content
after one day incubation. Isoleucine was added to the experiment as a
positive  control  because  firstly  it  has  some  level  of  anti-diabetic
properties according to previously published studies and secondly it
has similar  molecular  backbone as  4-hydroxyisoleucine.  BRIN-BD
11,  a  functional  and  glucose  responsive  pancreatic  beta  cell,  was
selected as a cell model which is not insulin-responsive and dependent
on the insulin signalling pathway for glucose uptake. Use of the model
provides the opportunity to study the mechanisms of action of both 4-
hydroxyisoleucine and isoleucine independently. We adopted a unique
approach using inhibitors to target suggested pathway and molecules
within the cell which may be involved in both 4-hydroxyisoleucine and
isoleucine  mechanism  of  actions.  The  results  revealed  that  4-
hydroxyisoleucine  and  isoleucine  could  increase  glucose  uptake  in
BRIN-BD 11 cells, but as previously suggested, 4-hydroxyisoleucine
activity  is  in  direct  correlation  with  glucose  concentration.  4-
hydroxyisoleucine  has  higher  activity  in  higher  concentrations  of
glucose.  4-hydroxyisoleucine  increased  the  glucose  uptake  much
greater than isoleucine at 11mM and 22mM concentration of glucose in
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cell culture medium.  Endpoint measurements of ATP content of the
BRIN-BD11 cells did not show any significant changes between 4-
hydroxyisoleucine and isoleucine groups and control as well as an
insulin level  measurement  in  culture  medium after  24 hours.  The
results  showed  that  there  are  substantial  differences  between
isoleucine  and  4-hydroxyisoleucine  mechanisms  of  action  unlike
their similar glucose uptake stimulatory effect  which is greater in 4-
hydroxyisoleucine.  4-hydroxyisoleucine activity strongly dependent
on new protein synthesis and GLUT 1 activity. GLUT 1 is widely
available in most of the cells and it controls the basal glucose uptake
independent  of  insulin.  The  connection  between  GLUT 1 and  4-
hydroxyisoleucine effect in cellular level, supports the idea that 4-
hydroxyisoleucine utilises the glucose basal consumption and uptake
of cells. Mitochondrial calcium channel signalling inhibition affects
4-hydroxyisoleucine  and  isoleucine  functionality  as  well  as
inhibition of mitochondria pyruvate carrier. Real time monitoring of
cell  metabolism  by  Seahorse  XF-24  autoanalyser  after  24  hours
incubation  with  4-hydroxyisoleucine  and  isoleucine  revealed  that
both  4-hydroxyisoleucine  and  isoleucine  activities  are  strongly
dependent  on  mitochondrial  respiration  but  4-hydroxyisoleucine
significantly  up-regulates  glycolysis  which  is  not  affected  by
isoleucine. The connection between mitochondria calcium signalling
and contradictory behaviour of 4-hydroxyisoleucine and isoleucine
support the very important role of mitochondria in their mechanisms
of action. 
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Chapter I
Introduction
1
Diabetes  mellitus  refers  to  a  group  of  metabolic  diseases  defined  by
hyperglycaemia (high blood sugar) and other classical symptoms such as
polyuria  (frequent  urination),  polydipsia  (increased  thirst)  and
polyphagia  (increased  hunger).  Diabetes  is  classified  into  four  main
types  based  on  the  pathogenic  process  which creates  hyperglycaemia
including  Type  1,  Type  2,  Other  Specific  Types  known  as  MODYs
(Maturity  onset  diabetes  of  the young)  and Gestational  Diabetes  (Fig
1.1). 
Type 1 diabetes is result of insulin deficiency which pancreatic cells can
not produce and secrete insulin. Type 2 diabetes is a group of progressive
disorders characterized by insulin resistance, impaired insulin secretion
and  increased  gluconeogenesis  (production  of  glucose).  Diabetes  can
happen with other types of pathogenesis, such as exocrine disease of the
pancreas,  genetic  defects  in  insulin  secretion,  mitochondrial
abnormalities and mutation in the insulin receptor, which are categorized
as  Other  Specific  Type.  Gestational  Diabetes  refers  to  glucose
intolerance during pregnancy due to metabolic changes of pregnancy and
increased insulin demands. 
Diabetes is one of the main public health concerns as a major cause of
mortality  in  most  countries  with  a  high  prevalence  rate,  which  has
increased dramatically in the last two decades (Fig 1.2).
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Fig  1.1.  Spectrum  of  glucose  homeostasis  and  diabetes  mellitus  (DM). The
spectrum from normal glucose tolerance to diabetes in type 1, type 2, other specific
types of diabetes, and gestational diabetes is shown from left to right. In most types
of  diabetes,  the  individual  traverses  from  normal  glucose  tolerance  to  impaired
glucose tolerance to overt diabetes (these should be viewed not as abrupt categories
but  as  a  spectrum).  Arrows  indicate  that  changes  in  glucose  tolerance  may  be
bidirectional in some types of diabetes. For example, individuals with type 2 diabetes
may return to the impaired glucose tolerance category with weight loss; in gestational
diabetes, diabetes may revert to impaired glucose tolerance or even normal glucose
tolerance after delivery. The fasting plasma glucose (FPG), the 2-h plasma glucose
(PG) after a glucose challenge, and the A1C (Glycated hemoglobin or glycosylated
hemoglobin or HbA1c) for the different categories of glucose tolerance are shown in
the lower part of the figure. These values do not apply to the diagnosis of gestational
diabetes. The World Health Organization uses an FPG of 110–125 mg/dL for the
prediabetes  category.  Some types of diabetes  may or may not  require  insulin  for
survival. *Some use the term "increased risk for diabetes" (ADA, American Diabetes
Associassion) or "intermediate hyperglycaemia" (WHO) rather than "prediabetes."
(Adapted from the American Diabetes Association, 2007.)
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Fig 1.2.  Worldwide prevalence of diabetes mellitus. Comparative prevalence (% of
total population) and estimates  numbers of diabetes patients (20–79 years), 2010.
(Used  with  permission  from  IDF  Diabetes  Atlas,  the  International  Diabetes
Federation,  2000  Adopted  from  Harrison's  Principles  of  internal  medicine,  18th
Edition)
Prevalence  of  Type  2  diabetes  is  increasing  more  rapidly  due  to
increasing obesity, reducing physical activity and industrialisation. The
increasing rate of diabetes will place a burden of large costs to societies
which puts this disease at the centre of attention for  all  public health
policy makers, researchers and medical groups. The number of people
with diabetes in the UK has increased from 1.4 million in 1996 to 2.9
million and most of the cases is Type 2 diabetes (www.diabetes.org.uk).
The figures announced by the WHO and the UK health authorities show
that diabetes, particularly Type 2 diabetes, is one of the biggest health
challenges in the world today. The seriousness and importance of this
issue  make  diabetes  research  more  in  demand  in  order  to  find  new
solutions to reduce the rate of diabetes prevalence and new treatments to
control diabetes and its complications.
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1.1 Type 1 Diabetes
Type 1 diabetes is characterised by total insulin deficiency as a result of
destruction  of  pancreatic  beta  cells  by  interactions  of  genetic,
environmental  and  immunological  (autoimmune  pancreatic  cell
destruction)  factors (Harrison's  Principles  of  internal  medicine,  18th
Edition). The main pathophysiology of type 1 diabetes is the activation of
an  innate  immune  system  response  towards  pancreatic  beta  cells,
involving expansion of auto-reactive immune system cells such as CD4 ,
CD8 and T-Helper cells and producing auto-antibodies against beta cells
(Bluestone et al. 2010).  Multiple genes are involved in susceptibility to
type  1  diabetes.  The major  susceptibility  gene  for  type  1  diabetes  is
located in the HLA region on chromosome 6 which account for 40–50%
of the genetic risk of developing type 1 diabetes (Bluestone et al. 2010).
In  addition to  MHC class  II  associations,  genome association studies
have  identified  at  least  20  different  genetic  loci  that  contribute
susceptibility to type 1 diabetes, such as  polymorphisms in the promoter
region  of  the  insulin  gene,  the  CTLA-4  gene,  interleukin-2  receptor,
CTLA4, and PTPN22, etc. (Grant et al. 2009).
Type 1 diabetes is fatal and should be treated by injecting appropriate
amounts of insulin to control high blood sugar levels. Type 1 diabetes
can  be  distinguished  from type  2  diabetes  by  measuring  endogenous
insulin  production  using  the  C-Peptide  assay.  Diabetic  ketoacidosis
(DKA) is the most important acute complication of untreated or poorly
controlled type 1 diabetes and which needs special  medical  attention.
DKA develops when the ratio of insulin to glucagon becomes decreased
in  a  severe  insulin  deficiency  condition,  leading  to  ketone  body
formation  in  the  liver  and  create  acidosis,  electrolyte  imbalance  and
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metabolic complications (Harrison's Principles of internal medicine, 18th
Edition). 
1.2 Type 2 Diabetes
Type 2 diabetes is the most common form of diabetes and has genetic
predisposing factors. It is characterized by insulin resistance, impaired
insulin  secretion,  obesity  and  abnormal  fat  metabolism (Harrison's
Principles of  internal  medicine,  18th Edition). Insulin resistance is  the
main underlying pathogenesis of type 2 diabetes, and in turn leads to
impaired insulin secretion and other metabolic disturbances. A glucose
tolerance  test  is  normal  or  near  normal  in  the  early  stage  of  disease
because pancreatic beta cells compensate insulin resistance by increasing
insulin  secretion (Harrison's  Principles  of  internal  medicine,  18th
Edition). 
It is expected that the level of serum insulin increases (hyperinsulinemia)
in the early stages of type 2 diabetes as a response to impaired insulin
action (Stefano Del Prato et al.  2002). Continuous stimulation of beta
pancreatic cells to keep the compensatory output of insulin high leads to
impaired  insulin  secretion  as  a  result  of  exhaustion  of  the  cells  and
failure to produce insulin (Fig 1.3). 
Type 2 diabetes risk increases with a positive familial history due to the
strong genetic component with concordance between 70%  and 90% in
identical twins (Harrison's Principles of internal medicine, 18th Edition).
The risk of type 2 diabetes can increase up to 40% if both parents are
diabetic. Apart from genetic factors, environmental factors such as food
intake,  and  exercise  play  an  important  role  in  developing  diabetes.
Studies show that there is a connection between consumption of sugar
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sweetened  drinks  and  risk  of  type  2  diabetes (Malik  et  al.  2010).
Lifestyle  and  diet  modification,  are  considered  as  a  very  effective
preventive  approach,  especially  for  those  people  with  higher  risk,
including people with obesity and a positive familial history for diabetes.
NICE guide line recommends bariatric surgery for people with type 2
diabetes with BMI higher than 35 kg/m2  as effect intervention to control
obesity and diabetes.  A recent study showed that bariatric surgery can
significantly improve type 2diabetes and other metabolic risk factors in
severely obese patients (Brethauer et al. 2013).  
Fig 1.3. Metabolic changes during the development of type 2 diabetes mellitus (DM).
Insulin secretion and insulin sensitivity are related, and as an individual becomes
more  insulin  resistant  (by  moving  from  point  A to  point  B),  insulin  secretion
increases. A failure to compensate by increasing the insulin secretion results initially
in impaired glucose tolerance (IGT; point C) and ultimately in type 2 diabetes (point
D). (Adapted from SE Kahn: J Clin Endocrinol Metab 86:4047, 2001; RN Bergman,
M Ader: Trends Endocrinol Metab 11:351, 2000) M Value is a score developed by
McCauley et  al in  2001  for  measuring the Insulin Sensitivity Index (ISI)  by the
euglycemic-hyperinsulinemic glucose clamp technique. The ISI is calculated for fat-
free body mass by dividing the whole body glucose disposal rate (M – mg/min or
µmol/min per Kg) by the average plasma insulin concentration over the final  60
minutes of the 120 minute test (McAuley et al. 2001). 
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Many  genes  are  involved  in  diabetes  with  subtle  variation  known as
single  nucleotide  polymorphism  (SNPs)  which  increase  the  risk  of
developing  diabetes.  Early  whole  genome  linkage  studies  identified
calpain 10 (CAPN10) and hepatocyte nuclear factor 4 alpha (HNF4A) as
directly linked to diabetes (Dean et al. 2004). More than 36 genes have
been identified in relation to the risk of type 2 diabetes (Herder  et al.
2011). Genome-wide association studies (GWAS) have identified novel
pathways  linked  to  fundamental  biology,  which  confirms  previous
epidemiological observations, showed the role of β-cell dysfunction in
type  2  diabetes,  explained  about  10%  of  disease  heritability,   and
determined possible targets for pharmacotherapy (Billings  et al. 2010).
GWAS has discovered the variant rs13266634, which encodes a R→W
change at  position  325 in the  beta  cell  zinc  transporter  ZnT-8 which
encoded by SLC30A8 gene with strong associations with type 2 diabetes
(Scott  et al. 2007). The GWAS method provided potential genetic links
between lipid  dysregulation  and glycemia  (FADS1,  GCKR,  HNF1A),
circadian rhythmicity and metabolic derangements (MTNR1B,  CRY2),
and low birth  weight  with  subsequent  type 2  diabetes  risk  (ADCY5)
(Billings   et  al.  2010). The  genomic  study  revealed  that  the  risk  of
developing  diabetes,  especially  type  2  diabetes  is  a  combination  of
genetic risk for pancreatic beta cell dysfunction superimposed on genetic
and environmental factors (e.g. obesity, Western diet, sedentary lifestyle)
that promote insulin resistance. 
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1.3 Diabetes Complications
Chronic long term complications can develop in both type 1 and type 2 
diabetes. The main chronic complications of diabetes  include:
• Diabetic cardiomyopathy and diabetic vasculopathy  
• Diabetic nephropathy
• Diabetic retinopathy
• Diabetic neuropathy 
Studies show that type 1 and type 2 diabetes complications arise from a
change in the balance of metabolites such as lipids, carbohydrates and
blood  coagulation  factors  (Mard-Soltani  et  al.  2011).  Chronic
complications may occur despite control of blood glucose. Studies show
that  rapid  tight  control  of  blood  sugar  levels  worsens  diabetes
complication rather than improving the conditions (Taubes. 2008). Other
studies showed that the improved glucose control after 41 months did not
improve complications (Brinchmann-Hansen et al. 1988). 
Hyperglycaemia  is  an  important  aetiological  factor  for  diabetes
complications but studies show there are many other unknown factors
that  may  be  involved  based  on  the  observation  that  complications
develop despite control of glucose. Type 2 diabetes is a chronic disease
with higher possibilities to develop chronic complications compared to
type 1 diabetes with a ten year shorter life expectancy. 
The  risk  of  cardiovascular  complications  including  ischaemic  heart
disease and stroke is increased by two to four times in type 2 diabetes
and there  is  a  20  fold  increase  in  lower  limb amputations  (Williams
textbook  of  endocrinology.  2012  (12th  ed,).  Philadelphia:
Elsevier/Saunders. pp. 1371–1435.ISBN 978-1-4377-0324-5). 
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Type  2  diabetes  is  associated  with  the  most  frequent  cause  of  non-
traumatic  blindness  and  kidney  failure.  Other  complications  such  as
sexual dysfunction and risk of infection are increased in type 2 diabetes
(Ripsin  et  al.  2009).  Abnormal  fat  metabolism  due  to  a  lack  of  or
impaired insulin secretion and insulin resistance lead to hyperlipidemia
in diabetic patients. Increased levels of cholesterol and triglyceride are
metabolic  complications  of  diabetes  and  increase  the  risk  of  organ
disease,  particularly  cardiovascular  disorders.  Elevated  serum  low
density lipoprotein ( LDL) is one of the most important side effect of
diabetes as a result of fat metabolism abnormalities and it is a target for
diabetes management to achieve an LDL level lower than 100mg/dl (2.6
mmol/l) (ADA, Standards of Medical Care in Diabetes - 2010. Diabetes
Care,  2010). Abnormal  lipid  metabolism,  increased  circulatory  lipid
concentration and elevated deposition of lipids in the skeletal muscle are
widely displayed in patients with type 2 diabetes and insulin resistance
(McGarry, Banting lecture. Dysregulation of fatty acid metabolism in the
aetiology of type 2 diabetes. Diabetes 2001; 51: 7-18).
Hypertension  is  another  complication  of  diabetes  which  affects
approximately  70%  of  diabetic  patients  (Rodrigo  et  al.  2007) and
directly increases the risk of cardiovascular  and kidney complications
which need special attention and management. 
Type  2  diabetes,  insulin  resistance,  and  untreated  lack  of  insulin  are
associated with high levels of serum uric acid (Cappuccio et al. 1993). It
has been shown that high serum uric acid increases the risk of Type 2
diabetes  independent  of  the  other  risk  factors  such  as  obesity  and
dyslipidemia  (Dehghan et al. 2008). High serum uric acid can occur in
Type  1  diabetes  and  it  is  directly  linked  to  renal  damage,  causes
increased morbidity and mortality (Rosolowsky et al. 2008).
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1.4 Diagnosis Criteria
Based on WHO guidelines, diabetes is defined by recurrent or persistent
hyperglycaemia and is diagnosed by demonstrating one of the following
criteria: ("Definition, Diagnosis and Classification of Diabetes Mellitus
and its Complications" (PDF). World Health Organisation. 1999)
• Fasting  Plasma  Glucose  level  in  greater  than  125  mg/dl  (7.0
mmol/l) from at least two  independent measurements.
• Two-hour plasma glucose greater than 200 mg/dl  (11.1 mmol/l)
after 75g oral glucose load (Oral Glucose Tolerance Test).
• Random blood glucose level greater than 200 mg/dl (11.1 mmol/l)
in presence of diabetes symptom including polydipsia,  polyuria
and  polyphagia.
• Haemoglobin A1C1 (Glycated Haemoglobin) greater than 6.5%. 
Fasting blood glucose levels from 110 mg/dl to 125 mg/dl (6.1 to 6.9
mmol/l) and oral glucose tolerance test above 140 mg/dl (7.8 mmol/l) but
less than 200 mg/dl (11.1 mmol/l) are considered as impaired glucose
homeostasis and are indicative of  pre-diabetic status. 
1 Glycated hemoglobin  or  glycosylated hemoglobin  (hemoglobin A1c, HbA1c, A1C, or
Hb1c;  sometimes  also  HbA1c) is  a  form of  hemoglobin  that  is  measured  primarily  to
identify the  average  plasma  glucose  concentration  over  prolonged periods  of  time.  It  is
formed in a non-enzymaticglycation pathway by hemoglobin's exposure to plasma glucose.
Normal levels of glucose produce a normal amount of glycated hemoglobin. As the average
amount  of  plasma  glucose increases,  the  fraction of  glycated hemoglobin increases  in  a
predictable way. This serves as a marker for average blood glucose levels over the previous
months  prior  to  the  measurement. (Adapted  from  www.wikipedia.org  ,
http://en.wikipedia.org/wiki/Glycated_hemoglobin )
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The people  at  this  stage  are  at  a  high risk  to  progress  to  full-blown
diabetes  mellitus  and   diabetic  complication  including  cardiovascular
diseases ("Definition, Diagnosis and Classification of Diabetes Mellitus
and its Complications" (PDF). World Health Organisation. 1999).
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1.5 Insulin 
1.5.1 Structure
Insulin is a polypeptide hormone with a molecular weight of 5808 Da
synthesized in the beta cells of the Islets of Langerhans in the pancreas
comprising two polypeptide chains, A with 21 amino acid residues, and
B with 30amino acid residues, which are linked by disulphide bridges.
Initially  insulin  is  synthesised  as  pre-proinsulin  with  110  amino  acid
residues which is processed in the endoplasmic reticulum to proinsulin
containing  82  amino  acid  residues  (Brunton  LL,  Chabner  BA,
Knollmann  BC:  Goodman & Gilman's  The  Pharmacological  Basis  of
Therapeutics,  12th Edition:The  McGraw-Hill  Companies,  2011).
Proinsulin is comprised of chains A, B and the C-peptide. The C-peptide
domain  has  31  amino  acid  residues  and  keeps  the  insulin  molecule
inactive. Proinsulin will be transformed into active insulin by cleavage of
C-peptide via endopeptidases which cleave the bonds between lysine 64
and arginine 65, and between arginine 31 and 32 (Fig 1.4).  
Conversion of  proinsulin  to  active insulin  is  called maturation and is
carried out in cytoplasmic granules by prohormone convertases 2 and 3
and  carboxy-peptidase  H  (Hutton  1994).   Insulin  has  a  variety  of
biological  effects  in  the  body  apart  from  maintaining  glucose
homeostasis.  Insulin  is  one  of  the  potent  anabolic  hormone  which
stimulates  protein  synthesis,  lipogenesis,  mitosis  and  cellular  growth
(Tamas Fulop et al. 2003). 
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Fig 1.4. Synthesis and processing of insulin. The initial peptide, preproinsulin (110
amino acids) consists of a signal peptide (SP), B chain, C peptide, and A chain. The
SP  is  cleaved  and  S-S  bonds  form  as  the  proinsulin  folds.  Two  prohormone
convertases, PC1 and PC2, cleave proinsulin into insulin, and C peptide. Insulin and
C peptide are stored in granules and co-secreted in equimolar quantities. (Adopted
from:  Brunton  LL,  Chabner  BA,  Knollmann  BC:  Goodman  &  Gilman's  The
Pharmacological Basis of Therapeutics, 12th Edition:The McGraw-Hill Companies,
2011)
1.5.2 Secretion
Insulin secretion from beta cells happens in two phases, rapid triggered
and a slow release phase. The rapid triggered phase happens in response
to various stimulator including glucose, arginine, leucin,  acetylcholin,
cholecyctokinin (CCK) (Cawston  et al.  2010),  glucagon-like peptide-1
(GLP-1),  glucose-independent  insulinotropic  peptide  (GIP)  and
epinephrine via ß2 receptors (Layden et al. 2010). Glucose is the major
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physiological stimulus of insulin release, entering beta pancreatic cells
via GLUT 2 transporters. Glucose is phosphorylated inside the cells by
glucokinase (hexokinase IV) to glucose-6 phosphate (G6P) which is a
rate-limiting step that controls glucose-regulated insulin secretion. G6P
enters the glycolytic pathway in cytosol, converted to pyruvate. Pyruvate
enters mitochondria to generate ATP through the citric acid cycle (Krebs
Cycle).  Increased  the  ATP/ADP ratio  and  elevated  ATP inhibit  ATP-
sensitive  potassium  channels  (Kir6.2,  known  as  the  sulfonylurea
receptor)  on  the  membranes  of  beta  cells.  Reduced  potassium efflux
leads to cell membrane depolarization which opens voltage- dependent
calcium  channels  and  an  influx  of  calcium  into  the  cell.  Increased
amounts  of  calcium  stimulate  exocytosis  of   insulin  previously
synthesized  granules  via  activation  of  phospholipase  C  (Fig  1.5)
(Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th
Edition:The McGraw-Hill Companies, 2011 and Harrison's Principles of
internal medicine, 18th Edition, 2012). 
Glucokinase acts as the glucose sensor in pancreatic beta cells, and has
unique features which distinguish it from other hexokinases and make it
function as a glucose sensor. It has lower affinity for glucose  compared
to other hexokinases (higher Km of 10 mM, 100 times higher than other
hexokinases with Km of 0.1 mM), such that the activity increases with
rising  concentrations  of  glucose  and  remains  a  half-maximal
concentration of glucose at 144 mg/dl (8 mmol/l). Other hexokinases are
inhibited by their products but glucokinase is not inhibited by G6P and
remains active to stimulate insulin release amid significant amounts of its
products (Matschinsky. 1996).
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Fig 1.5. Mechanisms of glucose-stimulated insulin  secretion and abnormalities  in
diabetes. Glucose and other nutrients regulate insulin secretion by the pancreatic beta
cell.  Glucose is transported by a glucose transporter GLUT 2; subsequent glucose
metabolism by the beta cell alters ion channel activity, leading to insulin secretion.
The SUR receptor is the binding site for some drugs that act as insulin secretagogues.
SUR,  sulfonylurea  receptor;  ATP,  adenosine  triphosphate;  ADP,  adenosine
diphosphate,  cAMP,  cyclic  adenosine  monophosphate.  IAPP,  islet  amyloid
polypeptide or amylin.  (Adopted from: Harrison's Principles of internal medicine,
18th Edition)
 1.5.3 Mechanism of Action of Insulin
Insulin elicits its biological effect through binding to insulin receptors on
cell plasma membranes expressed in all types of cells in the body.  The
insulin receptor is a member of the tyrosine kinase receptor family and
has  functional  similarity  to  the  insulin-like  growth  factor-1  (IGF-1)
receptor (Taniguchi et al. 2006). The insulin receptor is a transmembrane
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receptor comprising two extracellular alpha subunits and two membrane-
spanning  beta   subunits  attached  by  a  disulfide  link  shaped  a
heterotetramer with approximately molecular weight of 320 Da. Insulin
receptor  subunits  are  encoded  by  INSR  genes  on  chromosome  19
(Belfiore et al. 2009). 
Alpha  subunits  act  as  ligand  binding  sites  and  beta  subunits  have
inherent  tyrosine  kinase  activity.  In  the  normal  status  of  no  ligand
binding, the alpha subunits inhibit  the tyrosine kinase activity of beta
subunits.  Binding  of  insulin  to  the  alpha  subunits  changes  the
conformation of the receptor and releases inhibition of alpha subunits,
leading to activation of the beta subunit tyrosine kinase. One beta subunit
transphosphorylates the other one, resulting in autophosphorylation. Beta
subunit  activation  initiates  signalling  cascade  via  phosphorylation  of
intracellular proteins including insulin receptor substrate (IRS) and Src-
homology-2-containing  protein  (Shc)  (Brunton  LL,  Chabner  BA,
Knollmann  BC:  Goodman & Gilman's  The  Pharmacological  Basis  of
Therapeutics,  12th Edition:The  McGraw-Hill  Companies,  2011).
Phosphorylated  IRS-1  protein  binds  to  P85  regulatory  subunit  of
phosphatidylinositol 3-kinases (PI3Kinase) leading to activation of the
P110  catalytic  subunit  of  the  enzyme.  Activated  PI3Kinase
phosphorylates  phosphatidylinositol  4,5-bisphosphate  (PIP2)  in  the
plasma membrane to phosphatidylinositol (3,4,5)-triphosphate (PIP3). 
PIP3 activates protein kinase B (PKB or Akt) which facilitate GLUT 4
(glucose transporter 4) vesicle fusion to the plasma membrane resulting
in increased glucose uptake (Edward  et al. 2005). 
Activated  protein  kinase  B  inhibits  glycogen  synthesis  by  inhibiting
glycogen synthase kinase (GSK) through phosphorylation which leads to
inactivation of glycogen synthase (Xianjun Fang et al. 2000). 
PI3Kinase activation triggers several downstream kinases via producing
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PIP3 including Akt 2 (PKB), mammalian target of rapamycin (mTOR)
and  protein  kinase  C  (PKC)  (Huang  S  and  Czech  MP.  2007).   The
PI3Kinase  I/Akt2  activation  plays  a  major  role  in  mediating  insulin
action for  glucose transport in skeletal  muscle and adipose tissue and
glucose production regulation and liver cells (Zaid H et al. 2008).  
Phosphorylation  of  beta  subunits  of  insulin  receptors  activates  Src-
homology-2-containing protein (Shc) and Growth factor receptor-bound
protein 2 (Grb 2) which leads to initiation of a protein kinase cascade
involving mitogen-activated protein kinase (MAPK) and extracellular-
signal-regulated kinases  (ERKs)  that  mediate  insulin  actions  for  gene
transcription  and  cell  growth  (Fig  1.6) (Goodman  &  Gilman's  The
Pharmacological  Basis of Therapeutics,  12th Edition:The McGraw-Hill
Companies, 2011). 
MAPK  cascade  activation  induces  gene  expression  regulation,  cell
growth and differentiation actions of insulin (Louise et al. 2008). MAPK
inhibitors  inhibit  insulin-stimulated  glucose  uptake  without  any
detectable effect  on GLUT4 translocation (Sweeney  et  al. 1999).  The
MAPK  pathway  is  involved  in  intrinsic  GLUT4  regulation,  the
mechanism is still not well understood. 
Activation  of  small  GTP-binding  proteins  like  TC-10  and  Rac,
independent of PI3Kinase activation, is important for insulin action for
increasing  glucose  transport  in  peripheral  cells  as  these  proteins  are
critical for vesicle trafficking (Kjoller et al. 1999 , Chiang et al. 2001).  
Insulin  signalling  is  terminated  by  degradation  of  receptor  bound  to
insulin  and  decreases  the  amount  of  insulin  receptor  on  the  plasma
membrane  (Najjar.  2001). Dephosphorylation  of  tyrosine  residues  by
tyrosine phosphatases is another mechanism that leads to termination of
insulin signalling within the cells.
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Fig  1.6. Pathways  of  insulin  signalling.  The  binding  of  insulin  to  its  plasma
membrane  receptor  activates  a  cascade  of  downstream signalling  events.  Insulin
binding activates the intrinsic tyrosine kinase activity of the receptor dimer, resulting
in the tyrosine phosphorylation (Y-P) of the receptor's  beta subunits and a small
number of specific substrates (yellow shapes): the Insulin Receptor Substrate (IRS)
proteins, Gab-1 and SHC; within the membrane, a caveolar pool of insulin receptor
phosphorylates  caveolin  (Cav),  APS,  and  Cbl.  These  tyrosine-phosphorylated
proteins interact with signalling cascades via SH2 and SH3 domains to mediate the
effects of insulin, with specific effects resulting from each pathway. In target tissues
such as skeletal muscle and adipocytes, a key event is the translocation of the Glut4
glucose  transporter  from  intracellular  vesicles  to  the  plasma  membrane;  this
translocation is stimulated by both the caveolar and non-caveolar pathways. In the
non-caveolar pathway, the activation of PI3K is crucial, and PKB/Akt (anchored at
the membrane by PIP3) and/or an atypical form of PKC is involved. In the caveolar
pathway, caveolar protein flotillin localizes the signalling complex to the caveola; the
signalling pathway involves series of SH2 domain interactions that add the adaptor
protein CrkII, the guanine nucleotide exchange protein C3G, and small GTP-binding
protein,  TC10.  The  pathways  are  inactivated  by  specific  phosphoprotein
phosphatases (eg, PTB1B). In addition to the actions shown, insulin also stimulates
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the plasma membrane Na+,K+-ATPase by a mechanism that is still being elucidated;
the result is an increase in pump activity and a net accumulation of K+ in the cell.
Abbreviations: APS, adaptor protein with PH and SH2 domains; CAP, Cbl associated
protein;  CrkII,  chicken  tumor  virus  regulator  of  kinase  II;  GLUT4,  glucose
transporter  4;  Gab-1,  Grb-2  associated  binder;  MAP  kinase,  mitogen-activated
protein  kinase;  PDK,  phosphoinositide-dependent  kinase;  PI3kinase,
phosphatidylinositol-3-kinase;  PIP3,  phosphatidylinositol  trisphosphate;  PKB,
protein kinase B (also called Akt); aPKC, atypical isoform of protein kinase C; Y,
tyrosine residue; Y-P, phosphorylated tyrosine residue. (Adapted from: Goodman &
Gilman's The Pharmacological Basis of Therapeutics, 12th Edition:The McGraw-Hill
Companies, 2011)
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1.6 Glucose Transporters 
Glucose is a vital source of energy and important metabolic substrate for
mammalian cells. Glucose transporters are a broad group of membrane
proteins which are responsible for glucose uptake and transport through
the plasma membrane of cells. In general glucose transporters  comprise
two groups based on their function and structure including Na-dependent
glucose  transporters  (SGLT)  (Wright.  2001)  and  facilitative  Na  -
independent sugar transporters (GLUT family) (Mueckler . 1994). 
SGLTs are Na+/K+ ATPase pumps that facilitate glucose transport in the
small intestine (SGLT-1) and the proximal tubule of nephrons in kidney
(SGLT-1 and SGLT-2). SGLT-1 is a high affinity and SGLT-2 is a low
affinity Na-dependent glucose transporters (I. Stuart Wood et al. 2003).
GLUTs are tarnsmembrane proteins with 12 membrane-spanning helices
which facilitate diffusion of glucose and other sugars across the plasma
membrane.  Binding  of  glucose  to  the  extra-membrane  site  of  GLUT
provokes a conformational change of the transporter and leads to release
of glucose from the other intra-membrane side of the transporter (Hruz et
al. 2001).
The GLUT family consists of three subclasses (Class I,II,III)  with 13
members (Hruz  et  al.  2001, Joost  et  al.  2001).  Each GLUT isoform
plays  specific  role  in  glucose  uptake  in  different  tissues  and
physiological  conditions.  Substrate  specificity  and transporter  kinetics
are different in each isoform which creates a specific role for each GLUT
isoform in sugar metabolism (Thorens. 1996). Class I GLUTs are well
defined and comprise GLUT 1 to GLUT4 (Table 1.1).
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GLUT1 is a high affinity glucose transporter responsible for low-level
basal  glucose  uptake  when  the  glucose  concentration  is  low  and  is
widely expressed in erythrocytes and endothelial cells of vascular tissues
specially  barrier  tissues like the blood brain barrier  (BBR).  It  is  also
responsible for vitamin C uptake (Nelson et al. 2008).
GLUT2 is a very efficient glucose transporter with high capacity and low
affinity (Higher Km  ≥ 10 mM), acts as a glucose sensor in pancreatic
beta cells and also carries glucosamine as well as glucose (Efrat. 1997).
Glut2 is also expressed in small intestine cells, proximal renal tubules
and hepatocytes. It plays an important role in transporting glucose in fed-
state from the intestinal lumen (Bell  et al. 1990).  
GLUT3 is a glucose transporter with very high affinity, five times greater
than other class I GLUTs, and is mainly expressed in neurons (Simpson
et al. 2008, Vannucci et al. 1997). GLUT1 transporter in the brain blood
barrier and GLUT3 with high affinity for glucose play  a central role in
glucose uptake and metabolism in central nervous system at low glucose
concentration.
GLUT4 is the insulin-responsive glucose transporter  found in adipose
tissue, skeletal muscle and heart which is responsible for the reduction of
postprandial  plasma glucose rise  in response to insulin  (Rayner  et  al.
1994).  Insulin   increases  glucose  uptake  immediately,  10-20  fold  by
stimulating GLUT4 translocation in adipose tissue and skeletal muscle
(Shepherd et al. 1999). GLUT4 translocation in skeletal muscle can also
be increased by exercise, independent of insulin (Ploug et al. 1998). 
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Name Distribution Notes
GLUT1 Widely distributed in fetal tissues. In the adult, it is expressed
at highest levels in  erythrocytes and also in the endothelial
cells  of  barrier  tissues  such  as  the blood–brain  barrier.
However, it is responsible for the low-level of basal glucose
uptake required to sustain respiration in all cells.
Levels in cell membranes
are increased by reduced 
glucose levels and 
decreased by increased 
glucose levels.
GLUT2 A bidirectional  transporter,  allowing  glucose  to  flow in  2
directions. Is expressed by renal tubular cells, small intestinal
epithelial  cells, liver cells  and  pancreatic beta  cells.
Bidirectionality is required in liver cells to take up glucose
for glycolysis, and release glucose during gluconeogenesis.
In pancreatic beta cells, free flowing glucose is required so
that  the  intracellular  environment  of  these  cells  can
accurately  gauge  the  serum  glucose  levels.  All  three
monosaccharides  (glucose, galactose and fructose)  are
transported from the intestinal mucosal  cell  into the portal
circulation by GLUT2
Is a high-capacity and 
low-affinity isoform. 
There is some evidence 
that GLUT 1 and 3 are 
actually the functional  
transporters in beta cells.
GLUT3 Expressed mostly in neurons (where it is believed to be the
main glucose transporter isoform), and in the placenta.
Is a high-affinity isoform,
allowing it to transport 
even in times of low 
glucose concentrations.
GLUT4 Found  in adipose  tissues and striated  muscle (skeletal
muscle and cardiac muscle).
Is the insulin-regulated 
glucose transporter. 
Responsible for insulin-
regulated glucose 
storage.
Table 1. Class I glucose transporters GLUT1-GLUT4. (Bell et al. 1990 and Thorens
et al. 2010)
As GLUT4 translocation in response to insulin is strictly dependent on
PI3Kinase activation and PI3Kinase inhibition completely prevents the
insulin  activity  from increasing  glucose  uptake  via  GLUT4,  previous
studies show that inhibition of PI3Kinase by wortmannin has no effect
on  GLUT4  translocation  in  skeletal  muscle  in  response  to  exercise
(Brozinick et al. 1998).
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GLUT5 is  a  specific  transporter  for  fructose  widely  expressed  at  the
apical side of small intestine cells,  and is responsible for transport of
dietary fructose (Burant  et  al.  1992).  GLUT 5 is also found in many
other types of cells, such as skeletal muscle, adipose, brain and kidney.
GLUT 5 drew the attention in recent years researches because fructose is
an  important  component  of  human  diets.  Increasing  of  fructose
consumption  in  human diets  in  last  decades  raised  a  concern  about  the
contribution of fructose to development of metabolic disorders such insulin
resistance, diabetes and obesity as it  was shown in many literatures that
fructose-fed rodents could develop some degree of insulin resistance and
diabetes.  The peripheral cells uptake the fructose mainly via GLUT5 and
with  less  degree  with  other  GLUTs  and  it  will  go  into  the  metabolic
pathway  of  ATP  production  same  as  glucose  but  with  an  important
difference.  Fructose  unlike  the  glucose  which  converted  to  G6P   via
hexokinase, converts to fructose 1 phosphate via fructokinase and end up to
glyceraldehyde. It bypasses the rate controlled glycolysis process which is
controlled by hexokinase negative feedback.  Increasing G6P inhibits  the
hexokinase  and  controls  the  rate  of  glycolysis  and  glucose  metabolism
within the cell but conversion of fructose to fructose 1 phosphate does not
follow the same path. On the other hand, fructose could not increase the
insulin secretion from pancreatic beta cell  same as glucose  (Eliott  et al.
2002). 
Glucose  transporters  play  a  major  role  in  glucose  metabolism,
particularly  GLUT4 as  an  insulin-stimulated  rate  limiting  transporter.
Animal studies showed that suppression of GLUT4 expression leads to
insulin resistance and type 2diabetes (Stenbit  et al. 1997). 
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1.7 Insulin Resistance 
Insulin resistance refers to the condition in which responsiveness of cells
to insulin is decreased and leads to higher concentrations of insulin in the
blood required to maintain normoglycemic status. Insulin resistance is
one of the main pathogenesis pathways of type 2 diabetes and results in
defects in glucose uptake and metabolism. Insulin resistance creates an
imbalance  in  the  insulin/glucagon ratio  which leads  to   disruption  of
cellular energy production via decrease of glycolysis. It also increases
liver  glyconeogenesis  which  helps  plasma  glucose  levels  rise  and
worsens  the  situation.  In  adipose  tissue  insulin  malfunction  increases
triglyceride hydrolysis (lipolysis) which leads to elevated free fatty acid
concentration  in  blood  (Goodman  &  Gilman's  The  Pharmacological
Basis of Therapeutics, 12th Edition:The McGraw-Hill Companies, 2011). 
Insulin resistance pathology is still not well characterised but previous
studies revealed some risk factors including obesity, race,family history,
hypertension, low level of high density lipoprotein (HDL), gestational
diabetes and birth weight more than 4 kg, are associated with the insulin
resistance condition (Jennifer Mayfield. 1998 and Type 2 diabetes: Risk
factors. Mayo Clinic. Retrieved 21 December 2011). 
Among the risk factors, obesity and high fat intake especially saturated
fat  have   significant  positive  correlation  with  insulin  resistance  (J
Lovejoy et al. 1992, LH Storlien et al. 1991). The high level of free fatty
acid and triglyceride play an important role in the development of insulin
resistance ( Schinner  et al. 2005). Some studies suggested that fructose
contributes  to  insulin  resistance  development  as  it  is  metabolised  to
triglyceride in the liver, which increases triglyceride and free fatty acid
levels in the blood (Heather et al. 2005). 
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It  is  well  established  that  feeding  rats  with  fructose  creates  insulin
resistance  and  type  2  diabetes,  which  is  used  as  a  model  for  type  2
diabetes animal studies (Thorburn. 1989). 
Insulin  resistance  increases  insulin  levels  as  a  push  to  restore  the
normoglycemic status but excess insulin stimulates fat storage and new
fat tissue formation which accelerates weight gain. This defective cycle
makes the condition worse. Unhealthy diet like fast food with high fat
and  fructose  content  has  been  shown  to  play  a  fundamental  role  in
insulin  resistance  and  metabolic  syndrome  conditions  (Elvira et  al.
2005).
It is well established that elevated plasma free fatty acid concentration
reduces insulin-stimulated glucose uptake, and vice versa, reduction in
plasma lipid concentration improves insulin activity and  glucose uptake
in adipose tissue, skeletal muscle and liver (Moller. 2001). Elevated lipid
can create  functional  defects  in  insulin  receptors  and insulin  receptor
substrates (IRS) which change the binding of ligands, insulin receptor
expression, the phosphorylation state of insulin receptor kinase domain
and  the  activity  of  receptor  tyrosine  kinases.  High  free  fatty  acid
concentrations also affect insulin signalling downstream via inhibition of
IRS-1  associated  PI3Kinase  activation  in  muscle  and  IRS-1  serine
phosphorylation which decreases tyrosine phosphorylation of IRS-1 and
leads to impaired IRS-1 activation (Yu C  et al.  2002). It also inhibits
AKT  (PKB)  activation  by  increasing  the  amount  of  ceramide  and
diacylglyerol in skeletal muscle (Chavez et al. 2003).
Elevated free fatty acid (FFA) concentration decreases insulin receptor
activity  via activation and over-expression of protein kinase C (PKC)
(Greene et al. 2004). It has been demonstrated that activation and over-
expression of PKC lead to decrease of Akt (PKB) activity and insulin
receptor  down-regulation  which are  the  mechanisms involve  in  FFA-
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induced insulin resistance (Ikeda et al. 2001). The insulin receptor gene
expression is  regulated positively  by binding HMGA1 (High-mobility
group  protein  1)  to  its  AT-rich  sequences  (C2  and  E3)  within  the
promoter  region. Transfection of cells with HMGA1 increases insulin
receptor  expression which indicates the important  role  of  HMGA1 in
insulin receptor regulation (Brunetti et al 2001). There is some evidence
that FFA-induced PKC activation leads to phosphorylation of HMGA1
which reduces its mobility and binding capability and result in insulin
receptor down regulation and insulin resistance (Samir et al. 2007).
There is strong evidence for connections between malonyl-CoA, acetyl-
CoA carboxylase (ACC1& ACC2) and insulin resistance.  Injection of
ACC1  and  ACC2  anti-sense  inhibitors  restored  diet-induced  hepatic
insulin resistance in rat (Savage  et al.  2006). Acetyl-CoA carboxylase
(ACC)  is  an  enzyme  with  two  isoforms  that  converts  acetyl-CoA to
malonyl-CoA and plays an important role in fatty acid synthesis (Tong L.
2005). ACC2 concentrations are much higher than ACC1 in oxidative
tissues like skeletal muscle and heart. Both ACC1 and ACC2 are widely
expressed in hepatic cells where both fatty acid oxidation and synthesis
are important. ACCs are regulated by allosteric activators such as citrate,
glutamate and dicarboxylic acids (Martin et al. 1962 and Boone AN et al.
2000)  and  phosphorylating  inhibitor,  AMP-activated  protein  kinase
(AMPK) which leads to deactivation of ACCs (Park  et al. 2002). 
Activation of AMPK in muscle inhibits ACC2 and increases fatty acid
and  glucose  oxidation  and  decreases  levels  of  malonyl-CoA.  It  also
increases the GLUT4 content in membrane and up-regulates the GLUT 4
expression (Koistinen  et  al.  2003).  AMPK as  a  negative  regulator  of
ACC  activity  is  a  major  target  for  treatment  of  type  2  diabetes  and
insulin resistance (Ruderman et al. 2004). 
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Glucagon and catecholamines inhibit ACC via AMPK activation whereas
glucose  and  insulin  increase  ACC  activity  by  dephosphorylation  via
phosphatase activation (Kim et al. 1997, Witters et al. 1988). 
Regulation of malonyl-  CoA and fatty acid metabolism are playing an
important  role  in  beta  pancreas  cells  and insulin secretion as well  as
adipose  tissue and skeletal  muscle.  There  is  a  notion that  changes in
malonyl-CoA,  fatty  acid  synthesis  and  oxidation  regulation  could  be
involved  in  obesity  and  insulin  resistance  as  the  fundamental
pathogenesis of type 2 diabetes (Prentki et al. 1996). 
Abnormalities  in  energy homeostasis  regulation  is  a  key  point  in
metabolic syndrome that leads to a variety of conditions and diseases
like diabetes, insulin resistance, cancer and cardiovascular diseases. The
insulin/IGF (insulin-like growth factor) pathway is a major regulator of
energy  homeostasis  by  controlling  glucose  and  lipid  metabolism and
regulation of their homeostasis (Biddinger et al.  2006). 
Forkhead transcription factor (FOXO) is an important mediator for the
metabolic effects of the insulin/IGF pathway. FOXO family has three
main  variants encoded by three genes (FOXO1,3 and 6). FOXO1 is the
main  controller  of  glucose  homeostasis  in  peripheral  tissues  and
pancreatic beta cells (Accili et al. 2004). 
FOXO1 is a critical mediator of insulin signalling as over activation and
expression of FOXO1 in hepatic and pancreatic beta cells causes hepatic
insulin resistance and apoptosis of pancreatic beta cells (beta cell loss)
which are reversed by reduction of FOXO1 function (Kitamura  et al.
2002, Nakae et al. 2002).
The  mTOR  (mammalian  target  of  rapamycin) pathway  is  another
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important  mediator  of   insulin/IGF  pathway,  it  directly  controls  Akt
(Protein  Kinase  B)  function  via  its  phosphorylation.  It  also  suggests
dysregulation of mTOR signalling may have a role in pathogenesis of
metabolic syndrome and insulin resistance (Sarbassov et al. 2005).   
PPAR-γ  (Peroxisome  Proliferator-Activated  Receptors  Gamma)  is  a
nuclear protein and plays an  important role in insulin sensitivity and
glucose  homeostasis  (Picard  et  al.  2002).  Ligand  binding  to  PPAR-γ
creates conformational changes and stabilizes its interaction with  RXR
(Retinoid  X  Receptor).  PPAR-γ/RXR  interaction  stimulates  gene
expression by recruiting a set of coactivators to the promoter region of
the  targeted  gene  (Berger  et  al.  2002).  In-vivo  and  in-vitro  studies
showed that PPAR-γ activation increases insulin sensitivity and enhances
insulin-induced  glucose  uptake  in  adipocytes  (Norris  et  al.  2003  and
Nugent  et al. 2001). It also has been shown that PPARγ co-activator-1
(PGC-1)  has  a  crucial  role  in  glucose  homeostasis  via  regulation  of
GLUT4 gene expression in which PGC-1 strongly induces endogenous
GLUT4 gene expression (Michael  et al. 2001). 
Chronic low-grade inflammatory responses are associated with insulin
resistance in adipose tissue (Ruan et al. 2003,  Hotamisligil et al. 2003).
It was well demonstrated that macrophage content and pro-inflammatory
gene activation are  increased in  adipose  tissue  in  obesity  and insulin
resistance status. There is strong evidence that activation of the TNF-α
pathway,  as  an  inflammatory  cytokine  response  desensitizes  insulin
signalling  and  creates  insulin  resistance  (Hotamisligil  et  al.  1995,
Hotamisligil  et al. 1994, Hotamisligil  et al. 1993,  Uysal  et al. 1998).
TNF-α  pathway  activation  down-regulates  GLUT-4  expressions  by
phosphorylation  of  serine  residue  IRS-1  which  inactivate  IRS-1  and
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insulin signalling (Uysal  et al. 1997).  Several studies have shown that
PPARγ agonists inhibit secretion of TNF- α, macrophage activation and
also  reduce  the  TNF-  α  -induced  inhibition  of  insulin  signalling  in
adipose tissue (Ricote et al. 1998, Peraldi et al. 1997, Ruan et al. 2003). 
Mitochondrial  dysfunction  can  cause  insulin  resistance  and  diabetes,
since mitochondria are the main organelle in cells which maintain energy
homeostasis. Mitochondria density is reduced by 38% in the muscle of
young insulin-resistant offspring of type 2 diabetes parents (Morino et al.
2005). 
Other  regulatory  hormones  secreted  from  adipocytes,  known  as
adipokines,  are involved in glucose homeostasis modulation including
adiponectin,  resistin  and  leptin.  Leptin  is  a  16  KDa  protein,  which
regulates appetite and energy intake (Brennan  et al.  2006). Leptin has
both central and peripheral mode of actions. It was shown that interacts
with six types receptors encoded by LEPR (Wang et al. 1996). There is a
strong  connection  between  leptin  and  obesity.  Leptin   inhibits  the
neuropeptide Y secretes neurons in arcuate nucleus in the brain which
controls the satiety feeling (Baicy et al. 2007). Apart from leptin central
activity  in  connection  with  hypothalamus,  leptin's  receptors  are
expressed in wide types of peripheral cells. It has been shown that leptin
plays a  role  in cellular  energy expenditure  modulation via  interacting
with  metabolism  regulatory  hormones  and  other  energy  regulation
mechanisms  (Margetic  et  al.  2002).  People  with  leptin  receptor
mutations or leptin deficiency suffer from obesity (Montague et al. 1997,
Farooqi  et  al.  1999).  As  obesity  is  a  well  established  risk  of  insulin
resistance, leptin may be involved in insulin resistance. 
Adiponectin  is  another  important  modulator  which  increases  insulin
sensitivity and glucose uptake in both adipose tissue and muscles and
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reduces gluconeogenesis and glucose output in hepatic cells. It was also
shown  that  expression  of  adiponectin  decreases  in  obese  humans
(Stumvoll  et  al.  2002).  Opposite  to  adiponectin,  resistin  increases
gluconeogenesis  and  hepatic  glucose  output  and  decreases  insulin
sensitivity  and  insulin-induced  glucose  uptake  in  both  adipose  and
muscule tissues (Moon  et al.  2003, Pravenec  et al. 2003). There is a
strong belief  that  adipokines  may  contribute  to  insulin  resistance  and
pathogenesis  of  type  2  diabetes.  They  also  attracted  much  research
interest  in  recent  years,  not  only  for  understanding  the  molecular
pathology of insulin resistance, but also for new therapeutic approaches.
Other  genomic  regulators  in  insulin  secretion  and  signalling  are
microRNAs (miRNA) which are recently attracting many researches in
order to identify their role in pathogenesis of diabetes. MicroRNAs are
short single-stranded non protein coding gene products with length of
19-23 nucleotides which post-transcriptionally regulate the expression of
genes  by  interacting  with  specific  mRNAs  (Bartel.  2004,  Lagos-
Quintana  et al. 2001, Fabian  et al. 2010). MicroRNAs interaction with
targeted mRNAs lead to  mRNA degradation  or  inhibition of  mRNA
translation  which  results  in  negative  regulation  (Tranzer  et  al.  2006,
Ying  et  al.  2006).  It  was  established  that  microRNAs  are  directly
involved in glucose homeostasis, insulin secretion and insulin sensitivity,
as shown in Table 1.2.  A recent study showed that a plasma signature of
five miRNAs (miR-15a,miR-29b, miR-126, miR-223, and miR-28–3p) is
closely connected with  a high likelihood of developing type 2 diabetes
(Zampetaki  et al. 2010). These miRNAs are indicators of early type 2
diabetes and responsible for its progression (Regazzi. 2010). There is a
hypothesis that miRNA may transmit from one tissue to another and act
at a distance from their sites of biogenesis (Dinger et al. 2008). There is
31
supportive evidence for this hypothesis as it was shown that miR-150 is
taken up by target endothelial cells from the bloodstream (Zhang et al.
2010). It suggests that microRNAs may be involved in insulin resistance
and  diabetes  pathogenesis  at  the  genomic  level,  which  needs  further
detailed investigation. miRNAs could be targets for therapeutic purposes
and developing new medications.
Biological Process Specific MicroRNAs
ngn3-independent endocrine pancreas 
regeneration
miR-15a, miR-15b, miR-16 and miR-195
Regulates insulin expression miR-30d, miR-375, miR-124a2
Regulates insulin secretion miR-375, miR-9, miR-124a2
Regulates glucose-stimulated insulin 
secretion (GSIS)
miR-369-5p, miR-130a, miR-27a, miR-410, miR-200a, 
miR-337, miR-532, miR-320, miR-192 and miR-379, 
miR-375, miR-124a2
Regulates adipocyte differentiation miR-143, miR-27b, miR-130, miR-519d
Regulates insulin sensitivity miR-103,  miR-107,  miR-29,  miR-320,  mmu-mir-183-
96-182 (cluster)
Table  1.2. Summary  of  key  biological  processes  and  miRNAs  (Adopted  from:
Michael D.Williams et al. 2012) 
There is a strong genetic links between diabetes type 1 and many genes.
It was shown that there is a strong link between histocompatibility gene
loci on chromosome 6 which encodes MHC class II (HLA) proteins and
diabetes type I (Bluestone et al. 2010). It was shown in the same study
that  some variant  of  HLA gene including DRB1 (0401,  0402,  0405),
DQA 0301  and  DQB1(0302  and  0201)  increase  the  risk  of  type  1
diabetes.  However,  these  variants  are  also  found  in  the  general
population,  and  only  about  5  percent  of  individuals  with  the  gene
variants  develop  type  1  diabetes.  HLA  variations  account  for
approximately  40 percent  of  the genetic  risk  for  the condition.  Other
HLA variations appear to be protective against the disease. 
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1.8 Diabetes management and available therapeutics
Diabetes management has two main categories, insulin therapy and anti-
diabetic medications. Insulin replacement is the main treatment of type 1
diabetes in which the insulin producing capability of beta cells has been
lost.  Anti-diabetic  medication  has  got  no,  or  a  minimal  place  in  the
treatment  of  type  1  diabetes.  Insulin  therapy  in  type  1  diabetes  is
necessary in order to maintain normoglycemic status in the long term,
but increases the risk of small blood vessel disease and may promote
cardiovascular  complications  of  diabetes  (Sugimoto  et  al.  2003,
Mudaliar  .  2009). Insulin  therapy  remains  as  a  last  resort  for  type  2
diabetes particularly when other therapies with anti-diabetic medications
fail to control blood glucose level. 
The  goals  for  treatment  of  diabetes  based  on  the  American  Diabetes
Association (ADA) recommendations are:
• HbA1c lower than 7%
• Peripheral plasma glucose level between 70 to 130 mg/dl (3.9 to
7.2 mmol/l)
• Peak postprandial capillary plasma glucose (OGTT) lower than 
180 mg/dl(10 mmol/l)
• Low density lipoprotein (LDL) lower than 100 mg/dl (2.6 mmol/l)
• High density lipoprotein (HDL) greater than 40mg/dl (1 mmol/l) 
in men and 50 mg/dl (1.3 mmol/l) in women
• Triglyceride lower than 150 mg/dl (1.7 mmol/l)
The aims of treatment for both type 1 and 2 diabetes are to allow patients
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to achieve a  normal  lifestyle,  to eliminate  hyperglycaemic symptoms,
and  to  reduce  long  term  complications  of  diabetes,  especially
cardiovascular complication. 
Anti-diabetic  medications  are  divided  into  four  main  categories  as
sensitizers,  secretagogues,  alpha  glucosidase  inhibitors  and  peptide
analogues. 
Sensitizers: Biguanides, like metformin exert their anti-hyperglycaemic
action  by  suppressing  gluconeogenesis  in  liver  and  enhance  glucose
uptake  via  AMP-activated  protein  kinase  (AMPK)  activation
(Kirpichnikov  et  al.  2002,  Musi  et  al.  2002).  Thiazolidinediones  like
troglitazone, pioglitazone and rosiglitazone are another member of this
category.   Thiazolidinediones  are  PPAR-γ  agonists,  which  increase
insulin sensitivity. 
Secretagogues:  Sulfonylureas  like  tolbutamide,  glipizide,  gliclazide,
glibenclamide and Meglitinides know as non-sulfonylurea secretagogus
or  short-acting  secretagogus  like  repaglinide  and  nateglinide  are
members  of  this  family.  This  family  increases  insulin  secretion  by
inhibiting ATP-sensitive potassium channels in beta cells which leads to
beta  cell  membrane  depolarization  and  an  influx  of  calcium  and
exoytosis of insulin vesicles. 
Alpha Glucosidase Inhibitors:  Acarbose and miglitol are members of
this group, which reduce  glucose absorption by slowing down starch
digestion.  This  group technically  is not  categorized as hypoglycaemic
agents but they help glucose to enter the blood stream from the intestine
slowly,  which  can  be  matched  effectively  with  an  impaired  insulin
response.
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Peptide Analogues: Incretins including glucagon-like peptide1 (GLP-1)
and  glucose-dependent  insulinotropic  peptide  (GIP)  are  secreted  after
meals and stimulate insulin secretion. They have a very short half life up
to  few minutes.  GLP-1  is  effective  in  type  2diabetes  for  stimulating
insulin secretion whereas GIP is not. GLP-1 agonists including exenatide
and liraglutide are effective in type 2 diabetes patients after a meal by
stimulating  insulin  release,  inhibiting  glucagon  and  delaying  gastric
emptying  (Brunton  LL,  Chabner  BA,  Knollmann  BC:  Goodman  &
Gilman's The Pharmacological Basis of Therapeutics, 12th Edition:The
McGraw-Hill  Companies,  2011).  Incretins  are  rapidly  inactivated  by
dipeptidyl peptidase-4 (DPP-4). Recently a new category of anti-diabetic
medication has been developed as DPP-4 inhibitors like sitagliptin and
linagliptin.  DPP-4  inhibitors  reduce  HbA1C (Fig  1.7) (Amori  et  al.
2007). All the available medications as a treatment regiment for diabetes
work on utilising insulin secretion or increasing its effect on peripheral
cells to reduce the blood glucose level but not targeting the fundamental
metabolic disorder of diabetes. 
Fig 1.7. Incretins activity and action of DPP-4 inhibitors. DPP-4 normally inactivates
GLP-1. DPP-4 inhibitors block DPP-4 which in turn leaves GLP-1 active. 
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1.9 Fenugreek (4-Hydroxyisoleucine)
Trigonella foenum-graecum L. (Legominosae) known as Fenugreek (Fig
1.8) is one of the oldest medicinal plants and is native to southeastern
Europe, northern Africa and western Asia. Fenugreek seeds often have a
spicy and pungent aroma and bitter taste. Fenugreek seeds contain many
active compounds such as iron, vitamin A, B, C, phosphates, flavonoids,
saponins, alkaloids such as trigonelline and amino acids (Fenugreek seed
bioactive compositions and methods for extracting same. United States
Patent 7338675). The leaves and seeds have a long record of historical
usage in many countries  where it  was grown for  medicinal  purposes.
Applications of fenugreek were documented in ancient Egypt as incense
for  embalming mummies.  Fenugreek is used as a supplement in wheat
and maize flour for bread-making in modern Egypt (Morcos et al. 1981).
In  traditional  Chinese  medicine,  fenugreek seeds  are  consumed  as  a
tonic, as well as a remedy for weakness and oedema of legs (Basch et al.
2003). Fenugreek is commonly used as a condiment in India and used as
a  lactation  stimulant  as  well  (Yoshikawa  et  al.  1997). In  Iranian
traditional medicine the seeds have been used as a blood sugar lowering
herb  (Amin  Gh.  Popular  medicinal  plants  of  Iran.  Tehran:  Vice-
choncellor of Research of Tehran University of Medical Sciences, 1991,
pp: 101 – 2).
The possible  hypoglycemic  properties  of  oral  fenugreek seed powder
have been suggested by the results  of  preliminary animal  and human
trials.  The studies  showed that  defatted seeds  are  associated with the
hypoglycemic effects of fenugreek seeds. These effects have not been
observed in studies of lipid extracts (Basch  et al. 2003).
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Fig 1.8. Trigonella  foenum-graecum (Fenugreek) (Prof.  Dr.  Otto Wilhelm Thomé
Flora von Deutschland, Österreich und der Schweiz 1885, Gera, Germany)
Administration of 100 g of defatted  fenugreek seed powder to people
with  type  1  diabetes  in  10  days  showed  significant  amelioration  in
diabetes  associated symptoms  (Sharma  et al. 1990). Another study on
patients  with  type  2  diabetes  showed  that  fenugreek  seed  powder
administration for 6 weeks reduced blood glucose and cholesterols (Abu
Saleh  et al. 2006). Some studies conducted on  fenugreek have focused
on investigating the effect of a specific sub-fractions of the  fenugreek
seeds containing a unique amino acid known as 4-hydroxyisoleucine in
animals  and  humans  with  diabetes  or  lipid  disorder  (Fenugreek  seed
bioactive compositions and methods for extracting same. United States
Patent 7338675). 
The  previous  works  on 4-hydroxyisoleucine  proved that  it  acts  as  a
potent blood sugar lowering and anti-dyslipidemic agent  (Broca  et al.
2004, Sauvaire et al. 1998, Al-Habori et al. 1998). 4-hydroxyisoleucine
is a branch amino acid which has been extracted from fenugreek seeds
and it has not been found in any mammalian tissues  (Fig 1.9 &Table
1.3), or in other plants.
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A                                                                                   B
Fig 1.9.  A:  (2R,3R,4S) 4-Hydroxyisoleucine.  B: (2S,3R,4S) 4-Hydroxyisoleucine.
(Adapted from Toronto Research Chemicals Inc, http://www.trc-canada.com)
CAS Number 781658-23-9
IUPAC Name 2-amino-4-hydroxy-3-
methylpentanoic acid 
Synonym 2-Amino-2,3,5-trideoxy-3-methyl-D-
xylonic Acid 
Major Isomer (2S,3R,4S)-4-Hydroxyisoleucine 
Minor Isomer (2R,3R,4S)-4-Hydroxyisoleucine
Molecular
Formula
C6H13NO3
Molecular Weight 147.17g/mol
Melting Point >203°C
Table 1.3. 4-Hydroxyisoleucine chemical specifications. 
The  studies  have  confirmed  the  presence  of  4-hydroxyisoleucine  in
fenugreek seeds in two diastero-isomers: the major one is the (2S, 3R,
4S)  configuration,  representing  about  90% of  the  total  content  of  4-
hydroxyisoleucine in the  fenugreek seeds extract, and the minor one is
the (2R, 3R, 4S) configuration (Alcock et al. 1989). The major isomer is
presently interesting with respect to experimental evidence indicating its
ability  to  stimulate  glucose-induced  insulin  secretion  in  micromolar
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concentrations (Sauvaire et al. 1998). 
Some studies claimed that the natural analogue of 4- hydroxyisoleucine
is more effective as an anti-diabetic agent than a synthetic version. There
is,  therefore,  a  suggestion  that  the  therapeutic  effects  of  4-
hydroxyisoleucine are best obtained from extracts of the fenugreek seeds
(Fenugreek  seed  bioactive  compositions  and  methods  for  extracting
same.  United  States  Patent  7338675).  But  another  study  has  shown
synthetic  and  natural  4-hydroxyisoleucine  are  same  in  hypoglycemic
properties. (Rolland-Fulcrand et al. 2004) 4-hydroxyisoleucine is safe to
be consumed by human without geneotoxicity as tested based on FDA
(US  Food  and  Drug  Administration)  protocols  and  recommended  4-
hydroxyisoleucine for food ingredients (Flammang et al. 2004). 
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1.10 Isoleucine
Isoleucine (Ile) is an essential α-amino acid that cannot be synthesized by
humans. It is hydrophobic due its hydrocarbon side chains. Isoleucine
can have four possible stereoisomers but in nature it exists only as  one
enantiomeric form, (2S,3S)-2-amino-3-methylpentanoic acid. Isoleucine
is a glucogenic amino acid involved in the metabolism of carbohydrate
which can be converted to succinyl-CoA and acetyl-CoA and fed to the
TCA cycle (Tricarboxylic Acid Cycle) (Fig 1.10) (Table 1.4) (Tappy et
al. 1992).
 
Fig 1.10. L-Isoleucine. (Adapted from Sigma Aldrich, http://www.sigmaaldrich.com)
CAS Number 73325
IUPAC Name (2S,3S)-2-Amino-3-methylpentanoic
acid 
Molecular
Formula
C6H13NO2 
Molecular Weight 131.17g/mol
Table4. L-Isoleucine chemical specification.
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In-vivo study shows that isoleucine has hypoglycaemic properties and
can lower the blood glucose level and its hypoglycaemic effect reduces
when its blood level concentration reaches saturation (Doi  et al. 2007).
Both  Isoleucine  and  4-hydroxyisoleucine  with  very  close  molecular
structure  has  got  anti-diabetic  effects  (Ikehara  et  al.  2008) but
isoleucine's hypoglycaemic effect is not dependent on the concentration
of   glucose  as  4-hydroxyisoleucine  glucose  lowering  effect  is  only
observed in high glucose concentration. It seems the extra OH group in
4-hydroxyisoleucine creates some unique anti-diabetic properties which
are not  seen in isoleucine.  
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1.11 Background (4-Hydroxyisoleucine)
Diabetes is a progressive multi-factorial metabolic disease with serious
short and long term complications affecting different organs in the body
with high increasing prevalence in the world. Understanding the basis of
pathogenesis of diabetes specially type 2 diabetes which includes more
than 90% of diabetes cases worldwide and finding effective remedies are
very  important  as  perspective  of  public  health.  It  puts  any  potential
substances with anti-diabetic effect in the centre of attention in point of
view of researchers in relative fields.  Fenugreek seeds as mentioned in
the last chapter has got a strong historical track in traditional medicine of
several  cultures  in  Asia  and middle-east  for  treatment  of  people  with
diabetes symptoms. 
Sharma in 1990 fed  type 1 diabetes patients  with 100 g of  defatted
fenugreek seed powder per day divided in two doses for 10 days and
results showed a significant decrease in fasting blood glucose level, 54%
reduction in  24 hour  urinary glucose excretion and improved glucose
tolerance test. It also indicated that serum total cholesterol, LDL, VLDL
and triglyceride have been significantly modified after 10 days without
any changes in HDL level (Sharma et al. 1990). 
Another study of using 25 g twice a day of fenugreek seed powder in 30
type 2 diabetes patients with hyperlipidemia for 6 weeks showed that
serum  total  cholesterol,  LDL  and  triglyceride  have  been  reduced
significantly  compared  to  control  group  but  the  HDL level  remained
unchanged (Abu Saleh et al. 2006). 
Gupta  et  al  tested  the  effect  of  1  gm/day  hydroalcoholic  extract  of
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fenugreek seeds on 25 newly diagnosed type 2 patients which showed a
reduction in blood glucose level, an increase in insulin sensitivity using
HOMA-model1 insulin resistance and decrease in triglyceride after two
months treatment.  In this study they observed an increase in HDL level
in the treatment group as well (Gupta et al. 2001).
Analava et al showed that anti-diabetic and anti-dysplipidemic effect of
fenugreek seed powder is dose dependent and consuming more than 75
g/day  can  not  produce  significant  differences  in  its  effect  on  blood
glucose level. The blood glucose lowering effect between 75 g and 100 g
a day remained unchanged (Analava et al. 2006). 
It  was  important  question  to  determine  what  is  responsible  for  anti-
diabetic and anti-dyslipidemic effect of fenugreek seed powder or extract
which well established in several studies. In 1979, Hardman detected 4-
hydroxyisoleucine and its isomers in fenugreek seed extract (Hardman et
al. 1979). This unique amino acid which only existed in fenugreek seed
and has been never found in any mammalian tissues or other plants up to
now, drew the attention of researchers. It could be responsible for such
effect of fenugreek seed. 
There  is  no  strong  evidence  that  shows  fenugreek  leaves  extract
producing such effects. It strengthened the idea that these effects may be
1 Homeostatic model assessment (HOMA) has been described by  Matthews et al in 1985 and widely
employed in clinical research to assess insulin sensitivity. HOMA is calculated as the product of the
fasting values of glucose (expressed as mg/dL) times insulin (expressed as µU/mL) is divided by a
constant (405): HOMA= Glucose x Insulin /405. The constant 405 should be replaced by 22.5 if
glucose is expressed in S.I. units.  The HOMA calculation compensates for fasting hyperglycaemia.
HOMA and insulin values  increase in the insulin-resistant patient  while the Glucose/Insulin ratio
decreases. The HOMA value correlates well with clamp techniques and has been frequently used to
assess changes in insulin sensitivity after treatment.( Matthews et al. 1985)
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related to 4-hydroxyisoleucine as it is not that much inside the leaves. 
In  1998,   Sauvaire  Y  et  al  characterised  4-hydroxyisoleucine  from
fenugreek  seeds  and  showed  its  anti-diabetic  effect.  Their  study  of
administration of 4-hydroxyisoleucine directly to rat pancreas revealed
insuliotropic  effect  of  4-hydroxyisoleucine  in  the  concentration  range
100  micromol/l  to  1mmol/l.  They  also  determined  that  4-
hydroxyisoleucine effect on stimulating insulin secretion from islets of
Langerhans in pancreas strictly dependent on glucose concentration. 4-
hydroxyisoleucine insulin stimulatory is ineffective in 3 and 5 mmol/l
concentrations  of  glucose.  Insulin  secretion  is  induced  by  4-
hydroxyisoleucine  at  6.6  to  16.7  mmol/l  of  glucose  concentrations
(Sauvaire et al. 1998).
Broca and his colleagues in 1999 demonstrated that  administration of
50mg/kg/day  of  4-hydroxyisoleucine  to  type  2  diabetes  rat  model
significantly reduces basal hyperglycaemia and basal insulinemia. It also
improved glucose tolerance test. They showed that 4-hydroxyisoleucine
with concentration of 200 micromol/l induces insulin release from type 2
diabetic rat-isolated islets in exposure to high glucose concentration of
16.7 mmol/l (Broca et al. 1999). In 2000, Broca et al observed that the
insuliotropic  property  of   4-hydroxyisoleucine  only  seen  in  the
micromolar  range  of  major  isomer  (2S,3R,4S)-4-hydroxyisoleucine
(Broca et al. 2000). In 2004, Broca investigated extra-pancreatic effect of
chronic 4-hydroxyisoleucine treatment in insulin resistant Zucker fa/fa
rats and sucrose-lipid diet fed rats. 
Study results demonstrated that 4-hydroxyisoleucine increases peripheral
glucose utilization and decrease insulinemia in sucrose-lipid diet fed rats
and  reduces  hepatic  glucose  production  and  progression  of
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hyperinsulinemia in  insulin resistant Zucker fa/fa rats. He also showed
that  a  single  injection  of  18  mg/kg  of  4-hydroxyisoleucine  increased
PI3Kinase activity associated with IRS-1 in both muscle and liver same
as insulin. Combining insulin and 4-hydroxyisoleucine did not increase
PI3Kinase activity further. This study indicated that 4-hydroxyisoleucine
has got insulin sensitizing property as well and increases insulin effect
on utilizing peripheral  glucose via interaction with early signalling of
insulin (Broca et al. 2004). 
Fenugreek seed extract containing minimum 40% 4-hydroxyisoleucine
tested for genetic toxicity by Flammang et al from Abbott laboratories in
America  based  on  recommended  US  Food  and  Drug  Administration
(FDA)  genetic  toxicity  evaluation  protocols  using  a  reverse  mutation
assay,  mouse  lymphoma  forward  mutation  assay  and  mouse
micronucleus  assay.  The  negative  assays  results  demonstrated  that
fenugreek seed extract and 4-hydroxyisoleucine are not genotoxic and
safe to be consumed by human (Flammang et al. 2004). 
There  are  some  controversies  in  studies  of  4-hydroxyisoleucine  on
skeletal  muscle  glycogen  re-synthesis.  Ruby  et  al  evaluated  oral
fenugreek  seed  extract  containing   4-hydroxyisoleucine  with  glucose
drink and dextrose on trained male cyclist post-exercise skeletal muscle
glycogen resynthesis after 90 minutes intense ride. They found that  4-
hydroxyisoleucine  plus  glucose  increases  the  rate  of  glycogen
resynthesis  by  63%  compared  to  glucose  alone.  Results  of  dextrose
showed  the  glycogen  re-synthesis  significantly  enhanced  by   4-
hydroxyisoleucine compared to dextrose alone (Ruby et al. 2005). They
repeated the experiments few years later by changing the protocol from
90 minutes intense exercise to 5 hours at 50% of peak cycling powder
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and they reported that  4-hydroxyisoleucine does not improve glycogen
resynthesis. They suggested that the difference between the results of the
current study with previous work is due to differences in experimental
protocol.  Interestingly,  comparison  both  study  findings  shows  that  4-
hydroxyisoleucine  is  effective  in  enhancing  glycogen  re-synthesis  in
high intensity muscle activity rather than long term low intensity muscle
exercise (Slivka et al. 2008).  
It  is  suggested  that 4-hydroxyisoleucine  supplement  has  preventive
efficacy on obesity induced by high fat diet as shown in animal study
that  4-hydroxyisoleucine  reduces  body  weight  gain  and  plasma
triglyceride  gain  in  obese  fat  induced  by  high  fat  diet  and  oil
administration  treated  with  fenugreek  seed  extract  containing  4-
hydroxyisoleucine  (Handa  et al. 2005). It has also been shown that  4-
hydroxyisoleucine  significantly  decreases  plasma triglyceride  level  by
33%, serum total cholesterol by 22%  and plasma free fatty acid by 14%
in dyslipidemic hamster (Narender et al. 2006). 
Haeri et al in 2009 showed that long term treatment of fructose-fed rats
(insulin resistance model) and streptozotocin-induced diabetes type 2 rats
with  50  mg/kg/day  4-hydroxyisoleucine  for  8  weeks  restored
significantly  elevated  liver  damage  markers  including  aspartate
transaminase  (AST)  and  alanine  transaminase  (ALT)  to  near  control
group  values  in  fructose-fed  rats  but  not  in  streptozotocin-induced
diabetes  type  2  rats.  They  also  showed  long  term treatment  with  4-
hydroxyisoleucine  is  well  tolerated  in  both  models  and  4-
hydroxyisoleucine  increased  HDL  level  in  streptozotocin-induced
diabetes  type  2  rats  by  31%  compared  to  control  group  (Haeri  et
al.2009). 
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Singh and his colleagues in 2010 published a study using 50 mg/kg/day
4-hydroxyisoleucine isolated from fenugreek seeds on C57BL/KsJ-db/db
mice.  They  observed  that  4-hydroxyisoleucine  significantly  decreases
elevated blood glucose level, total cholesterol, LDL and triglyceride in
well-characterised  type  2  diabetes  mice  model.  They  also  noticed  a
significant increase in HDL level. It was suggested in this study that 4-
hydroxyisoleucine  suppresses  progression  of  type  2  diabetes  by
increasing insulin  sensitivity  and peripheral  glucose  uptake  (Singh  et
al. 2010). 
A recent  published  study  by  Jaiswal  N  et  al  on  rat  L6-GLUT4myc
skeletal muscle cells treated with 5 and 25 µ/ml 4-hydroxyisoleucine for
16  hours  showed  that  4-hydroxyisoleucine  significantly  and  dose
dependently  increases  glucose  uptake  and  time  dependently  GLUT4
translocation from plasma to the membrane of the cells after adding 100
nM insulin for 20 minutes. It was observed that incubation cells with 4-
hydroxyisoleucine and insulin together for 16 hours has not significant
effect  on  insulin-induced  GLUT4  translocation  compared  to  insulin
alone as a control. Treatment with 4-hydroxyisoleucine did not change
the cellular contents of GLUT1 and GLUT4 which prove that its effect
on glucose uptake is due to modification of signalling leads to GLUT4
translocation.  4-hydroxyisoleucine-induced  GLUT4  translocation
completely blocked by adding 1 µ/ml of cycloheximide (CHX) which is
a  potent  protein  synthesis  inhibitor.  Cycloheximide  (CHX)  can  not
inhibit GLUT4 translocation alone and it was suggested that  the increase
in  GLUT4 translocation  by  4-hydroxyisoleucine  requires  synthesis  of
new proteins. It is also shown that adding wortmannin, a potent inhibitor
of  PI  3Kinase  inhibits  the  4-hydroxyisoleucine-induced  GLUT4
translocation,  which  identifies  the  key  role  of  PI  3Kinase  in  4-
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hydroxyisoleucine  effect.  4-hydroxyisoleucine  also  significantly
increased  Akt  (PKB)  basal  phosphorylation  same  as  insulin  without
changing the mRNA expression of  Akt  (PKB),  IRS-1 and GLUT4 in
genetic level. This work confirms the effect of 4-hydroxyisoleucine on
utilizing  peripheral  glucose  and  increasing  insulin  sensitivity  via  its
signalling  pathway  as  demonstrated  in  previous  studies  (Jaiswal  et
al. 2012).
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1.12 Background (Isoleucine)
Ikehara and his colleagues published an animal study in 2008 about the
effect of L-isoleucine in diabetes. They treated glucose intolerant high-
fat diet (HFD) mice, severe type 2 diabetes db/db mice and normal mice
with oral isoleucine at a dose of 30-300 mg/kg for 6 weeks. The results
showed  that  isoleucine  significantly  and  dose-dependently  decreases
blood  glucose  level  in  all  groups  including  normal  mice.  It  also
significantly increases blood insulin levels only in high-fat diet (HFD)
mice  but  not  in  other  groups  which  suggests  different  mechanisms
involved  in  hypoglycemic  property  of  isoleucine  apart  from  its
insulinotropic  activity  on  HFD  mice.  Insulin  release  dramatically
reduced in high-fat diet (HFD) mice treated chronically with isoleucine
after an oral glucose challenge without any changes in glucose tolerance
curve  which  indicates  insulin-sensitizing  property  of  isoleucine.  This
study determined that both insulin secretion dependent and independent
mechanisms  are  involved,  but  based  on  results,  insulin  secretion
independent  mechanism is  playing a  major  role  in  its  hypoglycaemic
effect specially in normal and sever diabetic conditions  (Ikehara  et al.
2008). 
There  is  evidence  the  L-isoleucine  increases  insulin  release  from
pancreatic beta cells when added together with L-glutamine (Sener et al.
1981).  In-vitro study  on  muscle  C2C12  myotubes  in  the  absence  of
insulin  showed that  isoleucine  with  concentration  1  mM significantly
increased glucose consumption by 16.8% compared to control and l mM
leucine.  Isoleucine  did  not  increase  glycogen  synthesis  compared  to
leucine which significantly increased intra cellular glycogen synthesis.
The study also suggested that isoleucine stimulates insulin-independent
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glucose  uptake  mediated  by activating  PI3Kinase  and  independent  of
activation of mammalian target of rapamycin (mTOR) like leucine which
is  a  potent  activator  of  mTOR (Doi  et  al.  2003,  Zhang  et  al. 2007).
Another study by Doi et al showed that oral administration of 1.35 g/kg
L-isoleucine  to  fasted  rats  for  18  hours  significantly  reduced  blood
glucose level compared to 1.35 g/kg L-leucine and control. L-leucine did
not change the blood glucose level. Isoleucine  increased skeletal muscle
glucose uptake by 73% without changing glycogen synthesis and AMKP
alpha-1(  AMP-activated  protein  kinase).  In  contrary  leucine  increased
glucose incorporation into glycogen without changing AMKP alpha-1.
Isoleucine but not leucine significantly reduced AMKP alpha-2 activity.
The study suggested that reduced AMPK alpha-2 activity by isoleucine
administration is due to decrease in AMP content and the AMP/ATP ratio
probably because of improvement of ATP availability (Doi et al. 2005).
Isoleucine has been shown to increase the expressions of PPAR-α and
uncoupling protein  2  and  3  (UCP)  in  high fat  diet  rats  treated  for  6
weeks.  Hepatic  and  skeletal  muscle  triglyceride  concentration  and
hyperinsulinemia  were  significantly  lower  in  isoleucine  treated  rats
which show isoleucine is effective in modifying metabolic syndrome and
preventing obesity (Nishimura et al. 2010).
50
1.13 Summary 
It is well documented that both 4-hydroxyisoleucine and isoleucine have
anti-diabetic and anti-dyslipidemic effects. Previous studies have shown
both  of  these  molecules  have  insulinotropic  and  insulin-sensitizing
properties which are effective in diabetic and obesity conditions but still
their mechanisms of action remain unclear. Two main differences, based
on  well  established  studies,  exist  between  isoleucine  and  4-
hydroxyisoleucine in their mode of action as following:
• Isoleucine  elicits  its  significant  hypoglycaemic  and  anti-
dyslipidemic actions at a higher dose above 100mg/kg (Ikehara et
al. 2008) compared to 4-hydroxyisoleucine which is effective at a
much lower dosage.
• The most important difference between these two molecules is that
isoleucine is hypoglycaemic and anti-dyslipidemic activity is not
dependent on glucose concentration and it can produce its effects
in  normal  euglycemic  conditions  whereas  the  anti-diabetic  and
anti-dyslipidemic  activity  of  4-hydroxyisoleucine  is  completely
dependent on glucose concentration and it  is inactive at normal
glucose concentration less than 6.6 mmol/l. 4-Hydroxyisoleucine's
effects  have  a  direct  correlation  with  glucose  concentration  in
which higher glucose concentration creates more profound effects
of 4-hydroxyisoleucine (Sauvaire et al. 1998). This feature makes
the 4-hydroxyisoleucine a unique molecule with higher safety  and
without  any  hypoglycaemic  side  effect  in  normoglycemic
conditions,  unlike  most  available  anti-diabetic  medications  like
sulfonylureas.
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All available information about the action of 4-hydroxyisoleucine and
isoleucine are summarised in the following table (Table 1.5). After two
decades  from  identification  of  4-hydroxyisoleucine  with  unique
properties  from fenugreek seed extract  still  many  questions  remained
unanswered  and  mechanisms  involve  in  its  glucose  dependent  anti-
diabetic and hyperlipidemia modifying properties has not been clarified
yet.  Understanding  mechanisms  and  modes  of  4-hydroxyisoleucine's
actions not only important of its use in management of diabetes but it is a
great  help  to  understand  the  fundamental  metabolic  and  molecular
pathogenesis and pathophysiology of diabetes which help in designing
new remedies and management approach. All the previous works well
demonstrated the significant hypoglycaemic and lipid lowering activity
of  4-hydroxyisoleucine  in  both  in-vivo and  in-vitro conditions  in  the
presence  of  insulin  which  mean  4-hydroxyisoleucine  augments
peripheral  activity  of  insulin  on glucose  uptake.  It  is  claimed that  4-
hydroxyisoleucine anti-diabetic and anti-dyslipidemic activities are due
to its insulinotropic and insulin-sensitizing properties in type 2 diabetes. 
There is not sufficient published data about 4-hydroxyisoleucine efficacy
on type 1 diabetes or any high glucose condition without the presence of
insulin.  There  is  also  no  study  on  modifying  effect  of  4-
hydroxyisoleucine on uric acid level which rises in diabetic conditions
specially type 1 diabetes and it is directly linked to diabetic nephropathy
(Rosolowsky et al. 2008). 
52
Effect Fenugreek
Seed Extract 
4-Hydroxyisoleucine Isoleucine
Blood Glucose level ↓ (Effective in
diabetic, not
normal blood
glucose level)1
↓ (Effective in diabetic,
not normal blood glucose
level) 4
↓(Effective in both
diabetic and
normal blood
glucose level)8
Total Cholesterol ↓1 ↓4 No Data
LDL (Low Density 
Lipoprotein)
↓2 ↓4 No Data
HDL (High Density 
Lipoprotein )
↑/No change3 ↑/No change5 No Data
Triglyceride ↓ ↓4 ↓9
Uric Acid No Data No Data No Data
Glucose Uptake ↑1 ↑4 ↑8
Glut4 Translocation No Data ↑6 No Data
PI3 Kinase activity No Data ↑7 ↑(Not
Confirmed)10
Glucose Concentration 
Dependent 
No Data Yes4 No
Insulinotropic No Data Yes4 Yes8
Insuin-sensitizing Action Yes1 Yes4 Yes8
Insulin-independent 
hypoglycaemic activity
No Data No Data Yes8
Table 1.5. Summary of findings about fenugreek seed extract, 4-hydroxyisoleucine
and isoleucine based on previous studies covered in the background section.
1- Sharma et al. 1990, Abu saleh et al. 2006, Analava et al. 2006
2- Narendar et al. 2006          3- Gupta et al. 2001 
4- Sauvaire et al. 1998, Broca et al. 1999 and 2000 
5- Singh et al. 2010                6- Jaiswal et al. 2012        7- Broca et al. 2004
8-Ikehara et al. 2008              9- Nisimura et al. 2010      
10- Doi et al. 2003, Zhang et al. 2007 
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1.14 Questions  and study design notions 
The  study  in  this  work  was  designed  to  investigate  the  anti-diabetic
properties of 4-hydroxyisoleucine in-vivo and in-vitro with minimised
insulin effect.  
Question 1: Is 4-hydroxyisoleucine capable of decreasing blood glucose
level and modify dyslipidemia, as studied in previous works in type 2
diabetes or insulin-resistant animal models in type 1 diabetes model with
minimal insulin presence? If yes, is it effective in modifying the uric acid
level as well as plasma glucose and lipid levels?
Finding the answer for question 1 is very important which shows that 4-
hydroxyisoleucine is dependent on insulin for its action or not for the
first time in animal models.
Broca  showed  that  infusion  of  4-hydroxyisoleucine  directly  to  rat
isolated pancreas islet cells with high concentration glucose stimulates
insulin release (Broca et al. 1999) but there is no other study about the
direct effects of 4-hydroxyisoleucine on pancreatic beta cells. It has been
shown that isoleucine stimulates insulin secretion as well but there is no
direct study on beta cells.
Question 2:  Does 4-hydroxyisoleucine increase insulin secretion from
beta cells in the presence of different concentrations of glucose? Does it
increase  the  consumption  of  glucose  (Uptake)  in  beta  cells?  Does
isoleucine increase the insulin secretion and glucose consumption in beta
cells?  If yes is is  it  dependent  on glucose concentration? Is  isoleucin
action dependent on glucose concentration same as 4-hydroxyisoleucine?
The  reason  behind  the  question  2  is  based  on  the  fact  that  insulin
secretion  has  got  direct  correlation  with  glucose  concentration  and
glucose uptake by beta cells as explained in the early part under insulin
secretion section.
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There are evidences that 4-hydroxyisoleucine activates insulin signalling
via increasing phosphorylation of PI3Kinase and Akt. It also has been
demonstrated that 4-hydroxyisoleucine modulates glucose consumption
by increasing GLUT4 translocation mediated by PI3Kinase in glucose
disposal  cells  including  adipose  tissue  and  muscle  cells  (Jaiswal  et
al. 2012).  The  previous  study  about  isoleucine  suggested  isoleucine
activates  PI3Kinase and reduces the activity  of  AMPK alph-2 due to
decrease of AMP and ATP improvement (Doi et al. 2005). 
Question 3:  In beta cells GLUT4 is not the major glucose transporter,
and  GLUT1  and  GLUT2  are  mainly  responsible  for  glucose
transportation.  If  the  4-hydroxyisoleucine  and  isoleucine  increase
glucose consumption in beta cells, it is possibly related to GLUT1 and
GLUT2.  Does  inhibition  of  PI3  Kinase  in  beta  cells  affect  glucose
consumption  in  beta  cells  treated  with  4-hydroxyisoleucine  and
isoleucine?
Based  on  available  knowledge  of  biochemistry  how  can  we  find  a
unified explanation for all the effects of 4-hydroxyisoleucine mentioned
in table 5 considering its  glucose dependency mode of  action? Many
studies found that most of these activities can be explained by the energy
content  of  the  cell.  All  the  signalling  pathways  within  the  cells  are
handled by a group of enzymes, which are activated and deactivated by
phosphorylation and ATP is the major source of this phosphorylation.
Logically, if the ATP/ADP ratio within the cell is increased by converting
more  ADPs  to  ATPs,  it  is  probable  that  many  of  these  sensitizing
activities happens. Our aim was to identify any connection between 4-
hydroxyisoleucine and isoleucine and ATP within the cells.
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Question  4: Do  4-hydroxyisoleucine  and  isoleucine  increase  ATP
production and ATP content of  beta cells? If yes, can they create the
same  effect  in  other  cell  types  like  HepG2 as  a  cancerous  cell  with
minimal  aerobic  respiration?  Does  PI3Kinase  inhibitor  affect  ATP
production in beta cells treated with 4-hydroxyisoleucine and isoleucine?
As explained before insulin release is completely and directly regulated
by the ATP/ADP ratio.  As previous  studies  claimed on insulinotropic
effect  of  both  4-hydroxyisoleucine  and isoleucine,  this  effect  may  be
connected to the ATP level within the pancreatic beta cells. This was the
concept for selecting beta cell as a model to address question 4.  
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Chapter II
Material and Methods
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Part I
Animal Trial
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2.1 Animals
Male  Wistar  rats  were  purchased from the  Pharmacological  Research
Centre of Tehran University of Medical Sciences. Eight week-old rats
weighing between 220 and 250 g were used at the start of each treatment
protocol. Rats were housed in separate cages in an animal room kept at
constant temperature (25 ◦C) with a 12 h light–dark cycle. Standard rat
chow  pellet  and  water  were  provided  ad  libitum  throughout  the
experimental period. The animals were maintained in accordance with
the  Animal  Ethics  Committee  of  the  University  of  Medical  Science,
Qom, Iran. 
2.2 Preliminary Study
A preliminary  pre-experimental  screening,  animal  test  was  set  up  to
examine different streptozotocin (STZ) induction protocols for reaching
the optimized condition before proceeding to main experiment. The aim
of the project was to study the effect of 4-hydroxyisoleucine in an animal
model in which there was minimal insulin secretion. STZ was used to
reduce insulin secretion to make it  possible to study the effects of 4-
hydroxyisoleucine  on  glucose  metabolism  that  are  independent  of
insulin. STZ can be administered intravenously (iv) or intraperitoneally
(ip) to destroy pancreatic beta cells to create a diabetes type 1 rat model.
Intra-peritoneal administration is less effective than intravenous as inject
directly into the blood stream can produce a more profound effect with
lower dose but it was more suitable as it combines less risk of infection
and other  side  effects  in  rats  during long term experiments   because
direct  injecting  of  STZ to  vein  via  rat  tail  may  increase  the  risk  of
transferring germs directly to the blood stream and also there is no option
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to control bleeding after the injection. STZ was purchased from Sigma-
Aldrich  (London,  UK)  and  prepared  according  to  standard  protocols
(Motyl  et  al. 2009) by  mixing  STZ with  freshly  prepared  Na-citrate
buffer (1.47 g of Na-Citrate into 50 ml deionized water, adjusted PH to
4.5) immediately before injection. Eight rats with weight range of 190-
230 g were divided into four equal groups with two rats in each group.
STZ was injected with doses of single 60mg/kg, single 150 mg/kg and
60 mg/kg for five consecutive days. One group was allocated as control
without  STZ  injection  as  vehicle  control  (injecting  Na-citrate  buffer
without STZ). Glucose levels were measured using a micro-drop strip
glucometer (Accu-check,Germany) before the injection of STZ and five
days after injection to monitor glucose level. Glucometer was calibrated
by glucose solution prior to test to make sure accurate reading of blood
glucose. The blood glucose levels of all rats were in the range of 68 to 84
mg/dl as an indication of normoglycemic status as explained in chapter
3. Two weeks after receiving the injection rats were killed by volatile
inhalational  anaesthetics  (Ether)  using  gas  scavenging  apparatus  for
rodent and blood collected directly from the left  ventricle of heart by
blood sampling  vacutainer  for  glucose  and  insulin  measurement.  The
blood glucose level increased in all groups apart from the control group.
The blood insulin level was measured using an ELISA insulin kit (DRG
International, NJ, USA) to measure the amount of insulin five days after
the injection as described below.  
2.3 Main Experiment 
Rats  were  divided  into  three  groups  each  of  six,  comprising  normal
controls (NC),diabetic controls (D) and diabetic rats treated with 4HO-
Ile (D4H). Rats were rendered type 1 diabetic by intraperitoneal injection
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of streptozotocin (60 mg/kg) dissolved in 0.1 M citrate buffer (pH 4.5)
for five days consecutively (Motyl  et al. 2009). After one week blood
glucose concentration was measured with a Glucometer  on a drop of
blood from the tail. Rats were considered to be diabetic if blood glucose
levels were greater than 300 mg/dl. The treatment group of diabetic rats
were intubated daily  with a  solution  of  4-hydroxyisoleucine  in  saline
(Extracted  from  fenugreek  seeds  with  98%  HPLC  purity).  4-
Hydroxyisoleucine  was  a  preparation  extracted  from fenugreek  seeds
with 98% HPLC purity (Haeri  et  al.  2009),  and was given at  a dose
equivalent  to  50  mg/kg/day  for  four  weeks.  Normal  control  rats  and
diabetic control rats were intubated with an equivalent volume of saline
alone. 
2.4 Insulin Assay 
The Blood samples immediately centrifuged at  1000 × g for  15 min.
Plasma  was  removed  and  stored  at  −20  ◦C  and  insulin  level  was
measured  in  each  sample  by  DRG  Insulin  ultra  sensitve  ELISA Kit
(DRG International,  NJ,  USA) which  is  a  solid  phase  enzyme-linked
immunosorbent  assay  (ELISA)  based  on  the  sandwich  principle  with
measurement range of 0.02 to 5.5  μg/l . The microtiter wells of kit are
coated with a monoclonal antibody directed towards a unique antigenic
site on the Insulin molecule. 
25 μL of each standard, control and samples were dispensed with new
disposable  tips  into  appropriate  wells.  25  μL enzyme  conjugate  was
added into each well and thoroughly mix for 10 second following 30
minutes incubation at room temperature. 50 μL of enzyme complex were
added to each well after 3 times wash with a diluted wash solution (400
μL per well) and incubated at room temperature for 30 minutes. 50 μL of
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substrate  solution  were  added  to  each  well  after  3  times  wash  and
incubated at room temperature for 15 minutes. Enzymatic reaction was
stopped by adding 50 μL of stop solution to each well and absorbance
(OD) of each well was measured at 450 ± 10 nm with a microtiter plate
reader.  A  standard  curve  was  constructed   by  plotting  the  mean
absorbance obtained from each standard against its concentration with
absorbance  value  on  the  vertical  (Y)  axis  and  concentration  on  the
horizontal (X) axis. The concentration of the samples was read directly
from this standard curve. 
2.5 Serum lipid profile, glucose and uric acid 
At the end of the experiment rats were  killed by volatile inhalational
anaesthetics (Ether) using gas scavenging apparatus for rodent and blood
samples were collected by cardiac puncture from the left ventricle into
heparinised tubes and immediately centrifuged at  1000 g for  15 min.
Plasma  was  removed  and  stored  at  −20  °C.  Fasting  plasma  glucose,
triglyceride,  cholesterol  and  LDL concentration  were  measured  on  a
fully  automated  autoanalyser  (Biosystem,  Spain)  by  the  university  of
Qom's medical school reference laboratory.
Plasma uric acid was measured using a timed endpoint method on a fully
automated Beckman Coulter Synchron LX20 clinical system which is an
automated computer-driven, general chemistry analyser designed for the
in vitro determination  of  a  variety  of  general  chemistries,  therapeutic
drugs, and other chemistries (Rosolowsky  et al.  2008). The tests were
done  and  verified  by  university  of  Qom's  medical  school  reference
laboratory.
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2.6 Statistical analysis 
Data were analysed using SPAW version 18.0 and are expressed as mean
± SD. ANOVA with Tukey and Bonferroni post hoc tests were used to
determine  significance  of  differences  between  groups.  Preventing  the
type  I  error  (considering  significant  a  difference  that  actually  isn't
significant)  was  the  main  reason  we  chose  to  use  both  Tukey  and
Bonferroni post hoc approaches. We tested all the results with Bonferroni
and repeated the analysis with Tukey test to make sure that we make a
correct translation of the results by eliminating type 1 error. P < 0.05 was
considered to be statistically significant. 
All the in-vitro results were analysed using only Bonferroni post hoc test.
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Part II
Laboratory In-vitro Studies
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2.7 Cell line and cell culture 
BRIN-BD11  is  a  hybrid  pancreatic  islet  cell  line  formed  by  the
electrofusion of a primary culture of NEDH rat pancreatic islets with
the rat insulinoma cells (RINm5F cell line). BRIN-BD11 is a stable,
glucose-responsive insulin secreting beta cell line expressing insulin,
glucokinase, Islet Amyloid Polypeptide (IAPP or Amylin) as detected
by  immunocytochemistry,  and  also  expresses  the  GLUT2  glucose
transporter (McClenaghan  et al. 1996). BRIN-BD11 was purchased
from the HPA (Health Protection Agency, United Kingdom). 4 x 104
Cells  were cultured in  RPMI1640 with 2 mM glutamine and 10%
FCS containing 11 mM glucose and incubated in 5% CO2  at 37°C.
The  cell  population  doubled  approximately  within  24  hours  and
reached more than 80% confluency within 48 hours in a 75 cm2 flask.
Cells were seeded for experiments in 24 well plates at 300,000 cells in
each well in 2 ml normal RPMI-1640 with 11 mM glucose for 24
hours  (more  than  80%  confluent).  The  medium  was  replaced  by
RPMI-1640 with 2 mM glutamine and 10% FCS containing 22 mM
glucose  and  loaded  with  treatment  compounds  at  different
concentrations, incubated for 24 hours with 5% CO2 at 37°C. All the
inhibitors and activators used in the current study were loaded at the
same time as  isoleucine  and  4-hydroxyisoleucine  added  to  culture
media.  The glucose concentration of medium with 22 mM glucose
was  measured  each  time  before  loading  using  an  optimized
glucometer as described below in order to create a baseline for the
glucose concentration at zero time.
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2.8 Glucose measurement
Glucose levels in the cell culture medium were measured using code-
free  glucooxygenase  based  strip  technology.  The  glucometer
measurement  accuracy  was  evaluated  by  50  independent
measurements of glucose in RPMI-1640 containing 11 and 22 mM
glucose separately.  The uncertainty  intervals  and relative deviation
from true value were calculated by following formulation:
Uncertainty Intervals = (highest reading value – Mean)+(Mean- lowest reading value) 
Relative Deviation = [(Mean – True Value)/True Value] x 100
The  test  showed  that  the  machine  reading  achieved  uncertainty
intervals  of  0.5  and  0.3  mM and  relative  deviation  of  8.34% and
4.29% in 11 and 22 mM RPMI-1640 respectively. The consistency
and accuracy of reading were important as we used the technique to
compare glucose changes in the medium. The glucose level of each
sample of cell culture medium was measured three times using the
same batch of strips and corrected using relative deviation.
2.9 ATP assay 
Cell ATP content was measured by a colorimetric assay from Abcam
(Cambridge,  UK)  using  the  manufacturer’s  standard  protocol  as
follows:
300,000 cells were lysed using 100 µl ATP assay buffer provided in
the kit and centrifuged at 15,000 x g and at 4ºC for 2 minutes to pellet
insoluble materials. 50 µl of supernatant was added to each well of a
96-well plate, and the final volume adjusted to 100 µl by adding 50 µl
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ATP assay buffer. 50 µl of ATP reaction mix  containing 44  µl  ATP
assay buffer, 2 µl ATP probe, 2 µl ATP converter and 2 µl developer
mix which prepared based on manufacturer protocol provided in the
kit,  was added to each well and incubated for 30 minutes at room
temperature.  A standard  curve  was  prepared  using  the  standards
provided  standards  in  the  kit  with  the  range  of  0  to  10  nmol.
Absorption was measured at 570 nm using BMG Labtech FLUOstar
reader.
2.10 Insulin measurement
Insulin in the medium was measured using an HTRF (Homogeneous
Time-Resolved  Fluorescence)  insulin  assay  kit  from  Cisbio
Bioassays,  (France) (Youl  et  al.  2010).  HTRF is  newly  developed
generic assay technology to measure analytes in a homogenous format
by  combining  fluorescence  resonance  energy  transfer  technology
(FRET) with time-resolved measurement (TR). In TR-FRET (HTRF)
assays,  a  signal  is  generated  through  fluorescent  resonance  energy
transfer  between a  donor  and  an acceptor  molecule  when in close
proximity  to  each other which significantly reduces the buffer  and
media interference using dual-wavelength detection. The final signal
is proportional to the extent of product formation which makes the
HTRF  assay  sensitive  and  robust  for  many  antibody-based  assays
including the insulin.
The HTRF® insulin assay is a sandwich immunoassay involving two
antibodies, one labeled with Europium Cryptate (Eu-K) and the other
with  cross-linked  allophycocyanin  (XL665).  As the  two antibodies
bind  to  insulin  molecules,  fluorescence  resonance  energy  transfer
(FRET) occurs between the Eu-K and XL665 tracers. This HTRF®
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signal  is  thus  proportional  to  the  insulin  concentration.  The
fluorescence emitted from the well is recorded at both 665nm (XL665
emission wavelength) and 620nm (Eu-K emission wavelength) in a
time-resolved  manner  to  differentiate  signal  from  the  medium
background and the free acceptor XL665 from the HTRF signal, using
a BMG Labtech FLUOstar plate reader using the following settings:
excitation  filter:  337  nm,  emission  filters:  620  nm  and  665  nm;
integration delay (lag time): 60 μs; Integration time:400 μs; number of
flashes: 200; gain: 2300 for 620 and 665 nm. The fluorescence ratio,
expressed as F665 / F620 x10,000, was calculated for each well in order
to  minimize  medium interferences.  A standard  curve  with  a  range
from 0 to 12.5 ng/ml was prepared using standard insulin supplied by
the manufacturer of the kit.
50 µl of each sample (Culture medium), 25 µl Ab-XL665 (supplied in
the kit) and 25 μL anti-insulin Ab-XL665 respectively, were added to
each  well  of  96  well-plate  and  covered  with  a  plate  sealer  and
incubated for 2 hours at  room temperature then the result  read  by
BMG Labtech FLUOstar plate reader.
2.11 Compounds
4-Hydroxyisoleucine: Synthetic 4-hydroxyisoleucine was purchased
from TRC, (Noth York, Canada) and had 98% purity as confirmed by
NMR spectroscopic and mass spectrometric analysis, according to the
manufacturer’s data  sheet.  It  contained  (2S,3R,4S)  4-
hydroxyisoleucine as the major isomer ( > 94%) and (2R,3R,4S) 4-
hydroxyisoleucine  as  the  minor  isomer  (<  4%).  100  mM  stock
solution was prepared in RPMI-1640 plain medium, filter sterilized
and stored at 4 °C.
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Isoleucine: Isoleucine  was  purchased  from  Sigma-Aldrich  (Poole,
UK) and had a purity of 99% (HPLC grade). 100 mM stock solution
in RPMI-1640 plain medium filter sterilized and stored at 4 °C.
Other compounds: the following table contains the list of  specialist
compounds used in experiments.
Name Molecular
Weight 
Effect Stock solution
Cycloheximide
(Abcam, UK)
281.35 Protein synthesis inhibitor 16mM (10X)
Kaempferol
(Abcam, UK)
286.24 Inhibition  of  topoisomerase-1,  MAO,
COX, estrogenic effects and activation
of the mitochondrial Ca2+ uniporter.
20mM 
KU 0063794
(Sigma-
Aldrich, UK)
465.5 Selective inhibitor of mammalian target
of rapamycin (mTOR) (IC50 ~10 nM
for mTORC1 and mTORC2). Displays
no activity at  PI 3-kinase or 76 other
kinases  tested.  Inhibits  activation  and
hydrophobic  motif  phosphorylation  of
Akt,  S6K  and  SGK,  but  not  RSK.
Suppresses cell growth and induces G1
cell cycle arrest in vitro. (10nM)
10mM
Ruthenium Red
(Abcam, UK)
786.35 Inhibitor  of  calcium  signalling  with
multiple  actions.  Inhibits  the
mitochondrial  Ca2+  uniporter,  Ca2+
dependent  ATPase,  troponin  C  and
calmodulin.  Attenuates  capsaicin-
induced  cation  channel  opening  and
inhibits  Ca2+  release  from
ryanodinesensitive  intracellular  Ca2+
stores.  Blocks  large-conductance  Ca2+
activated potassium channels. 
10 mM(10X) 
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STF-31
(Merck) 
423.5 A  cell-permeable  sulfonamide  that
selectively inhibits the growth of VHL-
deficient renal cell carcinomas (RCCs)
dose-dependently (0-5 μM) by directly
targeting  glucose  transporter  1
(GLUT1),  which  is  up-regulated  by
HIF  (hypoxia-inducible  factor)
transcription  factor  in  VHL-deficient
cells.  It  elicits  decreased  oxidative
phosphorylation  associated  with
aerobic  glycolysis  and  leads  to
necrosis,  which  is  consistent  with  the
effect  induced  by  GLUT1  RNA
interference.  It  does not  bind to other
glucose  transporters,  and  does  not
inhibit  a  broad  range  of  50  tested
kinases. 
10mM
Wortmannin
(Sigma-
Aldrich, UK)
428.43 PI3 Kinase inhibitor 10mM 
UK-5099
(Sigma-
Aldrich, UK)
288.3 Inhibitor  of  plasma  membrane
monocarboxylate  transporters  (MCTs)
and the mitochondrial pyruvate carrier
(MPC). 
20mM
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2.12 Cell metabolism and mitochondrial respiration analysis
The Seahorse Bioscience XF24 instrument was developed and designed
to measure the rate of change of dissolved oxygen and pH in the media
immediately surrounding living attached cells cultured in a microplate in
real time mode. Changes in the extracellular media are caused by the
consumption  or  production  of  oxygen  and  protons  by  the  cells.
Therefore,  a sensitive measurement  of  the media flux can be used to
determine  rates  of  cellular  metabolism with  great  precision  and  in  a
totally  non-invasive,  label-free  manner.  Accurate  and  repeatable
measurements of consumption and production of oxygen and proton in
as little as five minutes are the  unique feature of the XF technology. This
is accomplished by isolating an extremely small volume (less than 10 μl)
of media above the cell  monolayer. Cellular metabolism causes rapid,
easily  measured  changes  to  the  “microenvironment”  in  this  small
volume. Typically, a measurement cycle is performed for 2-5 minutes.
During this time, the media are gently mixed and is followed by a short
temperature recovery period. The analyte levels are then measured until
the oxygen concentration drops approximately 20-30% and media pH
declines approximately 0.1-0.2 pH units. The measurement is performed
using 24 optical fluorescent biosensors embedded in a sterile disposable
cartridge  that  is  placed  into  the  Seahorse  24  well  tissue  culture
microplate. The XF analyser measures oxygen consumption rate (OCR)
as  an  indicator  of  mitochondrial  respiration  and  extracellular
acidification  rate  (ECAR)  as  the  result  of  glycolysis  at  intervals  of
approximately 2-5 minutes. Baseline metabolic rates typically measure
3-4  times,  and  are  reported  in  pmol/min  for  OCR  PPR  (Protons
Production Rate)  and in  mpH/min for  ECAR.  The compound is  then
added to the media and mixed for 5 minutes, and then the post-treatment
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OCR and ECAR measurements are made and repeated.  As cells shift
metabolic pathways, the relationship between OCR and ECAR  changes.
Cellular  oxygen  consumption  (respiration)  and  proton  excretion
(glycolysis)  causes  rapid,  easily  measurable  changes  to  the
concentrations of  dissolved oxygen and free protons in this  "transient
microchamber"  which are  measured every few seconds by solid  state
sensor probes residing 200 microns above the cell monolayer. Seahorse
analyser continues to measure the concentrations until the rate of change
is linear  and then calculates the slope to determine OCR and ECAR,
respectively (Seahorse Bioacience; http://www.seahorsebio.com).
2.13 Optimisation of cell number for Seahorse XF-24 
In this experiment, BRIN-BD 11 cells were seeded at four different
densities,  20000,  30000,  40000  and  50000  per  well  with  five
replicates to indicate the best density of cells for seeding to achieve
optimum responses in Seahorse cell culture plates. The basal oxygen
consumption (OCR) rates were measured to the establish baseline rate
in different densities of cells in order to identify the optimum cell
density for experiment repetition. 
Cells were dispensed into each well in 100µL RPMI-1640 with 11
mM glucose and left to attach; the plate was left out in the vertical
laminar  flow hood (VLFH) for  about  30  minutes  before  returning
them to the incubator as this helped to evenly disperse cells across the
well. All the wells were topped up with medium to 300µL and placed
into CO2 incubator as normal. The growth medium was removed from
each well and the cells were washed with 1ml of pre-warmed RPMI-
1640 without bicarbonate and with 1% FBS because bicarbonate and
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FBS  affect  the  buffer  capacity  of  the  medium  and  interfere  with
protons measurement of the Seahorse XF-24 sensors. Each well was
loaded with 625 μl of RPMI-1640 without bicarbonate and with 1%
FBS medium and incubated in a 37˚C incubator without CO2  for 60
minutes to allow cells to pre-equilibrate with the assay medium. 
BRIN-BD11 cells were seeded onto 20 wells of a 24-well Seahorse
special microplate and 4 wells were left and filled with RPMI-1640
only  for  calibration  purposes,  as  instructed  by  the  manufacturer’s
standard protocol, and shown in the following layout (Fig 2.1). Sensor
Cartridge (Proper orientation: notch at lower left) was loaded to the
machine  and  pre-warmed  RPMI-1640  running  medium  (without
bicarbonate  and  with1%  FBS)  plus  0.3%  DMSO  was  loaded  to
control wells (A1, B4, C3 and D6). The Seahorse XF-24 command
was adjusted to 3x loop start and 3 minute measurement at each loop. 
Figure 2.1. The layout of negative controls in the Seahorse microplateplate. The
green wells were filled with  RPMI-1640 medium without cells for the purpose of
machine calibration during test runs.
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2.14 Results of cell number optimization
The results of two preliminary experiments to verify the best density
of BRIN-BD 11 cells for use in Seahorse XF-24 microplates showed
that  the density  of  40000 cells  per  well  achieved the best  oxygen
consumption  rate  (OCR)  measurements  compared  with  other  cell
densities within the machine reading range (Fig 2.2). The density of
50000 cells produced out of range results. As a conclusion, the density
of  40000  BRIN-BD11  cells  is  the  maximum  cells  which  can  be
loaded to create enough cells for a robust mitochondrial respiration
measurement with Seahorse XF-24. To eliminate probable bias, five
replicates for each density were measured simultaneously.
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   a)
   b) Red: 20K      Blue: 30K      Green: 40K      (Green in the bottom is baseline without cells)
Figure 2.2. Five replicates of 20000, 30000, 40000 and 50000 BRIB-BD 11 cells
were seeded respectively from column A to D of the microplate. A1, B4, C3 and D6
were  filled  by  RPMI-1640  without  cell  for  calibration  during  the  test  (a).  The
measurements of  oxygen consumption rate (OCR) in 50 minutes shows the density
of  40000  BRIN-BD11  cell  creates  more  robust  reading  compared  to  others  and
density of 50000 cells creates out of range result (b). 
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Chapter III
Animal Trial
All the facilities for carrying this  animal study were provided by Qom
medical university, Iran and Dr Mohammadreza Haeri. He also helped
me in all the steps of handling animals, collecting samples and analysing
data. Dr Kenneth White also provided me with immense help in
statistically analysing data and writing the paper which has been
published in Phytomedicine journal (Appendix I) 
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3.1 Type 1 diabetes animal model
The main characteristic of type 1 diabetes is a lack of insulin production
due to the destruction of the pancreatic beta cells, which can be achieved
in animal via chemical destruction of beta cells or breeding a genetically
modified  rodent  who  develop  pancreatic  beta  cell  destruction  due  to
spontaneous  autoimmune  response.  Steptozotocine  (STZ)  and  alloxan
are  two  main  compounds  which  use  for  chemically  induced  type  1
diabetes. They compete with glucose to enter pancreatic beta cells due to
their structural similarity with glucose. Chemically induced diabetes is
an easy and cheap technique to create a type 1 diabetes model for  testing
drugs  or  therapies  where  the  main  mechanism of  action  is  lowering
blood  glucose  in  a  non  beta  cell  dependent  or  insulin  independent
manner (Sheshala  et al., 2009). Both STZ and alloxan can be toxic at
other organs of the body and this should be considered when drugs are
being tested in these models. STZ tolerates better than alloxan and has a
wider diabetogenic ratherthan alloxan with a narrow diabetogenic dose.
Alloxan light  overdosing can cause general  toxicity,  especially  to  the
kidney (Szkudelski,2001).
Streptozotocin (STZ) is particularly toxic to pancreatic beta cells and has
been used  for  several  decades  to  induce  the  diabetic  state  in  rodents
(Davidson  et  al.  1977,  Rees  et  al.  2005).   STZ  is  a  glucosamine
nitrosourea  compound  similar  to  glucose,  that  is  recognised  and
absorbed by GLUT2, but not  other  glucose transporters.  STZ induces
DNA damage by activation of  poly  ADP-ribosylation  within  the  beta
cells (Szkudelski. 2001), and  is particularly toxic to pancreatic beta cells
because they express high level of GLUT2 (Wang et al.1998). 
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Figure  3.1.  Streptozotocin  chemical  structure.  (Adapted  from  Sigma  Aldrich,
http://www.sigmaaldrich.com)
The type 1 diabetes rat model can be produced using single high dose STZ
and  multiple  injection  of  STZ  over  5  days.   Single  high  dose  STZ
administration could create a simple hyperglycaemia model, but it is not
stable for long term model due to spontaneous regeneration of endogenous
beta cells (King. 2012). Multiple injection of STZ could create more stable
damage to pancreatic beta cell which could not be regenerated after a few
weeks (King.  2012).  Chemically  induced  animal  is  not  a  appropriate
model for studying the pathogenesis of type 1 diabetes. The  spontaneous
models of autoimmunity is more close to human disease for such study
(Reddy et al. 1995). We adapted the STZ technique to create a suitable
model  for  our  study  as  our  aim  is  to  investigate  the  effect  of  4-
hydroxyisoleucine on blood glucose level in an animal model close to type
1 diabetes not studying the pathogenesis of the disease. 
We were looking to create a type 1 diabetes rat model with minimum
insulin  secretion  in  which  the  animal  can  survive  throughout  the
experimental period without the need to administer insulin. This would
allow us to assess the effect of 4-hydroxyisoleucine on condition with a
significant  reduction  in  insulin  production  ability  and  the amount  of
insulin in circulation. 
We  compared  three  protocols  of  STZ  administration,  using  intra-
peritoneal  (IP)  injection  to  achieve  a  stable  model  with  high  blood
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glucose level and significantly reduced insulin production capability. A
single IP injection of STZ at doses of 60 mg/kg or 150 mg/kg were
compared with the procedure of  daily single IP injections of STZ at 60
mg/kg  for  five  consecutive  days  (Motyl  et  al.  2009). We  ran  a
preliminary test to compare these different protocols to achieve the best
possible selection of a suitable rat model for the study. Eight rats with
the weight of 190-230 g were selected and divided into 4 equal groups
with  two  rats  in  each  group (Table  3.1).  The  glucose  level  was
measured using a micro-drop strip glucometer before the injection of
STZ,  at  day 5 after  injection.  The rats  were  killed  two weeks after
injection and blood collected directly from the heart for glucose and
insulin measurement.
Group A Single dose STZ 60 mg/kg IP injection 
Group B Single dose STZ 150 mg/kg IP injection 
Group C Multiple dose STZ 60mg/dl consecutive 5 days IP Injection
Group D Normal Control without STZ
Table 3.1. Different protocols of intraperitoneal injection of STZ.
Single doses of  STZ induced increases in  glucose levels,  but not  to
levels greater than 300 mg/dl, the threshold for a diabetic phenotype
(Table 3.2). Repeated doses of STZ induced glucose levels of 520 ± 13
mg/dl compared with 79 ± 3 mg/dl for controls (n = 2), and insulin
levels  were below the limit  of  detection (0.2 µg/l)  using automated
clinical reader compared with an average of 1.79 µg/l in controls. We did
not use ultra sensitive ELISA kit for preliminary study for its high cost, but
the method of detection was accurate enough for our purpose. We used
different  insulin  measurement  using  ultra  sensitive  rat  insulin  kit  with
detection range of 0.02 µg/l to 5.5 µg/l. On this basis the repeated doses of
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STZ could be used to induce a state in rats as close as possible to type 1
diabetic.  Multiple  STZ  injection  created  a  desired  model  with
hyperglycaemia  and  minimized  insulin  production,  which  suggest  a
massive destruction of pancreatic beta cells. Using such model could make
it possible the activity of 4-hydroxyisoleucine in different angle.
Group Blood Glucose
mg/dl
Blood Glucose
mg/dl
Blood Glucose
mg/dl
Insulin 
µg/l
A1
A2
82
77
SD ± 3.54
118
109
SD ± 6.36
127
123
SD ± 2.83
1.19
0.94
SD ± 0.77
B1
B2
68
79
SD ± 7.78
201
177
SD ± 16.97
247
262
SD ± 10.61
0.59
0.51
SD ± 0.06
C1
C2
71
84
SD ± 9.19
497
441
SD ± 39.6
530
511
SD ± 13.4
lower than
measurement level
D1
D2
71
76
SD ± 3.54
80
73
SD ± 4.95
77
81
SD ± 2.83
1.81
1.76
SD ± 0.04
Table 3.2. Comparison of blood glucose and insulin in rats treated with different STZ
injection protocols.  Two rats were allocated in each group as explained in Table 1.
Blood glucose levels before injection, in day 5 and two weeks after injection was
shown in columns 2, 3 and 4 respectively. Group C shows highest sustained blood
glucose level with no trace of insulin within 2 weeks of  60mg/kg STZ injection for
five consecutive days. Rats in group C survived with high blood glucose level for
two weeks and it demonstrates a  suitable diabetic rat model close to diabetes type 1
for our experiment .
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3.2 Animal study results and discussion
Rats were divided into three treatment groups, each with six animals.
Two groups were treated with a single dose of 60 mg/kg STZ for
five  consecutive days and the third group received a vehicle control.
Animals treated with STZ were left for seven days to develop diabetes,
as  confirmed by measurement of blood glucose  (glucose level of tail
blood  over  300  mg/dl)  before  starting  treatment  with  4-
hydroxyisoleucine. The diabetic treatment group was intubated with 50
mg/kg/day of 4-hydroxyisoleucine, and the diabetic control group with
saline  vehicle,  continuously  for  four  weeks.  One  week  after  STZ
administration rats had a markedly elevated plasma glucose compared
with controls, and this was sustained for a further four weeks (Fig 3.1,
groups D and D4H). Fasting blood glucose, triglyceride, cholesterol,
LDL, HDL and uric acid were measured using methods described in
chapter II and data analysed statistically with the ANOVA  Bonferroni
and Tukey tests to avoid type 1 error. The correlation with P value less
than  0.05  in  both  tests  was  accepted  as  significant.  Treatment  of
diabetic  rats  with  4-hydroxyisoleucine  for  four  weeks  induced  a
reduction  in blood glucose  from 500[±SD] mg/dl to 330[±SD] mg/dl
which is statistically significant (P<0.05).  The blood glucose level in
both control and diabetic control groups remained steady during the
experimental  period  without  significant  changes,  comparing  blood
glucose levels at the beginning and the end of the  experiment in each
group (Fig 3.1). It shows that damaged pancreatic beta cells were not
restored  naturally  in  the  STZ  induced  diabetic  group  during  the
treatment period of four weeks and the diabetic status was constant.
The fact that blood glucose levels remained steady over the four week
period of the experiment in the non-diabetic group, after being housed
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in the same conditions as the  other groups, suggests that the prevailing
environmental  and  dietary  conditions  did  not  influence  blood
glucose  levels.  Generally  the  diabetic  animals  treated  with  4-
hydroxyisoleucine  had  an  improved  appearance  and  it  was
noticeable that the heavy ocular vascularization induced by STZ was
being reversed as the treatment with 4-hydroxyisoleucine progressed
(Haeri et al. unpublished data). 
Insulin was measured by ultrasensitive ELISA kit with the detection
limit of  0.02 µg/l to 5.5 µg/l. All the samples measurement were
within  the  detection  range.  Insulin  levels  in  the  diabetic  groups
were significantly lower than normal controls with levels decreased
by  60  %  from  0.7  µg/l  to  less  than  0.3  µg/l.  There  is  not  a
significant difference in insulin levels between the diabetic control
and  diabetic  group  treated  with  4-hydroxyisoleucine,  after  four
weeks (Fig 3.2). 
These data suggest that restoration of pancreatic beta cells does not
play  a  role  in  improving  diabetic  conditions  in  the  4-
hydroxyisoleucine treatment group. 
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Figure  3.1.  Fasting  plasma  glucose  at  the  beginning  and  end  of  the  4-
hydroxyisoleucine treatment. Mean and SD plasma glucose of five or six rats per
group. Control rats (C). Diabetic (D) and treatment (D4H) groups were made diabetic
by repeated  doses  of  STZ.  Treatment  with 4-hydroxyisoleucine started one week
after the STZ treatment and continued for four weeks. Glucose was measured at the
start of the 4-hydroxyisoleucine treatment (White Columns) and at the end of four
weeks treatment (Grey Columns). 4HO-Ile induced a significant (*p < 0.05) decrease
in plasma glucose within the treatment group after four weeks. 
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Figure 3.2. Plasma insulin after treatment with 4-hydroxyisoleucine. Plasma insulin
was measured by ultrasensitive insulin ELISA kit with the detection limit of  0.02
µg/l to 5.5 µg/l. Data are mean + SD of five or six rats per group at the end of the
treatment period. Insulin levels were significantly lower in diabetic groups [D, D4H]
compared with control [C] (*p < 0.05). 
The  diabetic  rats  had  a  markedly  higher  intake  of  food  and  water
compared with controls (Fig 3.3), but the hyperphagia did not cause any
increase  in  body  weight  in  the  diabetic  rats  compared  with  controls.
Body weights (mean ± SD) at the end of the study were 289 ± 31 g (C),
269 ± 15 g (D) and 267 ± 5 (D4H). There was no significant difference
between groups. 
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Figure 3.3. Water and food intake over treatment period. Intake of water (a) and food
(b) over the four week period of 4-hydroxyisoleucine treatment. Data are mean + SD
daily intake per animal over weekly periods for control (C), diabetic (D) and diabetic
rats treated with 4-hydroxyisoleucine (D4H). Data are for the four consecutive weeks
of the period of treatment with 4HO-Ile: week 1 (   ), 2 (   ), 3 (   ), 4 (   ). Significant
differences between means of group D compared with groups C or D4H, for a given
week, are indicated where p < 0.05 (*) or p < 0.01 (**). 
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The lipid profile of the diabetic rats was also consistent with a diabetic
phenotype,  with  significantly  elevated  triglyceride,  cholesterol,  HDL
(High  Density  Lipoprotein)  and  LDL  (Low  Density  Lipoprotein)
compared with the control group (Fig 3.4). The changes in glucose and
lipids coupled with the marked decrease in insulin indicate that a type 1
diabetic phenotype is induced by the repeated intraperitoneal doses of
STZ.  The levels of triglyceride, LDL and HDL in the treated diabetic
animals were not significantly different to those of control, non-diabetic
rats and total cholesterol was reduced to near control levels  (Fig 3.4b)
More  strikingly  the  4-hydroxyisoleucine  treatment  also  resulted  in
significant  decreases  in  all  lipid  markers  compared  with  untreated
diabetic rats.
The levels of triglyceride, LDL and HDL in the treated diabetic animals
were not significantly different to those of control, non-diabetic rats and
total  cholesterol  was  reduced  to  near  control  levels   indicating  that
treatment with 4-hydroxyisoleucine had restored the diabetic lipid profile
to an almost  normal  one.  In  type 1 diabetes  levels  of  HDL typically
decrease but in our model the STZ-treated animals had elevated HDL.
The reason for this is unclear,  but similar behaviour in STZ-rats have
been found by others  (Islam. 2011). In our study the treatment with 4-
hydroxyisoleucine could reverse the changes in HDL induced by STZ
and restore levels close to that of control non-diabetic animals (Fig 3.4). 
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Figure  3.4. Serum  lipid  profile  of  rats  after  four  weeks  treatment  with  4-
hydroxyisoleucine. Triglyceride (a), cholesterol (b), LDL (c) and HDL (d) measured
at the end of the treatment with 4-hydroxyisoleucine are shown as the mean + SD of
five or six rats per group. Levels were significantly lower in control (C) and treated
diabetic (D4H) groups compared with untreated diabetic animals (D) (*p < 0.05, **p
< 0.01). 
Uric acid levels in the STZ-induced diabetic rat group were elevated
significantly, about 40% compared to the non-diabetic group, and this
increased  hyperuricemia  of  the  diabetic  rats  was  restored  to  levels
found in normal rat controls  after treatment with 4-hydroxyisoleucine
(Fig 3.5). There is a relationship  and biochemical interaction between
high serum glucose  and high serum  uric  acid  levels  as  uric  acid  is
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increased during hyperglycaemia  (Cook  et al. 1986). The relationship
between serum uric acid and metabolic diseases has been explored in a
number of studies. There is  a  positive relationship between levels  of
blood insulin and blood uric acid level  and uric acid concentration is
closely related to pancreatic beta cell activity (Robles-Cervantes  et al.
2011, Sinagra et al. 1996).  Hyperuricemia is directly linked to damage
to  the  kidney,  which  is  one  of  the  major  causes  of  morbidity  and
mortality  in  diabetes  (Rosolowsky  et  al.  2008). There  is  increasing
evidence  from  clinical  data  that  high  levels  of  uric  acid  are  an
independent risk factor for kidney disease (Miao et al. 2011).  It also has
been demonstrated that high blood uric acid level is directly associated
with  macro  and  microangiopathies  and  also  independently  associated
with coronary heart disease and renal dysfunction  in diabetic patients
(Ito  et  al.  2011). It  is  notable  in  this  study  that  the  reduction  in
hyperuricaemia caused by treatment with 4-hydroxyisoleucine is more
pronounced than the reduction in hyperglycaemia, in that uric acid levels
return to those of  normal  controls  (Fig 3.5 compares groups C and
D4H) whereas levels of blood glucose remain three times higher than
normal  controls  (Fig  3.1  compare  groups  C and D4H) and  insulin
levels remained unchanged  (Fig 3.2 compare groups D and D4H). It
remains to be seen whether or not the effects of 4-hydroxyisoleucine on
serum uric acid are mediated through improved, but not fully restored
glucose levels, or by another mechanism without increasing insulin level.
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Figure 3.5. Serum uric acid after four weeks treatment with 4-hydroxyisoleucine.
Data are mean + SD serum uric acid in rats at the end of the period of treatment with
4-hydroxyisoleucine.  Levels  were  significantly  lower  in  control  (C)  and  treated
diabetic (D4H) groups compared with untreated diabetic animals (D) (*p < 0.05). 
The effective correction of the diabetes induced dyslipidemia by 4-
hydroxyisoleucine is  similar  to  results  of  the  4-hydroxyisoleucine
treatment of rats or mice with a type 2 diabetes phenotype, in which 4-
hydroxyisoleucine induced improvements in  both  lipid  profile  and
hyperglycaemia  (Haeri  et  al.  2009;  Singh  et  al.  2010). anti-
dyslipidemic activity of 4-hydroxyisoleucine has also been demonstrated
in a hamster model of dyslipidemia (Narender et al. 2006). The findings
presented  in  this  thesis  show that  4-hydroxyisoleucine is  capable  of
modifying diabetes type 1 condition as a new mode of action in addition
to the known beneficial effects of 4-hydroxyisoleucine in type 2 diabetes.
Previous studies of the anti-diabetic properties of 4-hydroxyisoleucine
have focused on diabetes type 2 and animal models of insulin resistance
and have suggested that 4-hydroxyisoleucine produces its anti-diabetic
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effects  via  stimulating  insulin  secretion  from  pancreatic  beta  cells
(Insulinotropic) and by an insulin sensitizing mechanism (Sauvaire Y et
al. 1998, Broca et al. 1999, Broca et al. 2000, Jette et al. 2009). In the
work presented in this thesis it is notable that 4-hydroxyisoleucine did
not induce an increase in insulin levels in diabetic rats compared with
untreated diabetic controls  (Fig 3.2). Both groups had insulin levels of
about  0.3  g/l,  which  were  approximately  65%  lower  than  the  non-
diabetic control group (Fig 3.2). 
These data show that 4-hydroxyisoleucine has no insulinotropic activity
in this model of type 1 diabetes, despite the high levels of glucose in the
diabetic rats. Thus, even though insulin levels were low, indicative of a
small amount of pancreatic activity, they were unchanged by treatment
with 4-hydroxyisoleucine. 
The  improvement  by  treatment  with  4-hydroxyisoleucine  on  the
metabolic parameters of glucose, lipid profile and uric acid in a model of
type  1  diabetes  model  with  low  level  of  insulin  availability  and
pancreatic  beta  cell  activity  as  well  as  diabetes  type  2  and  insulin
resistant  conditions  suggest  that  4-hydroxyisoleucine  has  a  systemic
effect  on  metabolically  active  tissues,  including  liver,  muscle  and
adipose tissue, that is independent of insulin. The data from our study
and  from  previous  literatures  cited  above  suggest  that  4-
hydroxyisoleucine could be used as a treatment for  both type1 and type
2  diabetes  independently  or  in  combination  with  other  treatments.
Analysing  the  data  from  the  current  study   show  that  4-
hydroxyisoleucine's main mechanism of action is not  insulin stimulating
or insulin sensitizing as was determined in previous studies. 
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We assume that  4-hydroxyisoleucine produces its anti-diabetic effects
by  facilitating  glucose  utilization  in  tissues  independent  of  insulin
considering the fact that  4-hydroxyisoleucine exhibits its activity in a
high glucose concentration without glucose lowering effect  in  normal
blood glucose level  (Sauvaire  et al. 1998).  4-hydroxyisoleucine could
be a promising candidate for of diabetes treatment and understanding its
mechanism  of  action  to  control  diabetes  metabolic  disturbances  also
could  shed  a  light  to  new  treatment  approaches  and  designing  new
medications.
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3.3 Animal study findings at a glance 
• 4-hydroxyisoleucine  is  effective  in  modifying  diabetes  type 1
metabolic conditions as well as those of diabetes type 2 and
insulin resistance.
• 4-hydroxyisoleucine produces its anti-diabetic effects independent
of  insulin  as  no  increase  in  insulin  was observed through  the
duration  of  the  study.  It  challenges  the  previously
suggested  mechanism  of  action  such  as  an  insulinotropic
activity for 4-hydroxyisoleucine.
• 4-hydroxyisoleucine  restores  LDL (Low  Density  Lipoprotein)
and triglyceride close to normal levels in  diabetic rats, which
demonstrate its effectiveness in reducing the risk of cardiac and
vascular complications of diabetes.
• The effect of 4-hydroxyisoleucine on uric acid has been studied
for the first time and it was demonstrated that 4-hydroxyisoleucine
can  restore  diabetic  hyperuricemia  without  increasing  insulin
secretion or pancreatic beta cell activity.
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Chapter IV
In-Vitro Study
BRIN-BD11 Cell 
In-vitro studies discussed in this chapter have been carried out with the
help of my colleague, Dr  Ravi Velga. He helped me during all the steps
for preparation, cell culture and running tests. I would like to thank him
for all his help. I would like to thank Dr Kenneth White for his
constructive advices throughout this phase of the study.
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4.1 Introduction
The  animal  studies  described  in  Chapter  III  showed  that  4-
hydroxyisoleucine  decreases  plasma  glucose,  concentration  and
modifies other diabetes-related adverse effects such as hyperlipidemia
and  hyperuremia,  independently  of  insulin.   This  mode  of  action
contrasts with previous suggestions that 4-hydroxyisoleucine’s mode
of action is as an insulinotropic and insulin sensitizing agents (Broca
et al. 2004, Sauvaire et al. 1998, Al-Habori et al. 1998), and raises the
question  as  to  how  4-hydroxyisoleucine  decreases  blood  glucose
levels.  Interestingly,  isoleucine,  which  is  structurally  close  to  4-
hydroxyisoleucine,  also  had  an  insulin-independent  hypoglycaemic
effect on diabetic mice (Ikehara et al. 2008), and it increased glucose
uptake in muscle of fasted rats without changing insulin levels (Doi et
al. 2007). Accordingly isoleucine was included in cell based studies,
described  below,  which  attempted  to  elucidate  the  mechanism  of
action of 4-hydroxyisoleucine.
In view of the published literature about isoleucine and of the data from
our  animal  study,  we  hypothesized  that  4-hydroxyisoleucine
increases glucose uptake and utilisation in peripheral tissues, which
leads to its anti-diabetic effects.  Evidence to support the  hypothesis
that  4-hydroxyisoleucine  increases  glucose  utilization  in  peripheral
tissues which is not  insulin mediated includes the observation that
chronic,  but  not  acute,  treatment  with  4-hydroxyisoleucine  produces
hypoglycaemia (Broca  et  al.  2004),  that  the  activity  of  4-
hydroxyisoleucine is insulin independent (Haeri et al. 2012), that the
anti-diabetic  effects  of  4-hydroxyisoleucine  directly  correlate  with
glucose  concentration  (Sauvaire  et  al.  1998) and  that  the  chemical
structure is similar to isoleucine, which has been shown to increase
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glucose  uptake  independent  of  insulin  (Doi  et  al.  2007). To
investigate the insulin-independent effects of 4-hydroxyisoleucine and
isoleucine on  glucose uptake and utilization a cell  model was used
which is not insulin-responsive and dependent on the insulin signalling
pathway for glucose uptake. Use of the model provides the opportunity
to  study  the  mechanisms  of  action  of  both  isoleucine  and  4-
hydroxyisoleucine independently. 
The  model  will also  shed  light  on  the  question  whether 4-
hydroxyisoleucine  is  an  insulin  sensitizing  agent,  or  whether  its
independent  effect  on  increasing  basal  glucose  utilization  facilitates
insulin action as well - if any molecule can increase glucose consumption
independently in peripheral tissues, it can increase the insulin sensitivity.
4.1.1 BRIN-BD 11 cell as a model for In-vitro study 
Neural cells, kidney tubular cells and pancreatic beta cells all possess an
insulin-independent glucose uptake mechanism. Neural cells possess both
insulin independent and insulin mediated glucose uptake mechanisms
(Schulingkamp et al. 2000). Glucose uptake in pancreatic beta cells is not
mediated by insulin due to their glucose sensory nature and any insulin
mediated glucose uptake mechanism would interrupt the sensory function.
Glucose uptake is independent of insulin in pancreatic beta cells. Insulin has
autocrine activity on beta cells as a modulator, and has different roles
such  as  enhancing  beta  cell  survival  and  inducing  proliferation,
through mechanisms that are unclear (Emilyn et al. 2010). 
In contrast to adipose tissue and muscle cells, which express high levels
of  GLUT  4,  an  insulin  regulated  glucose  transporter,  the  glucose
transporters mainly expressed in beta cells are GLUT 1 and GLUT 2. In
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mouse beta cells GLUT 2 is expressed at higher levels than GLUT 1 and
is responsible for glucose-stimulated insulin secretion, while in human
beta  cells  both  GLUT 1  and  GLUT 2  are  responsible  for  glucose-
stimulated insulin secretion (Ohtsubo et al. 2011). 
Considering the physiological and biological properties of a variety of
cell lines,  beta cells make an appropriate model for investigating the
effects of 4-hydroxyisoleucine and isoleucine on glucose uptake by
minimising the interference of insulin. The search for a cell model that has
the  normal functionality of beta cells, with a well established record
and the ability to be grown in normal laboratory conditions, guided us
towards the BRIN-BD11  cell  line. BRIN-BD11 is a hybrid cell  line
formed by the electrofusion of a primary culture of NEDH rat pancreatic
islets with RINm5F (a cell line derived from a NEDH rat insulinoma)
and unlike other  tumoral  cell  lines,  it  spreads and grows evenly in
culture as monolayers with an epithelioid morphology (McClenaghan et
al. 1996).  
BRIN-BD11 cells  also have the unique advantages that they retain key
attributes of normal pancreatic beta cells for glucose responsiveness,
insulin synthesis and secretion (McClenaghan et al. 1996). They are also
immortalised  and  provide  stable  growth  and  function  up  to  50
passages. Other attributes include a high capacity for glucose sensing,
specificity, transport and metabolism, and appropriate responses to
a range of non-glucose nutrients  and receptor-mediated modulators of
beta  cell  function,  including  amino  acids,  neurotransmitters  and
sulphonylurea  drugs.  Preliminary studies showed that amino acids
may  act  on  BRIN-BD11  cells  by  diverse  mechanisms,  including
metabolism to ATP and uptake of cationic amino acids (McClenaghan et
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al.  1996).  BRIN-BD11  cells  are  also  suitable  for  nutrient
interaction  studies  of  the  regulation  of  insulin  secretion  by
sulphonylureas and other compounds.
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4.2  The effect  of  4-hydroxyisoleucine  and isoleucine  on glucose
consumption in BRIN-BD11 cells
In the first set of experiments using BRIN-BD11 cells, different
concentrations of  glucose  were used to  assess  the effects  of  4-
hydroxyisoleucine and isoleucine on glucose uptake. 
The glucose  concentration  of  the culture medium is  one of  the
criteria considered to model the diabetic status in order to evaluate the
effect  of  isoleucine  and  4-hydroxyisoleucine  on  glucose
consumption. Exposure of BRIN-BD11 to 500 µM of isoleucine and 4-
hydroxyisoleucine added to RPMI-1640 medium contains 5, 11 and
22 mM of glucose for 24 hours, showed a very significant increase in
glucose consumption in cells incubated with 4-hydroxyisoleucine with
22  mM  glucose  RPMI1640  compared  with  control  and  other
groups  (Fig  4.1).  Glucose  consumption  increased  constantly  and
significantly  in  all  groups  compared  to  4-hydroxyisoleucine  which
showed activity in 11 and 22 mM glucose containing medium. 
The  results  of  the  first  experiments  demonstrated  the  correlation
between  4-hydroxyisoleucine  activity  and  glucose  concentration,  in
which 4-hydroxyisoleucine is  only  active at  higher concentrations  of
glucose  and  the  activity  increases  with  increase  in  glucose,  and  are
consistent with previous observations (Sauvaire et al. 1998). The effect
of  isoleucine,  to  stimulate  a  relatively  constant  increase  in  glucose
uptake  in all  concentrations  of  glucose,  indicates  its  activity  is
independent of glucose concentration.
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Figure 4.1. The Effect of Ile and 4HO-Ile on glucose consumption by BRIN-
BD11 cells. Comparing glucose consumption in BRIN-BD 11 cells incubated with
500 µM isoleucine and 4-hydroxyisoleucine for 24 hours in variable concentrations
of 5,  11 and 22 mM of glucose in RPMI-1640 medium. Glucose consumption is
increased very significantly by both 4-hydroxyisoleucine and isoleucine in 22 mM
group  (p<0.01) and significantly in 11 mM group (p<0.05).  The experiment  was
repeated three times with five sets of replicate in each experiment and results analysing
by  ANOVA Bonferroni  test.  Isoleucine  shows  a  consistent  increase  in  glucose
consumption independent of glucose concentration compared to 4-hydroxyisoleucine
which its activity increased correlatively with glucose  concentration. Both 4-
hydroxyisoleucine and isoleucine exhibit optimal activity in 22 mM concentration of
glucose. 
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4.3  The  effect  of  4-hydroxyisoleucine  and  isoleucine  on  insulin
secretion from BRIN-BD11 cells
The  experiment  was  set  up  to  assess  the  effect  of  4-
hydroxyisoleucine  and  isoleucine  on  insulin  secretion  in  BRIN-
BD11 cells.  The  amount  of  insulin  within  the  medium has  been
measured as a  reflection of insulin secretory activity of BRIN-BD 11
cells. There was no significant increase observed in insulin secretion
between 4-hydroxyisoleucine and isoleucine compared to control in all
groups (Fig 4.2). The increase in insulin secretion was consistent with
the  increase  in  glucose  concentration,  as  expected,  which
confirms  the  normal  glucose  responsiveness  of  the  insulin
secretion activity of BRIN-BD 11 cells and hence the  reliability of
using BRIN-BD 11 cells as a model for normal pancreatic beta cells.
Figure  4.2. The  Effect  of  isoleucine  and  4-hydroxyisoleucien  on  insulin
secretion by BRIN-BD11 cells. The measurement of insulin in cell culture medium
showed  a  very  significant  increase  in  insulin  secretion  by  increasing  glucose
concentration (p<0.01). There is no significant differences in insulin secretion in cells
incubated  with  500  µM  4-hydroxyisoleucine  and  isoleucine  for  24  hours.  The
experiment was repeated three times with five sets of replicate in each experiment
and data were analysed by ANOVA Bonferroni test. 
100
Insulin measurements revealed that  both 4-hydroxyisoleucine and
isoleucine  did  not  stimulate  insulin  secretion,  whilst  they  both
increased  glucose uptake  (Fig 4.1).  This finding confirms the results
from  animal  studies  in  which  4-hydroxyisoleucine lowered  blood
glucose  without  increasing  plasma insulin. The current results  from
BRIN-BD 11 cells and animal studies do not support the findings of
Sauvaire in 1998 and Broca 1999 (Sauvaire et al. 1998, Broca et al.
1999) which  suggested  that  4-hydroxyisoleucine produces its anti-
diabetic effect by stimulating insulin  release from pancreatic beta cells.
Current observations reconfirm an insulin independent mechanism of 4-
hydroxyisoleucine  in  utilizing  glucose  consumption.  A  similar
conclusion  was  arrived  at  when  it  was  shown  that  4-
hydroxyisoleucine  stimulated  glucose uptake in skeletal muscle L6
cells in the absence of insulin (Jaiswal et al. 2012). 
Significant increase in glucose consumption in beta cell exposed to high
concentration  of  glucose  (22  mM)  and  long  incubation  with  4-
hydroxyisoleucine  without  changing  insulin  secretion  explains  an
insulin-independent  glucose  utilization  mechanism  involves  in  4-
hydroxyisoleucine anti-diabetic effects. Isoleucine follows the pattern of
4-hydroxyisoleucine  with  a  substantial  difference  in  dependency  to
glucose concentration. The glucose concentration dependent activity of
4-hydroxyisoleucine  makes  it  an  interesting  molecule  with  a  unique
mode of action, only active in hyperglycaemic condition and does not
show hypoglycaemic effect in lower glucose concentrations. It is active
when it needs to create an effect. 
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4.4 The effect of 4-hydroxyisoleucine and isoleucine on ATP content
of BRIN-BD11 cells
Incubation  of  BRIN-BD  11  cells  with  4-hydroxyisoleucine  and
isoleucine  did not  increase ATP levels  in  BRIN-BD 11 cells  after  24
hours whilst the glucose uptake was increased. The increase of ATP level
was in direct correlation with the glucose concentration of the culture
medium as expected (Fig 4.3). Doi's study shows that isoleucine did not
change the ATP level in liver cells whilst it increases glucose uptake (Doi
et al. 2007). Current study iterates that isoleucine produces the similar
effect in beta cell as well as observed in liver cell. Exposure of the beta
cell  to  higher  glucose  concentration  stimulates  insulin  secretion  by
increasing the ATP production within the beta cell  and the amount of
insulin  secreted  from  cell  has  a  direct  correlation  with  glucose
concentration.  ATP measurement  results  in  BRIN-BD 11 also showed
that  insulin secretion increases in higher concentrations of glucose (Fig
4.2)  which  suggest  that  BRIN-BD11  resembles  the  normal  beta  cell
attributes.  
The glucose concentration of 22 mM was adapted as a standard glucose
concentration  for  all  the  experiments  during  the  current  study.  There
were  no  significant  differences  observed  in  glucose  consumption  in
BRIN-BD 11 in the presence of 22 mM glucose between the variable
range  of  4-hydroxyisoleucine  and  isoleucine  concentration  from  100
micro molar to 1 mM.  It is in line with Sauvaire et al study in 1998
which  suggested,  4-hydroxyisoleucine  glucose  lowering  activity  is
present  in  concentration range from 100 micro  molar  to  1 mM. This
finding  also  shows  that  4-hydroxyisoleucine  dose-dependent  effect
pattern in lower concentration (lower than 50 micro mole) as observed in
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Jaiswal et al in 2012, is not seen in dose above 100 micro mole up to
1mM.  The  concentration  of  500  micro  molar  of  both  4-
hydroxyisoleucine and isoleucine was used for all the future experiments
in  this  study  as  an  average  effective  dose.  The  pattern  of  glucose
consumption and cellular ATP level were consistent with the findings as
shown in figure 1 and 2 in all the run through the study (Fig 4.4).
 
Figure 4.3.  The Effect of isoleucine and 4-hydroxyisoleucine on ATP content
of BRIN-BD11 cells after 24 hours. ATP level in BRIN-BD 11 cell measured after
24 hours with HTRF ( homogeneous time-resolved fluorescence) technique. There is
a very significant increase in the amount of ATP within the cells in medium with11
mM and 22 mM glucose concentration compared to each other and medium with
5mM  glucose  (p<0.01).  There  is  no  significant  difference  in  ATP  level  of  4-
hydroxyisoleucine and isoleucine groups. The experiment was repeated three times
with five sets of replicate in each experiment and data were analysed by ANOVA test.
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a)                                       b)
Figure 4.4.  Glucose consumptions in the same batch of BRIN-BD 11 cells used
for  ATP content  measurements.  Glucose  consumption  in  BRIN-BD11  cells
increases  very  significantly in  treatment  group  with  500  µM 4hydroxyisoleucine
(p<0.01)  and significantly with 500  µM isoleucine  (p<0.05)  compared to  control
group after 24 hours in the presence of 22 mM glucose (a). There is no significant
changes in ATP level between groups (b). 
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4.5  Cycloheximide  (CHX)  and  protein  synthesis  role  in  4-
hydroxyisoleucine and isoleucine mechanism of actions
 
A recent published study by Jaiswal et al in 2012 showed that increase in
glucose  uptake  and GLUT 4 translocation  in  L6-GLUT4myc skeletal
muscle  cells  in  the  presence  of 4-hydroxyisoleucine  are  blocked  by
adding 1 microg/ml of cycloheximide (CHX) which is a potent protein
synthesis  inhibitor.  CHX is  a selective inhibitor  of  eukaryotic  protein
synthesis which blocks tRNA binding and release from ribosome (Obrig
et al.  1971). Incubation of BRIN-BD11 cells with 4hydroxyisoleucine
and isoleucine in the presence of 0.8 μM (1 µg/ml) of CHX showed that
CHX  significantly  inhibits  the  effect  of  4-hydroxyisoleucine  on
increasing glucose uptake but not isoleucine (Fig 4.5). ATP measurement
also did not show any changes in the content of ATP within the cells in
front of CHX after 24hours (Fig 4.5).
Isoleucine  significantly  increases  the  glucose  consumption  in  the
presence of CHX, suggests a synergistic effect in isoleucine mechanism
and  also  signifies  that  isoleucine  glucose  lowering  effect  does  not
dependent  in  synthesis  of  new  proteins  whilst  4-hydroxyisoleucine
mechanism is noticeably dependent on protein synthesis in beta cells and
skeletal  muscles  which   previously   observed  by  Jaiswal  (Jaiswal  et
al. 2012). Observing the same result in different cells and different dose
extends the conclusion that  4-hydroxyisoleucine hypoglycaemic effect
and  in  some  extent  anti-diabetic  properties  directly  or  indirectly  are
mediated by a protein or proteins which need to be synthesised. It can be
concluded that protein or proteins are involved in 4-hydroxyisoleucine
mechanism do not have a long life,  may be due to rapid degradation
cycle or not abundantly available in normal condition within the cells
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which need to be synthesised newly. This observation also suggests that
there are different mediators are involved in isoleucine mechanism of
action from 4hydroxyisoleucine.
Figure  4.5.  The  effect  of  cycloheximide  (CHX)  on  glucose  uptake  and  ATP
content  in  BRIN-BD  11  cells.  BRIN-BD11cells  incubated  with  500  μM 4-
hydroxyisoleucine and isoleucine in the presence of 0.8 μM cycloheximide (CHX).
There is a significant changes in glucose consumption between 4-hydroxyisoleucine
and  4-hydroxyisoleucine  control  group.  There  is  significant  increase  in  glucose
consumption observed in isoleucine group (p<0.01). There is no changes in ATP level
in all groups. 
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4.6  Wortmannin  and  PI3Kinase  role  in  4-hydroxyisoleucine  and
isoleucine activities in BRIN-BD11 cells 
Broca  et  al.  (2004)  showed  that  4-hydroxyisoleucine  can  increase
PI3Kinase activity in both muscle and liver independently of insulin in
the presence of high glucose concentration, and the study by Jaiswal et
al. (2012) confirmed that adding wortmannin, a potent inhibitor of PI
3Kinase,  inhibits  the  4-hydroxyisoleucine-induced  GLUT4
translocation and glucose uptake in muscle. These studies  suggest a
key  role  for  PI  3Kinase  in  mediating  the  effects  of   4-
hydroxyisoleucine. Adding 5nM of wortmannin (IC50 = 2 - 4 nM) to
the  culture  medium  of  BRIN-BD11  at  the  same  time  with  a  4-
hydroxyisoleucine and isoleucine and incubated for  24  hours  did  not
inhibit 4-hydroxyisoleucine increasing effect on glucose consumption
(Fig  4.6).  It  was  interestingly  observed  that  wortmannin blocks
isoleucine effect even glucose consumption significantly  reduces  in
front  of  wortmannin  compared  to  isoleucine  control
group (Fig 4.6). It suggested that the PI3Kinase plays role in isoleucine
effects on increasing glucose uptake but not in 4-hydroxyisoleucine
in BRIN-BD 11 cells. It seems that inhibiting PI3Kinase activity in
BRIN BD 11 cells does not inhibit 4-hydroxyisoleucine action contrary
to previous  findings in muscles reported by Jaiswal  et al. It can be
concluded that there is a strong relation between the  mechanism of
hypoglycaemic  action  of  isoleucine  and  PI3  Kinase  activity  as
reported by Doi et al in 2003. 
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Figure  4.6.  Glucose  consumption  in  BRIN-BD11  cell  was  not  affected  in  4-
hydroxyisoleucine group in front of 5 nM wortmannin after 24 hours. There is a
significant reduction in glucose  consumption in the isoleucine group  in front of
wortmannin  (p<0.01).
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4.7  Wortmannin  and  Cycloheximide  (CHX)  increase  glucose
consumption in BRIN-BD11 cells
It  was noticeable in our several runs with wortmannin and CHX that
glucose  consumption  in  experiments  with  both  compounds  was
significantly  higher  individually  compared to  the  control  without  any
compound  (Fig  4.6).  To  verify  it  we  set  up  an  independent  trial  to
investigate the effect of 10 nM and 5 nM wortmannin and 0.8 μM CHX
on BRIN-BD11 cell's glucose consumption. We used both cell count and
protein assay together for normalisation to reduce the bias as much as
possible.  The  results  confirmed  our  previous  findings,  which  both
wortmannin  and CHX significantly  increased glucose  consumption in
BRIN-BD 11 cells incubated with RPMI-1640 medium contains 22mM
glucose after 24 hours (Fig 4.7). 
Figure 4.7. BRIN-BD11 cells were incubated with 5 nM and 10 nM wortmannin (W)
and  0.8  μM CHX  in  RPMI-1640  with  22  mM  glucose  for  24  hours.  Glucose
measurements  show  a  very  significant  increase  in  glucose  consumption  in  both
wortmannin  and  CHX  groups  (p<0.01).  No  significant  difference  was  observed
between 5 nM and 10 nM wortmannin group (ns). 
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The same finding has been observed in rat epididymal fat pad exposed to
0.8  mM (1  microg/ml)  CHX and there  is  no  clear  explanation  for  it
(García-Sáinz et al. 1977). Current study shows that CHX produces same
effect  on  beta  cell  with  unknown  mechanism.  It  also  clarifies  that
increase of glucose uptake baseline in all CHX groups respect to non-
CHX groups are due to the CHX stimulatory effect on glucose uptake
and  adding  4-hydroxyisoleucine  to  the  cells  before  CHX  unlike
isoleucine  does  not  stimulate  the  glucose  uptake  further  than  CHX
control group baseline. 
Current  study  finding  about  the  effect  of  wortmannin  on  increasing
glucose uptake in beta cell is new as there is no such a report found in
the  literatures.  It  was  shown  in  previous  works  that  wortmannin  as
inhibitor of PI3Kinase, amplifies glucose-stimulated insulin secretion in
beta  cells  (Zawalich  et  al.  2002)  and  it  has  also  suggested  that
wortmannin induces insulin secretion in high glucose concentration (16.7
mM) by inhibiting phosphodiesterase to increase cAMP content which
indicates  that  PI3-kinase  inhibits  insulin  secretion  by  activating
phosphodiesterase  to  reduce  cAMP  content  (Nunoi  et  al.  2000).
Considering  wortmannin  stimulatory  effect  on  glucose  uptake  and
glucose-dependent  insulin  secretion  hypothesizes  that  inhibition  of
PI3Kinase may activates parallel compensatory mechanisms within the
beta  cell  which  results  in  a  glucose  influx  into  the  cell  and  insulin
secretion respectively. It creates unique research opportunity to address
this finding. 
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4.8  The  mTOR  role  in  4-hydroxyisoleucine  and  isoleucine
mechanism of actions 
PI3kinase plays an essential role in insulin-stimulated glucose uptake,
GLUT 1  and  GLUT 4  translocations  in  adipose  and other  peripheral
tissues responsible for glucose disposal which is   blocked completely by
wortmannin (Okada et al. 1994, Clarke et al. 1994). mTOR (mammalian
Target  of  Rapamycin)  as  downstream  molecules  in  PI3Kinase-AKT
(protein kinase B) pathway is a critical  cellular  regulator.  The mTOR
signalling pathway integrates a large number of environmental changes
and cellular  stresses,  including reactive  oxygen species,  hyperosmotic
and  nutrient  depletion  stress  as  well  as  growth  factor  and  cytokine
signalling (Corradetti  et al. 2006). Previous studies showed that mTOR
enhances  the intrinsic  activity  of  GLUT1 transporters (Wieman  et  al.
2007), GLUT 1 expression and glucose uptake (Buller  et al. 2008). It
was  observed  that isoleucine  stimulates  insulin-independent  glucose
uptake mediated by activating PI3Kinase and independent of activation
of  mammalian  target  of  rapamycin  (mTOR)  like  leucine  which  is  a
potent  activator  of  mTOR  (Doi  et  al.  2003,  Zhang  et  al. 2007).  In
previous  experiments  it  was  determined  that  PI3  Kinase  activity  is
directly involved in both isoleucine and 4-hydroxyisoleucine ability in
stimulating  glucose  uptake  in  the  beta  cell.  Considering  the  role  of
mTOR in PI3 Kinase signalling pathway and glucose uptake, the effect
of isoleucine and 4-hydroxyisoleucine were studied in the presence of 10
nM KU 0063794, a selective inhibitor of mammalian target of rapamycin
(mTOR)  (IC50 =10  nM  for  mTORC1  and  mTORC2)  without  any
activity  at  PI3-kinase  or  76  other  kinases  within  the  cells  (García-
Martínez et al. 2009).  
111
Results revealed that inhibition of mTOR solely with a specific inhibitor
does  not  change  the  effect  of  isoleucine  and  4-hydroxyisoleucine  on
increasing glucose consumption in beta cells (Fig 4.8) which reiterate the
Doi's  findings about isoleucine and extends it  to 4-hydroxyisoleucine.
Persistent results in each set of experiments by KU 0063794 determine
that mTOR does not play essential role in the mechanisms of action of
isoleucine and 4-hydroxyisoleucine. 
Figure 4.8. The effect of  mTOR inhibitor on glucose consumption rate of  4-
hydroxyisoleucine and isoleucine in BRIN-BD11 cell. mTOR inhibition does not
change the glucose uptake in BRIN-BD11 cells indicates that mTOR does not play
main role in uptaking glucose by pancreatic beta cells. There are also no changes in
the activity of  isoleucine and 4-hydroxyisoleucine in  the presence of  10 nM KU
0063794,  a  selective  mTOR  inhibitor.  Isoleucine  and  4-hydroxyisoleucine
significantly  increased  glucose  consumption  in  BRIN-BD11  cells  incubated  with
RPMI-1640 with 22 mM glucose (p<0.01).
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PI3 Kinase-AKT-mTOR pathway plays important role in glucose uptake
regulation  as  one  of  the  major  downstream  intracellular  signalling
pathways in response to binding of many substances like growth factor
and insulin to their receptors on the surface of the cell. Activation of PI3
Kinase-AKT-mTOR pathway  increases  glucose  uptake  via  interacting
with GLUT 1 and in less extent GLUT 3 expression and activity through
mTOR  (Fig  4.9) (Bryan  et  al.  2005).  GLUT1  plays  critical  role  in
maintaining basal glucose uptake required to sustain cellular respiration
in all cells. Expression levels of GLUT1 in cell membranes are increased
by reducing glucose levels and decreased by increased glucose levels.
GLUT1 is able to compensate for GLUT2 deficiency or under expression
in  beta  cells  and  maintains  an  appropriate  rate  of  glucose  uptake  to
sustain glucose metabolism in pancreatic beta-cells (Liang et al. 1997). 
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Figure 4.9.  AKT and mTOR are  activated  by membrane receptors  and stimulate
glycolysis in part by AKT-induced localization of the glucose transporters, including
GLUT1 and GLUT3, to the cell surface, and maintenance of hexokinase function in
the  absence  of  extrinsic  factors  with  resultant  glucose  production.  PI3K,
phosphatidylinositol-3-kinase. (Adapted from  Bryan et al. 2005)
It drew the attention to investigate the role of the GLUT 1 in the effect of
isoleucine and 4-hydroxyisoleucine on glucose uptake considering that
the GLUT1 is the most abundant glucose transporters in the beta cell
which facilitates a main glucose influx into the cell. 
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4.9 Role of GLUT1 in 4-hydroxyisoleucine and isoleucine mechanism
of actions in BRIN-BD11 cells
BRIN-BD11  cells  were  incubated  24  hours  with  isoelucine  and  4-
hydroxyisoleucine in RPMI 1640 medium containing 22 mM glucose in
front  of  5  μM STF 31,  a  cell-permeable  sulfonamide that  selectively
inhibits  GLUT1 and glucose  uptake  (Chan  et  al.  2011)  to  achieve  a
specific  GLUT1  inhibiting  status  without  compromising  other
transporters  in  order  to  evaluate  the  role  of  GLUT1 in  the  effect  of
isoleucine and 4-hydroxyisoleucine. 
STF 31 was shown to inhibit the growth of VHL-deficient renal cell
carcinomas (RCCs) dose-dependently (5 μM) by directly targeting
GLUT1 without binding to other glucose transporters, and it does not
inhibit  a  broad  range  of  50  tested  kinases  (Chan  et  al.  2011).  4-
hydroxyisoleucine glucose consumption increasing effect in BRIN-BD11
cells reduced in front of STF 31 but GLUT1 inhibition did not show
any  significant  changes  in  the  activity  of  isoleucine  on  glucose
consumption in  BRIN-BD11 cells   (Fig 4.10a).  ATP measurements
confirmed a remarkable reduction in ATP content of the cell in STF 31
groups after 24 hours  (Fig 4.10b). The  findings determine that   4-
hydroxyisoleucine mechanism of action is profoundly dependent on
GLUT1  activity  and  it  is  in  line  with  its  mode of  actions,  insulin-
independent increase of  basal  glucose  uptake  in  peripheral  tissues  as
GLUT1 is responsible for basal glucose uptake in cells. 
The beta pancreatic cell membrane has a very high capacity of transporting
glucose into the cytoplasm compared to other  cells.   High capacity  of
glucose transport in beta pancreatic cell is  due to  GLUT2  which has a
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very  high Vmax and  high  Km of  15-20 mM (Guillam  et  al.  1997).
GLUT1 with low Km is also expressed in pancreatic  beta cells.  A
previous study showed thatGLUT1 expression is higher when glucose is
low, and GLUT2 expression is more profound when glucose is high in
the culture media (Tal et al. 1992). Incubation of BRIN-BD11 cell with
22 mM glucose and selective GLUT1 inhibitor, STF 31 for 24 hours
increases glucose uptake significantly,  which implicates that GLUT1
inhibition may lead to over-expression of GLUT2 or shifting towards
other uptake mechanisms as a compensatory phenomena. Rabuazzo et
al in 1993 showed that  inhibition of only GLUT1 when GLUT2 is
functioning in hamster-derived pancreatic beta cell line (HIT) enhances
insulin release. In our study,  STF 31 increased glucose consumption,
which can be explained by referring to Rabuazz's findings as an insulin
release enhancement depends on higher rate of glucose transport which
means  more  glucose  consumption.  If   GLUT1  inhibition  enhances
insulin secretion in beta cell as shown in Rabuazzo study and insulin
secretion process consumes energy (ATP) and logically the ATP content
should  drop  after  an  increase  prior  to  release.  The  end  point
measurement of the cell ATP content after 24 hours incubated with STF
31 showed significant drop.
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Figure 4.10. Glucose consumption and ATP content in BRIN-BD11 cell in the
presence of STF 31. Glucose consumption was  increased  significantly  (p<0.01) in
BRIN-BD11 cell in the presence of 5 μM of STF 31 after 24 hours incubation. The
glucose  consumption  increase  was  inhibited  significantly  in  4-hydroxyisoleucine
group in front of STF 31(p<0.01) but not in isoleucine group (a).  The ATP content of
the cells decreased dramatically by STF 31 (p<0.001) and remained unchanged in all
STF 31 groups including isoleucine and 4-hydroxyisoleucine (b). 
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GLUT1  inhibition  dramatically  interferes  with  4-hydroxyisoleucine
activity as in all our previous findings the 4-hydroxyisoleucine had the
higher increasing effect on glucose consumption in BRIN-BD11 cell
compared to isoleucine but its effect reduced significantly in front of
STF 31.  It  can  be  hypothesized  by  reviewing  current  findings  that
GLUT1 plays a major role in 4-hydroxyisoleucine mechanism of action
but not in isoleucine.
4.10 The role of calcium on the effects of 4-hydroxyisoleucine and
isoleucine on glucose  consumption rate and ATP content in BRIN-
BD11 cells
The glucose transporter 1 (GLUT1) is expressed in a wide variety of cell
types and is largely responsible for maintaining the basal level of glucose
uptake. A previous study suggested that cytosolic calcium plays a role in
modulating basal  glucose uptake and GLUT1 activity.  It  also showed
that lowering extracellular calcium decreases basal glucose uptake in rat
epithelial cells (Quintanilla et al. 2000). It was observed that intracellular
calcium stimulates glucose uptake in skeletal muscle cell and  inhibition
of calcium release from the  sarcoplasmic reticulum (SR) reduces sugar
uptake,  whereas  the  increase  of  calcium  release  from  SR  stimulates
glucose  transporter  activity  (Youn  et  al.  1991).  A recent  study  using
shRNA-mediated  silencing  showed  that  the  recently-identified
mitochondrial  calcium  uniporter  (MCU)  is  essential  for  a  sustained
glucose-induced increase in the cytosolic ATP/ADP ratio in pancreatic
beta  cells  (Tarasov  et  al.  2012).  The mitochondrial  calcium uniporter
(MCU) is located in the mitochondrial inner membrane that regulates
calcium uptake into mitochondria and plays a key role in mitochondrial
calcium homeostasis  and cellular  physiology.  It  regulates  cytoplasmic
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calcium signals,  cell  bioenergetics  and also  glucose-dependent  insulin
secretion  in  pancreatic  beta-cells  by  regulating  mitochondrial  calcium
uptake (Alam et al. 2012, Mallilankaraman et al. 2012). 
Considering the related available data for the role of calcium and MCU
as a mitochondrial calcium homeostasis regulator drew the attention to
evaluate the role of mitochondrial calcium uniport channels in isoleucine
and 4-hydroxyisoleucine effects in BRIN-BD 11 cell glucose uptake. To
study the calcium role, Ruthenium Red has been used. Ruthenium Red is
an  inhibitor  of  mitochondrial  calcium uniporter  (MCU)  which  blocks
calcium uptake and release from mitochondria (Bernardi et al. 1984). It
also inhibits calcium release from ryanodine-sensitive intracellular stores
and blocks  cell  membrane-located  capsaicin-activated  cation  channels
(Bernardi  et al. 1984, Szallasi et al. 1999, Israelson et al. 2008). It was
shown that ruthenium red inhibits neurotransmitter release by blocking
voltage-sensitive  Ca2+ channels  (Xu  L  et  al.  1999).  Ruthenium  red
efficiently  blocks  the  L-type  calcium  channel  in  a  dose-dependent
manner  which reaches  an inhibition of  85% at  5  µM (Malécot  et  al.
1998). 
To investigate the role of calcium in the modulation of glucose uptake in
BRIN-BD11 cells  by  isoleucine  and  4-hydroxyisoleucine,   cells  were
treated  with  5  µM of  ruthenium  red  simultaneously  with  500  µM
isoleucine and 4-hydroxyisoleucine  leaded to very significant decrease
in glucose consumption in 4-hydroxyisoleucine group and inhibition of
the glucose consumption increase in isoleucine groups (Fig  4.11a).
Several  experiment  repeats  with five replicates in each set,  showed a
persistent result which implicates the roles of calcium in both isoleucine
and  4-hydroxyisoleucine  mechanisms  of  action.  Inhibition  of
mitochondrial calcium uniporter (MCU), calcium channels and calcium
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signalling  by  ruthenium  red not  only  inhibits  4-hydroxyisoleucine
activity  but  creates  a  reverse  activity  in  4-hydroxyisoleucine.  The
glucose  consumption  decreased  significantly  in  4-hydroxyisoleucine
group treated with  ruthenium red compared to controls  (Fig 4.11a).
Contrary  to  4-hydroxyisoleucine  group,  glucose  uptake  remarkably
increased in isoleucine group treated by ruthenium red compared to
controls(Fig 4.11a). It seems that intracellular calcium signalling does
not  play  an  equal  role  in  4-hydroxyisoleucine  and  isoleucine
mechanism of actions. It may be explained by referring to the previous
findings about the relation of calcium and glucose uptake that inhibition
of cytoplasmic calcium channels by ruthenim red alongside with MCUs
result in decrease of cytoplasmic calcium due to reducing the diffusion
of  extracellular  calcium  (Bernardi  et  al.  1984,  Szallasi  et  al.  1999,
Israelson  et  al.  2008).  Reducing  cytoplasmic  calcium  triggers  the
calcium release from sarcoplasmic reticulum (SR) and stimulates glucose
transporter activity (Youn et al. 1991).  We also observed that  ruthenium
red is solely  increasing glucose consumption in BRIN-BD11 cells (Fig
4.11a).  The  reduction  in  cellular  ATP content  after  24  hours  in  all
ruthenium  red  groups  and  more  significantly  in  isoleucine  plus
ruthenium red  (Fig  4.11b) shows  that  inhibition  of  calcium channels
affects  bioenergetic  status  of  the  cell  and indicates  important  role  of
calcium in both in isoleucine and 4-hydroxyisoleucine effects.  BRIN-
BD11 cell's glucose uptake paradoxical behaviour in isoleucine and 4-
hydroxyisoleucine groups in the presence of ruthenium red determine a
distinct difference in 4-hydroxyisoleucine and isoleucine mechanisms of
action which is in line with our previous findings. The ruthenium red
neutralizes the glucose uptake stimulatory effect of 4-hydroxyisoleucine
but  on  the  other  hand  it  has  synergy  with  isoleucine  glucose  uptake
activity.   
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   a)
b)
Figure 4.11.  The effect of ruthenium red on Isoelucine and 4-hydroxyisoleucin
activities in BRIN BD11 cells. The glucose consumption in the presence of 5 µM
ruthenium red in BRIN-BD11 cell in RPMI-1640 with 22 mM glucose after 24 hours
(a). Glucose consumption decreased very significantly in 4-hydroxyisoleucine group
treated simultaneously with ruthenium red (p<0.01) and there is no sign of inhibition
in  isoleucine  group.  Isoleucine  showed  higher  glucose  consumption  in  front  of
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ruthenium red compared to isoleucine control without ruthenium red (a) which shows
paradoxical behaviour of 4-hydroxyisoleucine in combination with ruthenium red on
glucose  uptake.  Ruthenium  red  is  solely  increasesing  glucose  consumption
significantly  (p<0.01)  (a).   The  ATP  concentration  of  cells  at  the  end  of  the
experiment shows a significant reduction in ATP content in all ruthenium red treated
groups (p<0.01) and with greater decreases in isoleucine group (b) Non treatment
groups did not show any significant difference in ATP content (c).
The  intracellular  calcium  level  is  regulated  by  the  sarcoplasmic
reticulum (SR) as a reservoir of calcium, mitochondria and cytoplasmic
membrane calcium channels.  Intracellular  calcium uptake into the SR
regulates by  the sarcoplasmic  reticulum  Ca2+-ATPase 2a (SERCA 2a)
calcium pump and remaining of cytoplasmic calcium is removed via the
Na+/Ca2+ exchanger  (NCX)  or  taken  up  into  mitochondria  by  the
mitochondrial calcium uniporter (MCU) (Bodi et al. 2005, Cingolani et
al. 2007). Mitochondrial oxidative phosphorylation as a source of ATP
production  is  dependent  on  mitochondrial  calcium  uptake  via  a
ruthenium red-sensitive  mitochondrial  calcium uniporter  (MCU).  The
MCU calcium transport rate is slow and its affinity for calcium is low
(Km 10-20 mM).  The Na+/Ca2+ exchanger is responsible for extruding
calcium from mitochondria  (Denton  et  al.  1985,Gunter  et  al.  1990).
Calcium release from SR is controlled by ryanodine receptors (RyR)
and inositol triphosphate receptors (IP3R). Depletion of the SR calcium
reservoir is sensed by stromal interaction molecules (STIMs) located
on the SR membrane and monitor its calcium content. Sensing of the
low  calcium  content  of  SR  by  STIMs  activates  store-operated
calcium channels  (SOCE) on the membrane leading to calcium influx
stimulation (Fig 4.12) (Mascia et al. 2012). G protein coupled receptor
activation  will  increase  the  release  of  calcium from SR through  the
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production of IP3, (Inositol 3 Phosphate) which binds to IP3 receptor on
the surface of SR (Mascia et al. 2012). 
Considering cellular calcium homeostasis shows that ruthenium red
reduces calcium release from SR in pancreatic beta cells by inhibiting
ryanodine  receptors  (RyR),  calcium  influx  by  blocking  calcium
channels  on   cytoplasmic  membrane  and  mitochondrial  calcium
uptake  by  inhibiting  MCUs  which  lead  to  intracellular  calcium
depletion. The cellular protective mechanism will try to compensate
intracellular calcium depletion via increasing calcium release from the
SR by activating IP3 receptors (parallel gate which is not blocked by
ruthenium  red)  through  triggering  production  of  IP3  by  intrinsic
enzymatic  activity,  reducing  calcium  uptake  by  sarcoplasmic
reticulum  Ca2+-ATPase  2a  (SERCA2)  and  stimulation  of  different
types  of  membrane  calcium  channel  to  increase  calcium  influx.
Activation  of  parallel  unblocked  calcium  gates  on  SR  leads  to
depletion  of  SR  calcium  and  activation  of  stromal  interaction
molecules  (STIMs)  as  SR  calcium  sensor.  Stromal  interaction
molecules (STIMs) stimulate calcium influx as well. Other important
pumps could help the cell to compensate the lack of cytosolic calcium
in such a condition is a sodium-calcium exchanger (NCX).               
The sodium-calcium  exchanger   (NCX)  is  a  high
capacity antiporter membrane  protein  uses  the  electrochemical
gradient  energy,  allowing sodium to  flow down its  gradient  across
the plasma  membrane in  exchange  for  the  counter-transport
of calcium ions.  The  NCX  is  important  in  cellular  calcium
homeostasis expresses in many different cell types and is capable of
exchanging a single calcium ion with three sodium ions in both ways
depend on a gradient (Yu SP et al. 1997, Dipolo et al. 2006).
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Figure 4.12.  Integration of the calcium signaling circuitry.  The major regulators  of
calcium homeostasis  in  keratinocytes  are  depicted.  Plasma membrane pumps and
channels  (PMCA, NCX,  and SOCE) regulate  flux  in  and out  of  the  cytosol.  G-
protein–coupled receptors (calcium-sensing receptor (CaR) and others not shown)
initiate signals that modify compartmentalized calcium stores (e.g.,  IP3). Calcium
ATPases on organelles (SERCA, SPCA1) monitor and replenish intracellular storage
sites.  CCa2+,  calcium;  DAG,  diacylglycerol;  ER,  endoplasmic  reticulum;  IP3R,
inositol  1,4,5-trisphosphate  receptor;  NCX,  Na+/Ca2+ exchanger;  NFAT,  nuclear
factor of activated T cells; PIP2, phosphatidylinositol 4,5-bisphosphate; PKC, protein
kinase C; PLC, phospholipase C; PMCA, plasma membrane Ca2+ ATPase; SERCA,
sarco  (endo)plasmic  recticulum  Ca2+ ATPase;  SOCE,  store-operated  calcium
channels; STIM, stromal interaction molecule; TRPC, transient receptor potential C.
The figure is modified from Savignac  et al. (2011) with permission from Elsevier.
(Completely adapted from Mascia et al . 2012) 
All these pathways for balancing disturbed calcium homeostasis need
energy and ATP production may slow down due to MCU blockage by
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ruthenium  red  (Fig  4.11b).  To  compensate  for  slow  energy
production, cells attempt to take up  more fuel by increasing glucose
uptake  to boost up energy production in mitochondria. On the other
hand  increasing glucose uptake  (Fig 4.11a)  itself  leads  to  beta  cell
membrane  depolarization and subsequent calcium influx  (Srinivasan
et al.  2002).  Ruthenium red indirectly increases glucose uptake via
disturbing intracellular  calcium homeostasis.  Previous  animal  trials
showed that  verapamil, a calcium channel blocker which blocks L-
type calcium  channels mainly and prevents cellular calcium influx,
reduces  blood  glucose  level  and  increased  insulin  levels  in  STZ-
induced diabetic  mice  by  increasing glucose uptake in beta cells and
enhancing pancreatic beta cell function (Xu G et al. 2012).   
Mitochondrial  calcium  uniporters  (MCUs)  and  calcium  roles  in  4-
hydroxyisoleucine  and  isoleucine  effects  attracted  the  attention  by
observing the effect of ruthenium red as an MCU inhibitor on isoleucine
and 4-hydroxyisoleucine activity. Does MCUs activator alter isoleucine
and 4-hydroxyisoleucine effects on glucose consumption, If it is assumed
based on current findings that MCUs inhibition can eliminate the effect
of the 4-hydroxyisoleucine. To answer the question, BRIN-BD 11 cells
were incubated with 500 µM isoleucine and 4-hydroxyisoleucine for 24
hours in  the presence of  20 µM of kaempferol,  a  naturally  occurring
flavonoid  found  in Gingko  biloba and  red  wines  that  activates  the
mitochondrial calcium uniporters (MCUs) (EC50 = 7 μM) (Montero  et
al. 2004, Vay  et al. 2007). 
Kaempferol is able to increase glucose uptake in 3T3-L1 adipocytes and
act  as  an  anti-diabetic  agent  via  multiple  targets  such  as  acting  as  a
partial agonist of PPARgamma (Fang et al. 2008). It was also observed
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that  Kaempferol metabolite, kaempferol 3-neohesperidoside, is capable
to  increase  glucose  uptake  in  myocytes  mediated  by  PI3Kinase  and
protein  kinase  C  (PKC)  pathways  (Zanatta  et  al.  2008).  Glucose
consumption  in BRIN BD11 cells increased significantly after 24 hours
incubation  with  20  µM of  kaempferol  without  noticeable  changes  in
cellular ATP contents at the end of the experiment  (Fig 4.13a,b). This
finding is in line with previous studies mentioned above and confirms its
glucose  uptake  stimulatory  property.  Kaemferol  produced  the  similar
amount  of  increase  in  glucose  consumption  as  isoleucine  alone,  but
significantly  lower  than the 4-hydroxyisoleucine  which shows that  4-
hydroxyisoleucine stimulates the glucose uptake in much greater extent
to the kaempferol and isoleucine. 
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 a)
b)
Figure  4.13.  The  effect  of  kaempferol  on  glucose  consumption  in  BRIN-
BD11cells. Glucose  consumption  was  significantly  increased  by  20  µM  of
kaempferol   (p<0.01) and dominantly in both isoleucine and 4-hydroxyisoleucine
groups incubated simultaneously with kaempferol (p<0.001) (a). A synergistic effect
of  kaempferol with 4-hydroxyisoleucine and in greater extent with isoleucine has
been  observed  (a).  ATP  content  of  cells  does  not  change  in  the  presence  of
kaempferol and kaempferol plus isoleucine but a noticeable decrease was observed in
4- hydroxyisoleucine plus Kaempferol group (p<0.05) (b). 
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Incubation of BRIN BD11 cells with 4-hydroxyisoleucine and isoleucine
alongside with 20 μM kaempferol in the same time for 24 hours   showed
a  remarkable  increase  in  glucose  consumption  in  both  4-
hydroxyisoleucine and isoleucine groups with kaempferol compared to
controls (Fig 4.13a). Interestingly, the glucose consumption in isoleucine
with Kaempferol group increased very significantly by more than 3 mM
compared to isoleucine alone (p<0.001). In all our previous findings, 4-
hydroxyisoleucine solely created greater effect than isoleucine but the
combination of isoleucine and kaempferol could create the equal effect
as  4-hydroxyisoleucine  with  or  without  kaempferol.  These  findings
indicate  a  strong  synergistic  effect  between  kaempferol  and  both
4hydroxyisoleucine  and  isoleucine  on  stimulating  glucose  uptake  in
BRIN BD 11 cells and also demonstrate the role of calcium and MCU in
mechanisms of action of 4-hydroxyisoleucine and isoleucine. The results
also  show  the  important  role  of  calcium  and  mitochondrial  calcium
uniporters  in  glucose  uptake  mechanism.  ATP measurements  did  not
show changes in ATP content between kaempferol and isoleucine plus
kaempferol  group  but  a  significant  decrease  were  observed  in  ATP
content  of  BRIN-BD 11 cells  in 4-hydroxyisoleucine plus kaempferol
group (Fig 4.13b).
A previous gene expression study using microarray and real-time PCR
identified a set of metabolically relevant genes were induced by 20 μM
kaempferol  after  24 hours including peroxisome proliferator–activated
receptor  coactivator-1,  carnitine palmitoyl  transferase-1,  mitochondrial
transcription  factor  1,  citrate  synthase,  and  uncoupling  protein-3  (da-
Silva et al. 2007). It is also shown that kaempferol increases the oxygen
consumption and cellular energy expenditure via increasing cyclic AMP
in skeletal  muscle  (da-Silva  et  al.  2007).   Synergistic  effect  between
isoleucine,  4-hydroxyisoleucine  and  kaempferol  suggests  that  the
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previously  identified  metabolically  relevant  genes  induced  by
kaempferol in da-Silva et al study could have direct or indirect roles in
the mechanisms of action of 4-hydroxyisoleucine and isoleucine which
create a new interesting area of further investigation. 
The results from ruthenium red and kaempferol experiments support
that  intracellular  calcium  signalling  and  mitochondrial  calcium
uniporters (MCUs) play an important role in 4-hydroxyisoleucine and
isoleucine glucose uptake stimulatory effect  but  their  roles are not
similar in isoleucine and 4-hydroxyisoleucine mechanisms of action.  
Analysing data from the effects of ruthenium red (Fig 4.11) as an MCU
and calcium signalling inhibitor and kaempferol as an MCU activator
(Fig 4.13) on isoleucine and 4-hydroxyisoleucine activity in BRIN-BD
11 cells indicate:
• Interference  with  calcium signalling  and  mitochondrial  calcium
uniporter  (MCU)  using  inhibitor,  inhibits  4-hydroxyisoleucine
effect  on increasing glucose  consumption,  but  not  the  effect  of
isoleucine  whereas  using  MCU  activator  enhances  both  4-
hydroxyisoleucine and in greater degree isoleucine effects which
means the important roles of calcium signalling and MCU in 4-
hydroxyisoleucine and isoleucine mechanisms of action.
• Isoleucine activity exhibits a significant increase in the presence of
both MCU activator  and inhibitors  ,  which is  different  from 4-
hydroxyisoleucine behaviour.  Unlike isoleucine,  inhibition of  4-
hydroxyisoleucine   effect  on  stimulating  glucose  uptake  in  the
presence of ruthenium red indicates that calcium signalling is an
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essential  for  its  mechanism  of  action.  It  also  reiterates  that
calcium's role in the mechanism of action of 4-hydroxyisoleucine
is different from isoleucine. 
• These findings support  that  different  mechanisms and pathways
are  involved  in   actions  of  isoleucine  and  4-hydroxyisoleucine
apart  from  some  similarities  in  their  effects   and  molecular
structures.
4.11 The effect of the UK-5099 as a mitochondrial pyruvate carrier
(MPC)  inhibitor  on  4-hydroxyisoleucine  and  isoleucine  glucose
utilisation in BRIN-BD11 cells
The results of previous experiments with ruthenium red and kaempferol
demonstrated  the  role  of  calcium  and  in  a  broader  spectrum,  the
mitochondria in 4-hydroxyisoleucine and isoleucine effects on glucose
uptake   in  BRIN-BD 11  cells.  We also  observed  in  all  the  previous
experiments that the ATP content of the cells using end point cell ATP
content  measurement  at  the  end  of  each  experiment  did  not  change
considering  the  increase  in  glucose  consumption  induced  by  4-
hydroxyisoleucine  and  isoleucine.  The  BRIN-BD  11  cell  is  a  beta
pancreatic cell which consumes glucose to make energy in the form of
ATP for  its  biological  activities  unlike  adipose  cell  which  can  store
excess glucose by transforming it to triglyceride. As the glucose uptake
is  an  energy  consuming  activity  and  considering  the  previous
observations  in   the  current  study  showing  the  glucose  consumption
increases in front of 4-hydroxyisoleucine and isoleucine while the ATP
content  unchanged  ,  suggest  that  energy  production  process  in
130
mitochondria is essential for 4-hydroxyisoleucine and isoleucine effects.
To evaluate the role of mitochondria and energy production cycle in the
effect of isoleucine and 4-hydroxyisoleucine, we designed an experiment
to  assess  4-hydroxyisoleucine  and  isoleucine  effects  on  glucose
consumption in BRIN-BD 11 cells in front of a mitochondrial pyruvate
carrier (MPC) blocker. Pyruvate is the end product of glycolysis and a
major substrate for the tricarboxylic acid (TCA) cycle in mitochondria
for producing ATP. Pyruvate is produced in cytosol and across the inner
mitochondrial  membrane  via  MPCs  which  are  located  in  inner
mitochondrial membrane (Herzig  et al.  2012). Mitochondrial pyruvate
carrier (MPC) is essential for producing ATP. 
The  BRIN-BD  11  cells  were  incubated  with  500  µM  4-
hydroxyisoleucine and isoleucine simultaneously  with 35 µM 0f  UK-
5099, an a-cyanocinnamate analogues which acts as specific and potent
inhibitors of mitochondrial pyruvate carrier (MPC) activity (Halestrap.
1978).  A recent  study  by  Divakaruni   et  al  showed  that  UK  5099
increases glucose uptake in myocytes which directly proportional to the
extent  of  respiratory  inhibition  by  UK  5099  but  our  study  results
indicated  that  UK 5099  did  not  change the  glucose  consumption  in
BRIN-BD 11  while  the  ATP content  dramatically  decreased  after  24
hours incubation (Fig 4.14). This finding is not in line with Divakaruni et
al study. The difference between the biology of beta pancreatic cell and
myocytes  which  used  in  Divakaruni  study  could  explain  different
behaviours. On the other hand we expected to see a significant reduction
in glucose consumption in the UK 5099 control  group as intervening
with ATP production cycle should reduce glucose uptake due to cellular
energy depletion but the glucose consumption in the UK 5099 groups
remained unchanged compared to no treatment control. However we did
not detect an increase in glucose uptake in the UK5099 group same as
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Divakaruni observed in his study  in myocytes but unchanged glucose
consumption  in  BRIN-BD  11  in  front  of  the  UK  5099  shows  that
mitochondrial respiratory inhibition in beta cell may activate a feedback
to push the cell to take up more glucose for compensating the disrupted
energy production cycle. 
Interestingly isoleucine and 4-hydroxyisoleucine effects were diminished
significantly  in  front  of   the  UK  5099  (Fig  4.14)  compared  to  the
controls.  The  results  indicate  that  mitochondria  and  ATP production
cycle within the mitochondria are essential for both 4-hydroxyisoleucine
and  isoleucine mechanisms of action.   It  raises a question for  further
study  about  the  effect  of  isoleucine  and  4-hydroxyisleucine  on
mitochondrial activity and glycolysis pathway in the cell. Theoretically
based on these findings,  it  is  expected that  the mitochondrial  activity
may increase in front of 4-hydroxyisoleucine and isoleucine to drive the
cells  towards  more  glucose  uptake  then  it  could  justify  why
mitochondrial pyruvate carrier inhibition blocks 4-hydroxyisoleucine and
isoleucine  effects.  It  is  very  important  to  investigate  the  effect  of  4-
hydroxyisoleucine and isoleucine on mitochondrial respiration because
of the essential role of mitochondria in diabetes and insulin resistance.  
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 a)
b)
Figure 4.14. The effect of UK 5099 on glucose consumption in BRIN-BD 11 cells.
There is no significant change in glucose consumption in BRIN-BD 11 cell after 24
hours incubation with 35 µM UK 5099 (a). Glucose consumption shows a dramatic
decrease in both isoleucine and 4-hydroxyisoleucine in front of UK 5099 (p<0.01)
compared to UK 5099 and no treatment control groups (a). ATP level significantly
reduced in all UK 5099 groups (p<0.01) without difference between isoleucine and
4-hydroxyisoleucine groups (b).
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4.12 Analysis of the effects of 4-hydroxyisoleucine and isoleucine on
mitochondrial respiration in BRIN-BD 11 cells with Seahorse XF-24
autoanalyser
We  used  the  Seahorse  cell  metabolism  analyser  to  evaluate  the
mitochondrial activity and glycolysis within the BRIN-BD 11 cells after
24 hours incubation with 500  µM isoleucine and 4-hydroxyisoleucine.
Seahorse XF (Extracellular Flux) analyser is the platform for metabolic
assays which simultaneously and in real time measures the two major
energy  producing pathways  of  the  cell,  mitochondrial  respiration  and
glycolysis,  in  a  microplate.  The  seahorse  XF  autoanalyser  measures
oxygen  consumption  rate  (OCR)  as  the  indicator  of  mitochondrial
respiration  and  extracellular  acidification  rate  (ECAR)  which  is
predominately the result of glycolysis at intervals of approximately 2-5
minutes.  We  measured  the  oxygen  consumption  rate  (OCR)  and
extracellular  acidification  rate  (ECAR)  in  BRIN-BD11  cells  after  24
incubation with isoleucine and 4-hydroxyisoleucine for  30 minutes in
three  replicates  for  each  group  to  study  changes  in  the   activity  of
mitochondria  and  glycolysis.  Results  after  normalisation  using  cell
counts  showed that  oxygen consumption rate  (OCR) in BRIN-BD 11
cells was significantly higher in cells incubated with isoleucine and 4-
hydroxyisoleucine  compared  to  control  (Fig  4.15a).  The  OCR  was
significantly  higher  in  4-hydroxyisoleucine  group  compared  to
isoleucine group (Fig 4.15a,b). Increasing in OCR indicates that both 4-
hydroxyisoleucine and isoleucine increase the mitochondrial activity, but
4-hydroxyisoleucine effect on mitochondrial metabolism is much greater
than  isoleucine  in  BRIN-BD11  cells.  Extracellular  acidification  rate
(ECAR) measurement  showed a significant rise in 4-hydroxyisoleucine
group, but not  in isoleucine group (Fig 4.15c) which indicates the higher
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glycolysis rate in the cells incubated with 4-hydroxyisoleucine compared
to  isoleucine.  The  OCR/ECAR  ratio  is  significantly  higher  in  both
isoleucine  and  4-hydroxyisoleucine  groups  compared  to  control  (Fig
4.15d)  with no significant difference between the 4-hydroxyisoleucine
and isoleucine groups. Seahorse study revealed that 4-hydroxyisoleucine
increases  both  mitochondrial  metabolism  rates  shown  as  OCR  and
glycolysis  rate  shown  as  ECAR  but  isoleucine  only  increases
mitochondrial  metabolism  rate  without  changing  the  glycolysis  rate
significantly. These findings explain the inhibitory effect of the UK5099
as an MPC blocker on both 4-hydroxyisoleucine and isoleucine activities
in  BRIN-BD  11  cells.  It  also  indicates  that  their  activities  firstly
dependent  on  mitochondrial  activity  and  secondly  are  not  limited  to
glucose uptake increase but they can increase cell metabolism. There is
possibility  that  increasing glucose  uptake  by 4-hydroxyisoleucine  and
isoleucine is not a direct action due to increased glucose transporters or
glucose  uptake  pathways  within  the  cell,  but  it  could  be  the  indirect
result of increasing the cell basal metabolism in the deepest layer. One of
the important common underlying pathophysiology in both diabetes type
1 and 2 is cellular metabolic defect due to lack of insulin and insulin
resistance, resulted in diabetic metabolic complications. Considering the
facts that our previous animal study showed a comprehensive modifying
effect of 4-hydroxyisoleucine on different metabolic parameter such as
blood sugar, triglyceride, cholesterol in diabetes type 1 models without
changing the level of insulin, and the role of calcium signalling specially
mitochondria  calcium  transporters,  support  the  idea  that  4-
hydroxyisoleucine  and  in  lesser  extent  with  probably  different
mechanism  isoleucine  exert  their  anti-diabetic  properties  through
increasing cellular metabolism. Theoretically, if the metabolism of cell
increases, it needs to produce more energy and accordingly it requires to
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uptake more glucose from the peripheral. It means that facilitating the
glucose  uptake  or  increasing insulin  sensitivity  as  suggested  in  some
previous  literatures  may  not  be  a  direct  mechanism  of  4-
hydroxyisoleucine's anti-diabetes effect like any available anti-diabetic
medications but they could be the results of its effect.    
Seahorse  measurement  findings  showed  a  lower  glycolysis  rate  in
isoleucine  compared  to  4-hydroxyisoleucine  which  could  support  the
previous  findings  of  the  current  study  in  the  sense  that  4-
hydroxyisoleucine and isoleucine mechanisms of action are not similar
in the cellular level and interacts with wider targets and pathways within
the cell leading to facilitate glucose utilisation probably via enhancing
glycolysis beside other mechanisms. 
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    b)
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c)                                                                          d)
Figure  4.15.  Seahorse  XF-24  autoanalyser  results. Oxygen  consumption  rate
(OCR) in BRIN-BD11 cells increased very significantly after 24 hours incubation
with 500 µM isoleucine and 4-hydroxyisoleucine (p<0.001) (a). OCR measurement
indicated much greater increase in mitochondrial metabolism in 4-hydroxyisoleucine
groups  in  comparison  with  isoleucine  groups  (p<0.01)  (a,b).  Extra  cellular
acidification  rate  as  an  indicator  of  glycolysis  increased  significantly  in  4-
hydroxyisoleucine  groups  (p<0.05)  but  not  in  isoleucine  groups  (c).  A  non
statistically significant reduction in ECAR has been observed in isoleucine groups
(c). Average OCR/ECAR ratio shows significant increase in metabolic rate in cells
incubated with isoleucine and 4-hydroxyisoleucine (d). Average OCR/ECAR ratio is
lower in 4-hydroxyisoleucine because of increase in both ECAR and OCR which is
not observed in isoleucine (d).
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Chapter V
Conclusions
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We tried to create a diabetic rat model as close as possible to diabetes
type 1 condition with high blood glucose level and significant reduced
plasma insulin  and insulin secretion  capability  of  pancreatic  beta  cell
using a multiple intraperitoneal streptozotocine injection. Multiple dose
of streptozotocine injection for creating a stable type 1 diabetes animal
model is a well established and affordable technique which leads to a
significant  reduction in pancreatic  beat  cells  number  and concomitant
reduction in insulin secretion capacity (King AJ. 2012). There is always
a limitation to create a right animal model, but our diabetic animal model
exhibits all expected metabolic complications of diabetes, including high
blood  glucose,  triglyceride,  cholesterol  and  uric  acid  with  noticeable
reduction  in  insulin  compared  to  non  diabetic  animals.  Treatment  of
diabetic animals with 4-hydroxyisoleucine for four weeks modified the
metabolic  complications  of  diabetes  without  changing  insulin  level
compared to the diabetic control group. Our study findings follow the
same results from previous studies with different animal models close to
type 2 diabetes (Broca et al. 2004, Sauvaire et al. 1998, Singh et al. 2010
and  Haeri  et  al. 2009).  It  shows  that  4-hydroxyisoleucine  is  not
necessarily  dependent  on  insulin  for  exhibiting  its  anti-diabetic
properties  as  concluded in previous works.  4-hydroxyisoleucine could
increase glucose uptake without increasing insulin, otherwise in diabetes
type 2 animal models with inulinemia in Broca's study we should see
more sever insulinemia instead of significant reduction in insulinemia.  It
also  sheds  a  light  on  the  fact  that  4-hydroxyisoleucine  effect  is  not
limited to insulin and it  could exert more profound effect  in utilizing
extra glucose and also modifies metabolic pathways. 
We  chose  a  pancreatic  beta  cell  as  a  model  to  investigate  the  4-
hydroxyisoleucine for further clarification of our animal study findings.
Studying the 4-hydroxyisolecine effect  on pancreatic  beta cell   which
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does  not  exhibit  insulin  induced  glucose  uptake  pathway  allowed  us
assess its effect without insulin interference.  Isoleucine was chosen as a
positive  control  because  of  its  close  molecular  and  anti-diabetic
properties to 4-hydroxyisoleucine. Incubation of  BRIN-BD 11 cells as a
pancreatic  beta  cell  model  in  a  medium  with  22mM  glucose
concentration and 4-hydroxyisoleucine and isoleucine simultaneously for
24  hourse  did  not  show any  significant  increase  of  insulin  secretion
compared  to  control  despite  the  significant  increase  in  glucose
consumption. This finding was in line with our previous animal study
with  4-hydroxyisoleucine  showing  its  insulin  independent  glucose
lowering effect and confirms that 4-hydroxyisoleucine does not act as a
insulinotropic agent. Increase of glucose uptake in beta pancreatic cell
without changes in insulin secretion and decrease of blood glucose level
in our diabetic rat  model without significant change of plasma insulin
level,  indicate  that  the  mechanism  of  action  involves  in  4-
hydroxyisoleucine   is  different  from previously  understood.   All  the
suggested  mechanisms  such  as  insulin  sensitizing  and  stimulation  of
insulin secretion by previous  researchers are  not  a  direct  effect  of  4-
hydroxyisoleucine but they could be the indirect effects which resulted
from the activity of 4-hydroxyisoleucine on other mechanisms within the
cells.  It seems that both 4-hydroxyisoleucine and isoleucine utilize the
glucose  consumption  via  modulating  the  cellular  basal  glucose
consumption  because  they are capable of stimulation of glucose uptake
in pancreatic beta cell which does not express GLUT 4. It means that the
increase  in  glucose  uptake  is  handled  by  GLUT  1  or  GLUT  2.
Considering the fact that GLUT 2 is mainly expressed in beta cells not
other peripheral cells and both 4-hydroxyisoleucine and isoleucine are
able to show a hypoglycaemic effect in animal models and  peripheral
cells, such as adipose and muscle cells,  GLUT 1 could be a potential
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candidate for handling increased glucose uptake. It is also in line with
the role of GLUT 1 in maintaining basal glucose uptake required for a
sustain cellular respiration in most of the peripheral cells.
Endpoint measurements of ATP content of the BRIN-BD11 cells did not
show any significant  changes between 4-hydroxyisoleucine, isoleucine
and control groups as well as an insulin level measurement in culture
medium after 24 hours. Study with different concentrations of glucose
(5, 11 and 22 mM) indicated a direct correlation between the increase of
glucose uptake, ATP content and insulin secretion  (Fig 4.2,4.3)  which
confirm  the  physiologically  responsiveness  of  BRIN-BD  11  cell  as
expected.  It  means  that  the cell's  behaviour  follows the  physiological
pattern, increasing glucose concentration in medium as expected leads to
more glucose uptake and more ATP production, resulted in more insulin
secretion.   
Endpoint measurement of cell's ATP contents in a specific point of time
is not a accurate and proper method to investigate the ATP production
within the cell. As ATP continuously recycles within the cell, we need
more accurate quantitative method to measure ATP in a real-time format.
It raises the question that how the cell utilizes the extra glucose, which
entered the cell. It would be a key point in mechanisms of action of both
4-hydroxyisoleucine and isoleucine,  which requires more detailed and
sophisticated study.
Rendering  these  data  suggest  that  unlike  insulin,  which  increase
immediate  glucose  uptake  via  translocation  of  GLUT4  in  peripheral
tissues,  4-hydroxyisoleucine  and  isoleucine  may  increase  the  cellular
basal  glucose  consumption  by  interacting  directly  with  the  cellular
metabolism and energy production cycle. It also could explain why their
hypoglycaemic effects appear in the long term not short treatment as it
requires more time that basal glucose consumption picks up. 
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Inhibiting  a  variety  of  pathways  related  to  glucose  uptake  and  cell
metabolism using selected inhibitors revealed that there are substantial
differences between  isoleucine and 4-hydroxyisoleucine mechanisms of
action unlike their  similar  glucose uptake stimulation  effect  and anti-
diabetic properties which is greater in 4-hydroxyisoleucine (Fig 5.1). 
Figure 5.1. Summary of the in-vitro studies, testing the effect of different inhibitors
and  activator  on  4-hydroxyisoleucine  and  isoleucine  glucose  uptake  stimulation
activity. 
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As previous study showed that 4-hydroxyisoleucine effect was blocked
by  protein  synthesis  inhibition  using  CHX (Jaiswal  et  al.  2012),  we
tested the effect of CHX on isoleucine and 4-hydroxyisoleucine activity
in  BRIN-BD  11.  Adding  CHX  to  BRIN-BD11  cells  loaded
simultaneously  with  4-hydroxyisoleucine  and  isoleucine  revealed  that
unlike isoleucine, 4-hydroxyisoleucine glucose uptake stimulatory effect
reduced significantly in front of protein synthesis inhibitor. It suggests
that intermediary protein or proteins are involved in 4-hydroxyisoleucine
mechanism of action but not isoleucine. It could add explanation to why
4-hydroxyisoleucine  exhibits  its  hypoglycaemic  effect  in  long  term
treatment. 4-hydroxyisoleucine is dependent on the synthesis of specific
proteins and up-regulation of protein expression requires time. It requires
more investigation to study the effect of 4-hydroxyisoleucine on proteins
and genes expression in BRIN-BD 11 cell and other cell models such as
adipose and skeletal  muscle.  It  could be an important  subject  for  the
future research, providing more detailed insight about the mechanisms
are involved in 4-hydroxyisoleucin activity. 
As  explained  in  the  beginning,  GLUT  1  plays  a  major  role  in
maintaining  the  basal  glucose  uptake  required  to  sustain  cellular
respiration in all  types of cell.  GLUT 1 is the most abundant glucose
transporters in the beta cells and it is able to compensate for the GLUT 2
deficiency or under expression in beta pancreatic cells and maintain an
appropriate rate of glucose uptake to carry on glucose metabolism and
insulin  secretion  activity  in  pancreatic  beta  cells  (Liang  et  al.  1997).
Partially blocking the GLUT 1 activity in BRIN-BD 11 cells with STF-
31 as a highly selective GLUT 1 inhibitor, showed a direct dependency
of 4-hydroxyisoleucine on GLUT 1 in comparison with isoleucine. The
direct  correlation  between  GLUT 1  activity  and  4-hydroxyisoleucine
glucose uptake stimulation, suggests that 4-hydroxyisoleucine directly or
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indirectly increases cellular basal glucose uptake in long term and it may
increase  GLUT 1  expression  as  well.  It  supports  the  notion  that  4-
hydroxyisoleucine  exhibits  its  activity  in  the  long  term  treatment  in
animal  models  and  it  does  not  show an  immediate  glucose  lowering
effect  like  some  anti-diabetic  medications  which  increase  insulin
mediated  glucose  uptake.  Unfortunately,  it  was  out  of  our  available
resources to examine GLUT 1 expression in protein and gene level in
BRIN-BD 11 but  it  is  recommended for  the  future research to  study
GLUT 1 protein and gene expression in BRIN-BD 11 cell incubated with
4-hydroxyisoleucine  in  high  glucose  concentration.  Based  on  our
findings,  GLUT 1  plays  a  critical  role,  but  only  increasing  GLUT 1
expression  or  activity  do  not  completely  explain  all  4-
hydroxyisoleucine's  anti-diabetic  properties  and other  mechanisms are
involved. 
GLUT  1  inhibition  by  STF-31  reduces  the  glucose  uptake  in  4-
hydroxyisoleucine group but not isoleucine group.  On the other hand,
isoleucine  effect  was  diminished  by  inhibiting  PI3Kinase  activity  in
BRIN-BD11  cells  with  Wortmannin  without  significant  change  in  4-
hydroxyisoleucine activity.  PI3Kinase plays a  variety of  roles in  beta
pancreatic  cells  including  increase  of  insulin  gene  transcription,  cell
proliferation  and  suppress  appotosis  (Cerf.  2013).  It  was  shown  that
PI3Kinase inhibition in pancreatic  beta  cell,  increased glucose uptake
and glucose-stimulated insulin secretion (Zawalich et al. 2002). Broca's
study in 2004 showed that 4-hydroxyisoleucine administration increased
PI3Kinase activity associated with IRS-1 in both muscle and liver same
as  insulin  but  combining  insulin  and  4-hydroxyisoleucine  did  not
increase  PI3Kinase  activity  further.  Our  finding  does  not  support  the
direct  connection  between  4-hydroxyisoleucine  and  PI3Kinase.
Increasing of PI3Kinase activity as detected in previous study could be
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result of other pathways activation within the cell. In contrary with 4-
hydroxyisoleucine,  our  finding  supports  the  role  of  PI3Kinase  in
isoleucine activity. It is important to emphasis that our experiment only
provide  a  snap  shot  of  interaction  between  4-hydroxyisoleucine  and
isoleucine with PI3Kinase and it requires more investigation to assess
the  role  of  PI3Kinase  in  both  4-hydroxyisoleucine  and  isoleucine
mechanism of actions as PI3Kinase is involved in many pathways within
the cell.
It  is  an  interesting  finding  of  the  opposite  behaviour  of  4-
hydroxyisoleucine and isoleucine in front of different inhibitors, despite
their similar effect on increasing the glucose uptake in BRIN-BD11 cells.
The different behaviours of isoleucine and 4-hydroxyisoleucine in front
of  selected  inhibitors  clearly  demonstrate  a  difference   in   mode  of
actions between 4-hydroxyisoleucine and isoleucine. 
Insulin  independent  increase  of  glucose  uptake  in  BRIN-BD 11 cells
incubated by 4-hydroxyisoleucine and isoleucine raised a question about
the effect of these molecules on the cellular metabolism. As previously
explained, 4-hydroxyisoleucine seems to increase basal glucose uptake
in longer treatment in both in-vitro and in-vivo studies. Theoretically, It
requires that 4-hydroxyisoleucine facilitate the glucose utilization within
the  cell  via  increasing  cytoplasmic  metabolism  and  mitochondrial
respiration. 
The  first  step  towards  understanding  the  role  of  mitochondria  was
assessed  using  mitochondrial  calcium uniporter  (MCU)  inhibitor  and
activator. It allows to study the role of calcium in 4-hydroxyisoleucine
and  isoleucine  mechanisms  of  action  as  well  as  mitochondria.  The
increase  of  intracellular  calcium  and  release  of  calcium  from  the
sarcoplasmic reticulum (SR), stimulate glucose uptake (Youn et al. 1991)
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which shows the role of calcium in glucose uptake mechanisms. MCU
plays an essential role for a sustained glucose-induced increase in the
cytosolic ATP/ADP ratio in pancreatic beta cells (Trasov  et al.  2012).
Partial inhibition of MCU in BRIN-BD 11 using ruthenium red created
an  opposite  effect  in  4-hydroxyisoleucine  and  isolecuine  groups.  4-
hydroxyisoleucine  effect  was  diminished  significantly,  but  isoleucine
showed  some  degree  of  synergistic  effect  with  ruthenium  red  in
increasing  glucose  uptake.  Both  4-ydroxyisoleucine  and  isoleucine
showed a significant increase in  glucose uptake  caused by activation of
MCU using kaempferol as an MCU activator. It does not only support
the crucial role of mitochondria and calcium in their mechanisms, but
shows  different  mechanisms  are  involved.  It  seems  both  4-
hydroxyisoleucine and isoleucine interact with mitochondria but in via
seperate mechanisms. This experiment raises a strong idea to develop a
new  research  in  the  future  to  examine  the  role  of  calcium  in  4-
hydroxyisoleucine and isoleucine activities which could be one of the
important aspects of  4-hydroxyyisoleucine and isoleucine mechanisms
of action. 
Mitochondrial  metabolism  interruption  in  BRIN-BD11  cell  using  the
UK5099, a specific mitochondrial pyruvate carrier (MPC) inhibitor when
loaded simultaneously with 4-hydroxyisoleucine and isoleucine led to
significant inhibition of both 4-hydroxyisoleucine and isoleucine glucose
uptake  stimulation  effect.  It  proves  the  notion  about  the  role  of
mitochondrial respiration in their mode of actions. Real time metabolic
activity analysis of the BRIN-BD11cells after 24 hours incubation with
4-hydroxyisoleucine  and isoleucine  in  the  presence of  22mM glucose
with seahorse  autoanalyser  confirmed such a  role  of  mitochondria.  A
significant increase in metabolic activity was observed in cells after 24
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hours incubation with 4 hydroxyisleucine and isoleucine but significantly
greater  in  4-hydroxyisoleucine  group.  It  explains  the  greater  glucose
uptake  in  front  of  the  same  concentration  of  4-hydroxyisoleucine
compared  to  isoleucine  which  was  persistent  throughout  our
experiments.  Reviewing  the  seahorse  data  shows  a   meaningful
difference between isoleucine and 4-hydroxyisleucine apart  from their
effect  on  mitochondrial  activity.  Both  oxygen  consumption  rate  and
extracellular  acidification  rate  were  significantly  increased  by  4-
hydroxyisoleucine  but  no  significant  increase  was  detected  in
extracellular  acidification  rate  as  the  indication  of  glycolysis  in
isoleucine group. 4-hydroxyisoleucine interacts with glycolysis cycle in
the  cytoplasm  as  well  as  mitochondrial  respiration  but  isoleucine
increases the mitochondria respiration without affecting the glycolysis
rate.  It  could  explain  the  different  behaviours  of  isoleucine  and  4-
hydroxyisoleucine in front of some inhibitors in this study. 
Seahorse autoanalyser results ignited the idea that there may be a link
between  4-hydroxyisoleucine  activity  and  glucokinase.  Glucokinase
requires  a  much  higher  glucose  concentration  for  maximal  activity.
Glucokinase is found in the liver and pancreatic beta cells and it plays an
important  role  in  liver  due  to  its  high  Vmax,  allowing  the  liver  to
effectively remove excess glucose, and minimize hyperglycaemia after
eating. Glucokinase unlike hexokinase which is inhibited by the product
of its reaction, is not inhibited by glucose 6 phosphate (G6P). Previous
studies showed that expression of glucokinase in cultured human muscle
cells  treated   with  AdCMV-GKL results  in  proportional  increases  in
insulin-independent glucose disposal,  and that  muscle  glucose storage
and utilization becomes controlled in a glucose concentration-dependent
manner in AdCMV-GKL-treated cells (Baqué  et al. 1998).  It can raise
the  hypothesis  that  4-hydroxyisoleucine  may  involve  in   facilitating
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glucokinase activity as the main regulator of glycolysis alongside with
other possible mechanisms which may be in common with isoleucine
considering  the  facts  that  the  hypoglycaemic  activity  of  4-
hydroxyisoleucine  is  seen  in  higher  concentration  of  glucose.  The
Seahorse autoanalyser results could support the idea of involvement of 4-
hydroxyisoleucine in the glucokinase pathway as it increases glycolysis
as well  as  mitochondrial  respiration unlike isoleucine which does not
affect glycolysis. It will require more detailed studies to be done in the
future  to  investigate  the  interaction  between  glucokinase  and  4-
hydroxyisoleucine.  Unfortunately, we could not carry such study due to
limited  resources  and  facilities,  but  it  would  be  a  great  idea  for  the
further research project. 
 
We  can  summarise  the  conclusions  from animal  and  cellular  studies
about 4-hydroxyisoleucine as follows:
• 4-hydroxyisoleucine has a unique long term anti-diabetic activity
as  observed  and  it  possibly  could  increase  the  cellular  basal
glucose consumption in high glucose concentration over a longer
period of time without a significant immediate effect on glucose
uptake similar to insulin.  
• 4-hydroxyisoleucine  anti-diabetic  effects  are  independent  of
insulin but its effect on increasing basal glucose uptake in long
term treatment  can  contribute  to  the  stronger  insulin  effect  on
peripheral tissues. Insulin binding to its receptor, creates a surge in
basal glucose uptake by promoting GLUT 4 translocation to the
plasma membrane. If the basal glucose uptake increases, the same
amount of insulin can create a stronger effect on lowering glucose
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level.  Increased  basal  glucose  uptake  in  peripheral  cells  via  4-
hydroxyisoleucine  could  explain  the  insulin-sensitizing  property
of 4-hydroxyisoleucine in insulin resistant diabetic models studied
before.
• 4-hydroxyisoleucine  modifies  metabolic  complications  of
diabetes,  most  importantly  dyslipidemia  by  decreasing
triglyceride, cholesterol, low density lipoprotein (LDL) levels in
blood.  It  also  reduces  plasma  uric  acid  in  diabetes  as  well  as
hyperglycaemia  and  dyslipidemia.  It  is  concluded  that  4-
hydroxyisoleucine  is  not  only  a  hypoglycaemic  agent,  but  it  is
capable  of  limiting  the  disabling  complications  of  diabetes
resulted from metabolic defects over a long period. 
• 4-hydroxyisoleucine  unlike  its  similarity  to  isoleucine  in  the
perspective  of  molecular  structure  and hypoglycaemic  property,
has wider activities via interacting with pathways which are not
affected  by isoleucine.  4-hydroxyisoleucine molecular  structure
core  is  similar  to  isoleucine,  but  its  extra  hydroxyl  group  at
position  four  creates  unique  distinctive  properties  from
isoleucine.Current  in-vitro  study  results  indicate  that  isoleucine
and  4-hydroxyisoleucine  have  different  modes  of  action.   Its
glucose lowering effect  is dependent on glucose concentration
and protein  synthesis  that  suggests  a different  pathway for  4-
hydroxyisoleucine and could explain the other extra effects of 4-
hydroxyisoleucine in modifying diabetes adverse effects compare
to isoleucine. 
150
• 4-hydroxyisoleucine activity is strongly dependent on new protein
synthesis and GLUT1 activity. GLUT1 is widely available in most
of the cells and it controls the basal glucose uptake independent of
insulin. The connection between GLUT1 and 4-hydroxyisoleucine
effect in cellular level, supports the idea that 4-hydroxyisoleucine
utilises the glucose basal consumption and uptake of cells. 
• PI3 Kinase plays essential role in the isoleucine mode of action
but not  4-hydroxyisoleucine as proposed in previous literatures.
Increasing  of  the  PI3Kinase  activity  in  tissues  treated  by  4-
hydroxyisoleucine  as  observed  in  previous  studies  could  be  an
indirect effect of 4-hydroxyisoleucin. 
• Both  4-hydroxyisoleucine  and  isoleucine  activities  are  strongly
dependent on mitochondrial respiration, but 4-hydroxyisoleucine
up-regulates  glycolysis  significantly  which  is  not  affected  by
isoleucine.  The  connection  between  mitochondria  calcium
signalling and contradictory behaviour of 4-hydroxyisoleucine and
isoleucine in front of reuthenium red support the very important
role of calcium in their mechanisms of action.  
• The  improving  effects  of  4hydroxyisoleucine  on  metabolic
parameters in diabetes including plasma glucose, lipid profile and
uric  acid  in  animal  study,  and increasing  glucose  consumption,
glycolysis and mitochondrial activity in BRIN-BD11 cells, suggest
that  4hydroxyisoleucine  has  a  systemic  effect  on  metabolically
active tissues, including the liver, adipose, muscle and pancreatic
beta cells that are independent of insulin.  It does not exclude the
role  of  insulin  in  combination  with  4-hydroxyisoleucine  which
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may  amplify  its  effect  as  shown  previously,  but  current  study
findings exclude the insulin secretion stimulation and interaction
directly  with  insulin  as  the  key  mechanism  of  action  of  4-
hydroxyisoleucine. 
• Current study findings indicate that both 4-hydroxyisoleucine and
isoleucine  have  mechanisms  beyond  the  insulin  regulatory
pathway  and affect  metabolism and energy  modulation  in  both
cytoplasmic  and  mitochondrial  levels  which  requires  more
profound and meticulous study. 
We tried to create an overview and basis about potential mechanisms
involved in 4-hydroxyisoleucine in our study to open a window for more
researches  in  the  future.  The  evaluation  of  4-hydroxyisoleucine  and
isoleucine on expression of a variety of genes in different types of cell
using microarray technique could provide an immense data about their
mechanisms of action.    
4-hydroxyisoleucine is an anti-diabetic molecule with multiple actions,
which is not only reduces plasma glucose in type1 and 2 diabetes, but
modifies other metabolic complications of diabetes and it is only active
in  high  glucose  concentration  unlike  other  antidiabetic  medications.
There  have  been  no  reports  of  any  adverse  effects  or  toxicity  of
4hydroxyisoleucine in previously published studies which indicate that it
is well tolerated and not toxic (Flammang et al. 2004). It makes the 4-
hydroxyisoleucine an intelligent molecule which only active in diabetic
conditions and its consumption do not produce the hypoglycaemic effect
in normoglycaemic or non-diabetic condition. It is a safe choice, unlike
other medications if it is consumed by non-diabetic patients or misused.
Analysing the data from our animal and in-vitro studies determine that 4-
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hydroxyisoleucine  could  be  a  promising  candidate  for  type  1  and  2
diabetes  solely  or  in  combination  with  other  therapeutic  regimen.
Unfortunately,  there  is  no precise  information about the dosage of  4-
hydroxyisoleucine  for  such  application  in  human.  There  are  some
suggestions  based  on  traditional  medicine  for  using  fenugreek  seed
extract  but  there  is  no  verifiable  scientific  data  about  the  dosage  of
fenugreek.  The  lack  of  such  useful  information  makes
pharamcokinetic  studies  an  important  field  to  understand  4-
hydroxyisoleucine  metabolism  in  the  body,  interaction  with  other
medications and dose response.
5.1 Future recommended studies
There are some ideas for  the future studies recommended in this chapter
based  on  the  current  study  finding  to  provide  a  better  and  clearer
understanding of 4-hydroxyisoleucine mechanisms of action.  Carrying
more fundamental  and accurate studies which obviously require more
resources and supports to discover 4-hydroxyisoleucine mechanisms of
action  which  not  only  allow  us  to  develop  more  efficient  and  safer
therapeutics,  but  also  guide  us  towards  a  better  understanding  of  the
pathophysiology of diabetes and insulin resistance.
There are a summary of suggested future studies for 4-hydroxyisoleucine
which may be used as ideas for designing better research projects in the
future.  
• Investigation of the GLUT 1 expression and its gene transcription
in  pancreatic  beta  cell,  liver,  adipose  and  skeletal  muscle  cell
models  incubated  with  4-hydroxyisoleucine  in  the  presence  of
high glucose concentration. It is suggested to use a dosage titration
to identify the relation of any changes with 4-hydroxyisoleucine.
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•  As we showed the role of calcium in 4-hydroxyisoleucine activity,
it  is  important to study the role of calcium signalling pathways
within the cell  in more details not only in pancreatic beta cell but
in  other  types  of  cells  incubated  with  4-hydroxyisoleucine  and
isoleucine for comparison. 
• Based  on  the  Seahorse  autoanalyzer  results  which  showed
increased activity in both glycolysis and mitochondrial respiration,
It  is  recommended  to  look  into  the  interaction  of  4-
hydroxyisoleucine with glucokinase and other enzymes within the
Krebs cycle. There is a potential possibility of direct or indirect
interaction  between  4-hydroxyisoleucine  and  Krebs  cycle's
enzyme. Investigation of the expression and activity of the Krebs
cycle enzymes in pancreatic beta cell and other cell models such
as liver and adipose could provide a valuable data about the role of
4-hydroxyisoleucine  in  energy  modulation  via  interacting  with
mitochondrial respiration.  
• Screening the whole genome expression level in the cell or tissue
models treated with 4-hydroxyisoleucine and isoleucine in front of
high concentration of glucose compared to non treatment control
using a microarray technique could reveal a valuable data about
their mechanisms of action. It also creates a database for different
kind  of  analysis  to  provide  a  wider  perceptive  about  4-
hydroxyisoleucine  and  isoleucine  activities  in  gene  level.
Unfortunately, carrying such experiment is expensive and requires
substantial resources and facilities.
• A  limited  human  clinical  trial  could  be  very  informative  to
evaluate the efficacy of 4-hydroxyisoleucine in diabetic patients
solely  or  in  combination  with  other  available  medication.  It
requires pharmacokinetics study prior to clinical study to set out a
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dose  response  and  more  information  about  4-hydroxyisoleucine
metabolism. It also requires more cost effective chemistry method
to produce an affordable synthetic 4-hydroxyisoleucine because it
is an expensive and a rare molecule from being used in milligram
dosage for clinical study.
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Appendix I
Animal study publication
 (Non-insulin dependent anti-diabetic
activity of (2S, 3R, 4S) 4-hydroxyisoleucine
of fenugreek (Trigonella foenum graecum)
in streptozotocin-induced type I diabetic
rats)
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Appendix II
4-Hydroxyisoleucine certificate of analysis
197
198
199
200
201
Appendix III
Glucometer accuracy measurements table 
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